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ABSTRACT 
 
Protein crystallography is an invaluable tool for the study of biological processes at the 
molecular level.  While several crystallization techniques are actively pursued in both 
academic and industrial laboratories to produce high-quality protein crystals, the use of 
microfluidic technology for structural biology was previously shown to improve protein 
crystallization over more traditional methods.  This thesis describes a microfluidics-based 
crystallization strategy that was developed to increase the success rate of crystallizing 
challenging proteins.  The crystallization strategy involves using multiple microfluidic 
devices to characterize the solubility trends of the crystallization target, to perform nanoliter 
volume free interface diffusion crystallization experiments designed around the solubility 
trends, and to enable in situ diffraction analysis of crystals grown in microfluidic devices.  
The crystallization strategy was applied to the crystallization of a dozen challenging proteins 
and increased the overall crystallization and diffraction success rates compared with 
conventional automation.  The crystallization strategy was also utilized to crystallize four 
metabolic proteins and provides the first demonstration of in situ structure determination for 
novel crystallization targets using a microfluidic crystallization platform.  Additional 
technological advances were accomplished by the development of a novel microfluidic 
device designed to address the specific challenges of membrane protein crystallography.  To 
date, this microfluidic crystallization strategy has produced four novel protein structures and 
holds great promise for future work in the field of protein crystallography.  
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Chapter 1 
OVERVIEW  
 
Introduction 
The underlying goal of structural biology is to enable biological systems to be understood at 
the molecular level.  In particular, macromolecular structures are used to study the function 
of proteins, macromolecule complex formation, the multiple conformations of proteins, and 
signaling pathways within cells.  Macromolecular structures have also proven to be an 
invaluable tool for rational drug design (1).  While over 40,000 protein structures have been 
determined using X-ray crystallography since the first crystal structure was solved almost 50 
years ago (2), this represents only a small fraction of the proteins involved in living 
processes.  As the list of known proteins continually expands due to advances in genome 
sequencing technology, parallel advances in X-ray crystallography techniques are required to 
keep pace.   
 
The success of large-scale protein crystallography efforts are currently limited by the 
production of protein crystals of sufficient size and quality for X-ray diffraction analysis.  
Crystal production is limited by bottlenecks in the expression, purification, and identification 
of successful crystallization conditions for crystallization targets (3).  Additional difficulties 
are encountered as more challenging crystallization targets, including membrane proteins and 
large macromolecule complexes, are attempted.  For crystallization targets that are difficult 
to express in large quantities, the number of crystallization trials that can be performed is 
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restricted.  Therefore, crystallization techniques for the high-throughput production of 
diffraction-quality crystals using limited amounts of protein are needed to advance structural 
biology efforts. 
 
Recently, microfluidic technology has been utilized to develop crystallization devices that are 
ideal for high-throughput crystallization experiments (4–6).  Microfluidic technology allows 
for the parallel implementation and automation of biological assays on a nanoliter scale, 
increasing speed and throughput compared to conventional laboratory techniques.  
Additionally, microfluidic devices provide economy of scale in protein and reagent 
consumption, reduce experimental costs, and increase the sensitivity of biological assays. 
Multilayer soft lithography (MSL) technology is used to fabricate microfluidic devices out of 
elastomeric materials with integrated valves (7).  Active valves can be used to create 
microfluidic devices with individually addressable chambers, peristaltic pumps, and mixers 
for complex fluid-handling capabilities (8–10).   
 
In particular, a suite of microfluidic devices was developed to address all stages of protein 
crystallography, from the identification of crystallization reagents to the production of larger 
format crystal for in situ diffraction analysis (4, 6, 10).  The microfluidic devices perform 
free interface diffusion crystallization experiments, which is enabled by the unique diffusion-
driven mixing of fluids in the microscale environment (11).  The work presented in this thesis 
utilizes the microfluidic crystallization platform for the structure determination of novel 
crystallization targets (12, 13).  
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Context 
This work builds on the microfluidic crystallization platform previously developed in our lab 
by Carl Hansen (4, 6, 10).  When the author began this work, three devices for protein 
crystallization had been developed using MSL technology.  The utility of each of the devices 
was validated with model proteins and it remained to be seen if the devices could be used to 
produce crystal structures of novel proteins.  As a starting point, the author began using the 
microfluidic crystallization platform to crystallize challenging proteins.  Since the 
microfluidic crystallization platform was essential for all aspects of this work, a brief 
description of the crystallization devices is provided.  Additionally, modified fabrication 
protocols for each of the devices are presented in Appendix A. 
 
The first component in the microfluidic crystallization platform is the formulator device 
(Figure 1.1).  The formulator systematically characterizes the solubility behavior of 
crystallization targets in the presence of thousands of chemical conditions to identify 
crystallization reagents.  Additionally, the formulator generates complete phase diagrams 
with each of the crystallization reagents that are used to design customized crystallization 
experiments.  Crystallization reagents are identified by their ability to manipulate protein 
solubility by causing protein aggregation.  The chemical conditions used in the solubility 
characterization are created within the device using a multiplexer with 40 input lines for 
different salt solutions, buffering agents, and precipitating agents.  All solubility 
measurements are performed in a rotary mixer in the center of the device and require only 
nanoliter volumes of the crystallization target.  The formulator setup is fully automated and 
solubility experiments can be carried out for days without any user input.  
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Figure 1.1: Microfluidic formulator device.  The reagent input ports for the multiplexer are 
located at the top and the right side of the device and are filled with red dye.  The control 
lines are filled with green dye and are pressurized through the input ports located at the 
bottom of the device.  The rotary mixer is located in the center of the device and a close up of 
the mixer is shown on the right.  The flow layer is filled with air, the peristaltic pump on the 
rotary mixer that creates different chemical conditions from the multiplexer is filled with 
yellow dye, the peristaltic pump controlling protein inlet into the mixer is filled with red dye, 
and the input and output control valves on the mixer are filled with green dye.  Protein 
aggregation is measured in the flat section at the bottom of the rotary mixer.  This figure was 
adapted from Figure 2 in (10).  The scale bar represents 1 cm. 
 
The second component in the microfluidic crystallization platform is the free interface 
diffusion screening device (Figure 1.2).  The screening device performs nanoliter volume 
free interface diffusion experiments to screen the crystallization reagents identified with the 
formulator device.  Each screening device tests 48 different crystallization reagents at five 
different protein:reagent mixing ratios for a total of 240 free interface diffusion experiments.  
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The screening device can be set up in a matter of minutes using only 3 µl of protein and 
crystallization experiments can proceed for weeks within the device. 
 
 
 
Figure 1.2: Microfluidic free interface diffusion screening device.  The crystallization 
reagents are loaded through large input ports at the top and the bottom of the device and the 
reagent chambers are filled with red dye.  Protein is loaded in the center of the device using a 
gel loading tip and the protein chambers are filled with yellow dye. The interface line 
separates the protein chambers from the reagent chambers during loading and is filled with 
green dye.  The containment lines isolate each of the free interface diffusion experiments 
from the rest of the device and are filled with blue dye.  A close up of the five free interface 
diffusion experiments for one reagent is shown on the right.  See (4) for details.  The scale 
bar represents 1 cm. 
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The final component in the microfluidic crystallization platform is the scale-up diffraction 
device (Figure 1.3).  The scale-up diffraction device performs larger format free interface 
diffusion experiments to produce crystals of sufficient dimensions for in situ diffraction 
analysis.  Each scale-up diffraction device performs 100 free interface diffusion experiments 
with one reagent and utilizes multiple free interface diffusion path lengths to manipulate 
crystal growth.  The crystallization experiments are encapsulated in a thin layer of elastomer, 
and sections of the device surrounding the crystals can be removed using a punching tool and 
placed directly into the X-ray beam for in situ diffraction analysis.  Osmotic solutions are 
placed on top of the thin elastomer layer during crystallization to prevent dehydration. 
 
 
 
Figure 1.3: Microfluidic scale-up diffraction device.  The crystallization reagent is loaded on 
one side of the device using a gel loading tip and the reagent chambers are filled with red 
dye.  Protein is loaded on the opposite side of the device using a gel loading tip and the 
protein chambers are filled with yellow dye.  The interface line is filled with green dye and 
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the containment lines are filled with blue dye.  A close up of the thin section of the device 
with one set of free interface diffusion chambers is shown on the right.  A circular disk is 
created when one section of the device is punched out and a small alligator clip is used to 
position the disk in the X-ray beam for diffraction analysis.  See (6) for details.  The scale bar 
represents 1 cm. 
 
 
Organization and Collaborations 
Chapter 2 describes a crystallization strategy based on the knowledge of the phase behavior 
of a protein that allows one to create rational crystallization screens to increase the success 
rate of crystallizing challenging proteins (12).  The strategy is based on using the 
microfluidic formulator device to perform large numbers of protein solubility experiments 
across a broad range of chemical conditions to identify reagents for crystallization 
experiments.  Phase diagrams were subsequently generated for the identified reagents and 
used to design customized crystallization screens for every protein.  This strategy was 
applied with a 75% success rate to the crystallization of twelve challenging proteins.  The 
overall diffraction success rate was 33%, about double what was achieved with conventional 
automation in large-scale protein structure consortia.  
 
Protein samples were provided by the following collaborators: Manal Swairjo, Scripps 
Research Institute; Stefan Habelitz, University of California, San Francisco; Marc Facciotti, 
Lee Hood Laboratory, Institute for Systems Biology; Michael Merckel, University of 
Helsinki; Takumi Koshiba, David Chan Laboratory, California Institute of Technology; 
Xavier Ambroggio, Douglas Rees and Raymond Deshaies Laboratories, California Institute 
of Technology; Pavel Strop, Axel Brunger Laboratory, Stanford University; Matthew Peters 
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and Peter Meinhold, Frances Arnold Laboratory, California Institute of Technology; Scott 
Gradia, James Berger Laboratory, University of California, Berkeley; Anthony Giannetti, 
Pamela Bjorkman Laboratory, California Institute of Technology; and Byron DeLaBarre, 
Axel Brunger Laboratory, Stanford University.  Carl Hansen, currently at the University of 
British Columbia, assisted with the early formulator experiments and data analysis.  
 
In Chapter 3 the crystal structure of an Escherichia coli glycerol kinase mutant Gly230→Asp 
is presented (13).  The structure was determined to 2.0 Å and is the first demonstration of in 
situ structure determination for a novel crystallization target using a microfluidics-based 
crystallization platform.  Parallel vapor diffusion experiments were performed and revealed 
the diffraction limit of crystals grown in the scale-up diffraction device was higher than the 
3.0 Å diffraction limit of crystals grown in the vapor diffusion format. 
 
The Escherichia coli genomic DNA for the glycerol kinase mutant was provided by Anu 
Raghunathan, Bernhard Palsson Laboratory, University of California, San Diego.  The 
structure was solved in collaboration with Byron DeLaBarre, Axel Brunger Laboratory, 
Stanford University. 
 
In Chapter 4 crystal structures of Escherichia coli glycerol kinase mutants Asp72 → Ala, 
235Lys-Gly-Gly insert, and Met271 → Ile were determined to 2.3 Å, 2.8 Å, and 2.9 Å, 
respectively.   Each of the structures was obtained using the microfluidics-based 
crystallization platform, including in situ diffraction collection from the scale-up diffraction 
devices.  
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The Escherichia coli genomic DNA for the glycerol kinase mutants was provided by M. 
Kenyon Applebee, Bernhard Palsson Laboratory, University of California, San Diego.  The 
structures were solved in collaboration with Pete Dunten, Stanford Synchrotron Radiation 
Laboratory. 
 
In Chapter 5 a novel microfluidic device was developed for membrane protein crystallization 
in the presence of lipids.  The dialysis device for membrane protein crystallization was 
designed to perform multiple crystallization experiments in a lipid environment using 
detergent-solubilized membrane protein samples.  The microfluidic device incorporates a 
dialysis platform for the removal of detergent monomers from purified protein-detergent 
micelles with a free interface diffusion crystallization platform.  A detergent-solubilized 
KcsA potassium channel was used to validate the utility of the microfluidic dialysis device 
for membrane protein crystallization. 
 
The KcsA channel protein was provided by Joel Butterwick, Roderick MacKinnon 
Laboratory, Rockefeller University. 
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Chapter 2 
PHASE KNOWLEDGE ENABLES RATIONAL SCREENS FOR PROTEIN 
CRYSTALLIZATION 
 
Introduction 
One of the main bottlenecks in the application of protein crystallography to large-scale 
structural biology efforts is the production of diffraction-quality crystals.  Protein 
crystallization relies on the identification of reagents that promote crystal formation and an 
understanding of protein solubility in the presence of these reagents to achieve optimal 
crystal growth.  Traditional techniques to identify reagents for crystallization include 
incomplete factorial searches across chemical space and sparse-matrix screening around 
reagents previously shown to crystallize proteins (14, 15).  While these techniques provide a 
starting point for crystallization experiments, they are not designed around the biophysical 
properties of individual proteins and have met with limited success for more challenging 
crystallization targets.  For example, the NIH Protein Structure Initiative (PSI) was able to 
generate diffraction-quality crystals from less than one in five of the 10,000 purified protein 
targets it has attempted to date (http://targetdb.pdb.org/statistics/TargetStatistics.html).  
  
Knowledge of protein solubility in the presence of a crystallizing reagent enables one to 
effectively utilize the reagent in a way that will promote crystallization.  The traditional 
method to study protein solubility in response to reagents is to construct a phase diagram that 
measures the solubility at different protein and reagent concentrations.  The protein solubility 
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curve outlined in each phase diagram depicts the most favorable protein and reagent 
concentrations to use in a crystallization experiment for optimal crystal growth.  Currently, 
phase diagrams are only generated for readily available model proteins and for proteins with 
known crystallization conditions to improve crystal morphology (16–25).  The infrequent use 
of phase diagrams for crystallization experiments is due to the large sample volumes and 
time required to construct the diagrams.  The general utilization of phase diagrams to analyze 
protein solubility before starting crystallization experiments would lead to a more physical 
and rational approach to protein crystallization. 
 
In this study, the utilization of a crystallization strategy based on a detailed understanding of 
protein solubility is shown to increase the crystallization success rate for challenging 
proteins.  A microfluidic formulator device is used to systematically screen hundreds of 
reagents against protein targets at several points on the phase diagrams to identify reagents 
that affect the solubility of the protein.  Next, each of the identified reagents is explored by 
constructing a complete phase diagram outlining the solubility limits of the protein in the 
presence of the reagent. The phase diagrams are then used to design individualized 
crystallization screens tailored to the solubility properties of the target protein.  This device 
was previously demonstrated to greatly enrich crystallization conditions for xylanase, UMP 
kinase, and the integral membrane protein SERCA (10, 26), although no novel crystal 
structures have been obtained using this device.  The customized crystallization screens are 
tested using a redesigned free interface diffusion screening device.  Successful crystallization 
conditions are transported to a larger scale crystal growth format for diffraction analysis.   
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This rational screening strategy was applied to the crystallization of twelve biologically 
diverse and challenging proteins, eight of which failed to crystallize using traditional 
techniques.  The crystallization targets range in size from 16 kDa to 360 kDa complexes and 
include membrane proteins, large multiprotein complexes, a protein/RNA complex, a 
metalloprotein complex, metabolic proteins, and an extracellular matrix protein.  
Identification of reagents and phase diagram generation for each target was completed using 
only microliters of sample, and the crystallization and diffraction success rates were roughly 
double that obtained by the PSI using conventional automation.  The increased success rates 
are noteworthy given the target diversity and that 67% of the targets are from eukaryotic 
sources while the PSI crystallization targets to date are biased towards prokaryotic sources 
with only 30% of the targets from eukaryotic sources 
(http://targetdb.pdb.org/statistics/TargetStatistics.html). 
 
Experimental Procedures 
Protein Preparation.  Protein samples were provided by the following collaborators: 98 kDa 
Aquifex aeolicus alanyl-tRNA synthetase (AlaRS) at 15 mg/ml from Manal Swairjo, The 
Scripps Research Institute; 22 kDa human amelogenin (AMG) at 2 mg/ml from Stefan 
Habelitz, University of California, San Francisco; 27 kDa Halobacteria bacteriorhodopsin 
(bR) and bacteriorhodopsin mutant D85S (bR D85S) at 18 mg/ml from Marc Facciotti, 
Institute for Systems Biology; 126 kDa Rhodobacter sphaeroides cytochrome cbb3 (Cbb3) at 
10 mg/ml from Michael Merckel, University of Helsinki; 16 kDa Saccharomyces cerevisiae 
Fis1 at 60 mg/ml from Takumi Koshiba, California Institute of Technology; 360 kDa 
Saccharomyces cerevisiae proteasome 19S Lid particle (19S Lid) at 25 mg/ml from Xavier 
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Ambroggio, California Institute of Technology; 45 kDa Mus musculus P2X at 6 mg/ml from 
Pavel Strop, Stanford University; the 54 kDa heme domain of Bacillus subtilis cytochrome 
P450 mutant 1-12G (P450 1-12G) at 30 mg/ml from Matthew Peters and Peter Meinhold, 
California Institute of Technology; 123 kDa Aquifex aeolicus SMC/ScpA complex at 22 
mg/ml from Scott Gradia, University of California, Berkeley; 72 kDa human 
tranferrin/transferrin receptor mutant complex (Tf/TfR) at 27 mg/ml from Anthony Giannetti, 
California Institute of Technology; and 254 kDa Rattus norvegicus VCP-97/Vimp complex 
(VCP/Vimp) at 10 mg/ml from Byron DeLaBarre, Stanford University. 
 
Solubility Screening and Phase Diagram Generation.  Solubility experiments were 
performed using a microfluidic formulator device developed by Hansen et al. (2004).  Device 
fabrication, automation, experimental setup, and data acquisition were previously described 
(10) (Appendix A).  The formulator device was used to create 448 unique reagents for 
solubility screening by systematically combining fourteen salt solutions, four buffering 
agents, and eight precipitating agents (see Appendix B for a complete list of the reagents).  
Salt solutions and precipitating agents were used near the maximal solubility and viscosity 
levels of each species.  Each of the reagents was tested against the protein targets at six 
different protein and precipitant concentrations across the boundary of the phase diagram 
while holding the salt solution and buffering agent at a fixed level for a total of 2,688 
solubility experiments for each protein target.   Protein aggregation was quantified by 
imaging the protein in solution with each reagent using a charge coupled device camera, 
calculating the pixel intensity standard deviation, and subtracting the background pixel 
intensity standard deviation of the reagent in the absence of protein.  Reagents that caused the 
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protein to aggregate above 3 pixel intensity standard deviation units for at least one of the six 
points tested were classified as potential crystallization reagents.  For 3.3% of the images, the 
pixel intensity standard deviation value was negative due to errors in the formulator device, 
and for these measurements the pixel intensity standard deviation was set to zero.   
 
Complete phase diagrams were generated for a subset of the crystallizing reagents identified 
with the solubility screening.  For each phase diagram, the reagent was combined with the 
protein at 72 different precipitant and protein concentrations.  The protein concentration was 
tested between 5–80% and the precipitant concentration was tested between 2.5–77.5%.  
Again, buffering agent and salt solution concentrations were held constant throughout the 
phase diagram at the concentrations used for the solubility screening.  Protein aggregation 
was measured at each point as described above.  Positions on the phase diagram that caused 
the protein to aggregate above 3 pixel intensity standard deviation units were classified as 
insoluble and positions below 3 were classified as soluble. 
 
Crystallization Experiments and Device Fabrication.  Initial crystallization experiments were 
performed using a modified version of the microfluidic free interface diffusion screening 
device (4).  The screening device design was modified to perform five free interface 
diffusion experiments per reagent instead of three.  The protein:reagent mixing ratios used 
are 1:4, 1:2, 1:1, 2:1, and 4:1, with a total reaction volume of 25 nl per free interface 
diffusion experiment.  One screening device is used to test 48 reagents for a total of 240 
parallel free interface diffusion experiments.  The previous design utilized a hybrid 
glass/elastomer device and was modified to consist solely of elastomer to facilitate faster 
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fabrication. The devices were fabricated using multilayer soft lithography (7) and the 
fabrication protocol is outlined in Appendix A.   
 
The crystallization experimental setup was previously described (4).  Crystal hits were 
verified using IZIT protein stain, the crush test, or diffraction analysis.  Crystal hits were 
transported to microfluidic scale-up diffraction devices, vapor diffusion format, or 
microbatch format for diffraction experiments.  Device fabrication and experimental setup 
using the scale-up diffraction device was previously described (6) (Appendix A).  Scale-up 
diffraction devices were incubated at room temperature up to two weeks and cryoprotectant 
was introduced by diffusion 24 hours before flash-freezing the crystals in the devices.  For 
vapor diffusion experiments, 1 µl of protein was combined with 1 µl of reagent and 
suspended over 500 µl of reagent and incubated at room temperature up to two weeks.  For 
microbatch experiments, a layer of paraffin oil was place over the microbatch wells and 1 µl 
of protein was combined with 1 µl of reagent under the oil and incubated at room 
temperature up to two weeks.  For vapor diffusion and microbatch experiments the crystals 
were looped from the drops and through cryoprotectant before flash-freezing in liquid 
nitrogen. 
 
Diffraction Studies.  Diffraction data for Cbb3 was collected at station 11.1 of the Stanford 
Linear Accelerator Center (Stanford University), at an incident wavelength of 1.0 Å with a 
15 second exposure and 1º oscillation.  Diffraction data for bR and bR D85S was collected at 
station 8.3.1 of the Advanced Light Source (Lawrence Berkeley National Laboratory), at an 
incident wavelength of 1.0 Å with a 20 second exposure and 1º oscillation.  Diffraction data 
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for P450 1-12G was collected on an R-axis IV (California Institute of Technology) at an 
incident wavelength of 1.54 Å with a 30 minute exposure and 1º oscillation. 
 
Results and Discussion 
Solubility Characterization.  The phase-diagram-based approach to protein crystallography 
was used to design and implement customized crystallization strategies for twelve 
challenging protein targets.  To begin, protein solubility was screened against an extensive 
set of chemical conditions to identify suitable reagents for crystallization trials (Figure 2.1).  
The solubility screening included a full factorial search of 448 reagents composed of unique 
precipitant, buffer, and salt combinations.  For each reagent, protein phase behavior was 
explored by sampling protein solubility at six different protein and precipitant concentrations 
across the phase diagram for a total of 2,688 solubility experiments per target.  The ability of 
each reagent to manipulate protein solubility was quantified by the amount of protein 
aggregation observed when the protein was introduced to the reagent.  Reagents that caused 
protein aggregation above a threshold level were considered to be potential crystallizing 
reagents for that target.  The solubility screening across chemical and phase space identified 
between 51 and 246 potential crystallizing reagents for each of the targets. 
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Figure 2.1: Solubility screening results for twelve protein targets.  Pixel intensity standard 
deviation represents the amount of protein aggregation seen in response to each reagent.  The 
proteins are displayed from top to bottom in the order of decreasing protein aggregation: bR 
D85S, bR, Cbb3, AlaRS, Fis1, P450 1-12G, SMC/ScpA, P2X, AMG, VCP/Vimp, Tf/TfR, 
and 19S Lid.  The solubility screening results are grouped by precipitating agent and are 
further subdivided by buffering agent.  See Appendix B for a complete list of the reagents 
screened. 
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Trends in the solubility screening results indicate protein phase behavior was predominately 
controlled by the precipitating component of the reagent (Figure 2.2A).  The effectiveness of 
each of the reagent components on protein aggregation was determined by comparing the 
solubility results of reagents with two of the three components held constant.  The 
precipitants utilized in the solubility experiments are polyethylene glycol (PEG) polymers 
with different chain lengths and end groups, giving each PEG polymer unique volume 
exclusion properties.  Since the volume exclusion effect is more significant in longer 
polymers due to their larger radius of gyration, the longer polymers were used at a lower 
concentration than the shorter polymers.  Polymers of four different chain lengths were 
examined and for every target the number of potential reagents identified with longer 
polymers surpassed the number of reagents identified with shorter polymers.  Additionally, a 
second PEG polymer with a modified monomethyl ether (MME) end group was screened at 
each polymer length; the MME polymers produced fewer identified reagents at each polymer 
length.  Therefore, increasing the polymer chain length of the precipitating agent increases 
the protein aggregation response, and the polymer chemical composition also influences 
protein aggregation.  
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Figure 2.2: Solubility trends for crystallization targets.  (A) Classification of identified 
reagents by the molecular weight of the precipitating agent.  (B) Classification of identified 
reagents by the deviation from the pI of the protein targets.  (C) Classification of identified 
reagents by the ionic strength of the solution.  (D) Classification of the identified reagents by 
the anion component of the reagent.  The anions acetate and tartrate are abbreviated as Ace 
and Tar, respectively.  (E) Classification of the identified reagents by the cation component 
of the reagent.  (F) Comparison of the target molecular weight and the identified reagents for 
each target.  For (A–F), the percentage of identified reagents is normalized by the number of 
reagents screened in each category. 
 
The solubility screening results also show that reagents with a pH value in the vicinity of the 
theoretical isoelectric point (pI) of the targets were identified as potential reagents with a 
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higher frequency than reagents that deviated from the target pI values (Figure 2.2B). This 
increased identification of reagents is consistent with the reduced intermolecular electrostatic 
repulsion of proteins near their pI. The variation in the identified reagents at different pH 
values was moderate in comparison to the variations seen for precipitant composition.  The 
ionic strength of the salt solutions used in the solubility screening exhibited the expected 
trend of increased identified reagents at higher ionic strengths (Figure 2.2C).  While ionic 
strength had a slight influence on the identified reagents, no trends were observable for the 
ionic composition of the reagents (Figure 2.2D–E).   The ions are displayed by increasing 
protein aggregation strength based on the Hofmeister series, and little variation in the 
identified reagents is seen for the cation or anion components of the reagent (27).  A trend is 
also evident between the decreasing molecular weight of the target and an increasing number 
of identified reagents (Figure 2.2F). 
 
Protein phase behavior was further characterized by the generation of complete phase 
diagrams for a subset of the reagents identified during the solubility screening.  Empirically 
determined solubility boundaries allow for the selection of precipitant and protein 
concentrations that maximize the chance of successful crystallization by excluding areas of 
phase space that lie far into the precipitation or soluble regions.  The complete phase 
diagrams were produced by combining protein and reagent at 72 different protein and 
precipitating agent concentrations across the phase diagram and measuring protein 
aggregation at each position (Figure 2.3).  Positions where the protein aggregated above a 
threshold level were classified as insoluble and positions where the protein did not aggregate 
above a threshold value were classified as soluble. The phase diagrams were used to design  
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free interface diffusion experiments that target the solubility boundary of the protein with 
each reagent.  For example, the phase diagram shown in Figure 2.3A suggests that targeting 
the position corresponding to 6 mg/ml bR D85S and 20% PEG 1500 would promote 
crystallization.  A free interface diffusion experiment targeting this position requires 
combining 12 mg/ml bR D85S with 40% PEG 1500 at a one-to-one protein-to-reagent ratio.  
As the free interface diffusion experiment proceeds, the trajectories for each solution will 
evolve to reach the desired position and promote protein crystallization (see Figure 3 in (4) 
for details).   Customized crystallization conditions were designed using this technique for 
the specific reagents identified for each of the targets. 
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Figure 2.3:  Phase behavior characterization.  One complete phase diagram is shown for 
each target.  (A) bR D85S with 0.125 M potassium acetate, 0.1 M sodium citrate (pH 6.5), 
and PEG 1500.  (B) bR with 0.125 M ammonium chloride, 0.1 M sodium acetate (pH 4.5), 
and PEG 1500.  (C) Cbb3 with 0.075 M sodium acetate, 0.1 M sodium citrate (pH 6.5), and 
PEG 1500.  (D) AlaRS with 0.1 M magnesium sulfate, 0.1 M sodium citrate (pH 5.5), and 
PEG 5000 MME.  (E) Fis1 with 0.1 M ammonium acetate, 0.1 M Tris·HCl (pH 8.5), and 
PEG 8000.  (F) P450 1-12G with 0.2 M ammonium sulfate, 0.1 M Imidazole pH 7.5, and 
PEG 8000.  (G) SMC/ScpA with 0.05 M magnesium sulfate, 0.1 M sodium citrate (pH 5.5), 
and PEG 2000 MME.  (H) P2X with 0.3 M sodium acetate, 0.1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (Hepes) (pH 7.5), and PEG 1500.  (I) AMG with 0.5 M 
sodium chloride, 0.1 M Tris·HCl (pH 8.5), and PEG 8000.  (J) VCP/Vimp with 0.4 M 
ammonium acetate, 0.1 M sodium citrate (pH 6.5), and PEG 1500.  (K) Tf/TfR with 0.2 M 
ammonium sulfate, 0.1 M Hepes (pH 7.5), and PEG 1500.  (L) 19S Lid with 0.1 M 
ammonium chloride, 0.1 M sodium citrate (pH 5.5), and PEG 5000 MME.  Each phase 
diagram screened protein solubility at 72 different precipitant and protein concentrations.  
The blue points represent concentrations where the protein is soluble and the yellow points 
represent concentrations where the protein is insoluble.  Refer to Appendix C to see all of the 
phase diagrams generated for each target. 
 
Crystallization Results.  Crystallization experiments were carried out with the individualized 
rational screens using a redesigned free interface diffusion screening device (4).  Each of the 
crystallization conditions was tested against the protein at five different mixing ratios to 
completely sample the solubility boundary of the associated phase diagram (see 
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Experimental Procedures for details).  Free interface diffusion experiments with the rational 
screens resulted in a 75% crystallization success rate for the proteins, while previous 
crystallization attempts in the labs of collaborators failed to identify crystallization conditions 
for the majority of the samples (Figure 2.4).  For the successfully crystallized proteins, 
between 12% to 79% of the reagents screened produced crystals.  The targets were bimodal 
in their crystallization success rates; the majority of the targets crystallized for a small subset 
of the reagents screened while the remaining targets crystallized for the majority of the 
reagents.  
 
The crystallization results show that the crystal hits fall within a well-defined region of 
precipitant and pH (Figure 2.5).  Among the precipitants used for crystallization experiments, 
more crystal hits occurred with larger precipitants and no crystal hits were identified for the 
smallest precipitants.  In contrast to the observed protein aggregation trends, more crystal hits 
were identified with the chemically modified MME precipitants for the larger precipitants.  
Although the variation in pH was larger, more crystal hits were identified from reagents near 
the pI value of the targets.  No trend is observed in the number of crystal hits and the ionic 
strength of the reagent.  As was observed for the protein aggregation results, the variation in 
crystal hits based on the ion identity of the reagent is small with no apparent trends. 
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Figure 2.4:  Crystallization using phase behavior information.   Nine of the twelve targets 
were crystallized in free interface diffusion screening devices.  (A) VCP/Vimp rhombohedral 
crystals were grown in 0.44 M sodium chloride, 0.1 M sodium citrate (pH 6.0), and 6% PEG 
1500.  (B) bR rod crystals were grown in 0.25 M ammonium chloride, 0.1 M sodium acetate 
(pH 4.5), and 35% PEG 1500.  (C) bR D85S rod crystals were grown in 0.125 M potassium 
acetate, 0.1 M sodium citrate (pH 6.5), and 35% PEG 1500.  (D) Fis1 crystals were grown in 
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0.1 M ammonium acetate, 0.1 M Tris·HCl (pH 8.5), and 20% PEG 8000.  (E) 19S Lid 
rectangular prism crystals were grown in 0.15 M sodium acetate, 0.1 M sodium citrate (pH 
5.5), and 15% PEG 8000.  (F) P450 1-12G plate crystals were grown in 0.28 M ammonium 
sulfate, 15% 1,3-propanediol, 0.1 M imidazole (pH 7.5), and 30% PEG 8000.  (G) AlaRS 
crystals were grown in 0.15 M magnesium sulfate, 0.1 M sodium citrate (pH 5.5), and 15% 
PEG 5000 MME.  (H) SMC/ScpA crystals were grown in 0.05 M magnesium acetate, 0.1 M 
sodium citrate (pH 5.5), and 60% PEG 550 MME.  (I) Cbb3 hexagonal crystals were grown 
in 0.125 M sodium chloride, 0.1 M sodium citrate (pH 6.5), and 15% PEG 1500. The scale 
bars represent 100 µm. 
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Figure 2.5: Trends in the crystal hits of targets.  (A) Classification of crystal hits by the 
molecular weight of the precipitating agent.  (B) Classification of crystal hits by the deviation 
from the pI of the protein targets.  (C) Classification of the crystal hits by the ionic 
component of the reagent.  (D) Classification of crystal hits by the ionic strength of the 
reagent.  The percentage of identified reagents is normalized by the number of reagents 
screened in each category. 
 
Various crystal morphologies appeared in response to different reagents, including 
rectangular prism crystals, rhombohedral crystals, hexagonal crystals, rod crystals, plates, 
needles, dendrites, and spherulites.  Optimization of the initial crystallization results with 
additional free interface diffusion experiments improved crystal size and morphology.  The 
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best crystallization conditions for each target were transported to larger experimental formats 
to generate crystals large enough for diffraction analysis (Figure 2.6).  The crystallization 
conditions were translated to scale-up diffraction devices (6), vapor diffusion format, or 
microbatch format with a 67% success rate.  Successful translation to larger formats was also 
clearly correlated with the crystal quality attainable in the smaller format crystallization 
experiments.   
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Figure 2.6: Larger format crystals for diffraction analysis.  Initial hits for six of the nine 
targets were transported to a larger scale growth format.  (A) bR rod crystals were grown in 
scale-up diffraction devices with 0.1 M potassium sodium tartrate, 0.1 M sodium acetate (pH 
4.5), and 35% PEG 1500.  (B) bR D85S rod crystals were grown in scale-up diffraction 
devices with 0.1 M sodium nitrate, 0.1 M sodium citrate (pH 6.5), and 25% PEG 1500.  (C) 
Cbb3 hexagonal crystals were grown in scale-up diffraction devices with 0.15 M ammonium 
acetate, 0.1 M sodium citrate (pH 5.5), and 30% PEG 1500.  (D) VCP/Vimp rhombohedral 
crystals were grown in scale-up diffraction devices with 0.4 M sodium chloride, 0.1 M 
sodium citrate (pH 6.5), and 10% PEG 1500.  (E) P450 1-12G plate crystals were grown 
using vapor diffusion with 0.3 M ammonium sulfate, 0.1 M imidazole (pH 7.8), and 28% 
PEG 8000. (F) 19S Lid rectangular prism crystals were grown in microbatch with 0.175 M 
sodium acetate, 0.1 M sodium citrate (pH 5.5), and 14% PEG 8000.  The scale bars represent 
100 µm. 
 
Diffraction Analysis.  Diffraction experiments were performed on the crystals grown in larger 
formats to evaluate the quality of the crystals.  Of the 6 crystals successfully transported to 
larger formats for diffraction studies, 67% of these crystals produced diffraction data (Figure 
2.7).  This corresponds to a 33% overall success rate of starting with purified protein and 
finishing with diffraction-quality crystals.  The membrane proteins diffracted to between 6.6 
Å and 16 Å, and the metabolic protein diffracted to 3.7 Å with a centered monoclinic unit 
cell of dimensions a = 220.0 Å, b = 62.2 Å, c = 188.7 Å, α = 90°, β = 118.91°, and γ = 90°. 
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Figure 2.7: Diffraction analysis of larger format crystals.  (A) P450 1-12G crystals were 
harvested using 25% ethylene glycol as a cryoprotectant and diffracted to 3.7 Å.  The unit 
cell is centered monoclinic with dimensions a = 219.9 Å, b = 62.2 Å, c = 188.7 Å, α = 90°, β 
= 118.91°, and γ = 90°.  (B) Diffraction data for Cbb3 crystals was collected at room 
temperature using scale-up diffraction devices and the crystals diffracted to 14.5 Å.  (C) 
Diffraction data for bR D85S crystals was collected through scale-up diffraction devices 
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using 20% Glycerol as a cryoprotectant and diffracted to 6.7 Å.  (D) bR crystals grown in 
scale-up diffraction devices were harvested using 15% PEG 1500 as a cryoprotectant and 
diffracted to 16 Å. 
 
A point of concern is that although this method is highly successful at generating diffraction-
quality crystals, the diffraction resolution has not been high enough to solve the structures.  
In contrast, the PSI has been quite successful in transitioning from diffraction-quality crystals 
to solved structures.  Reasons for this discrepancy could include the inherent crystallization 
difficulty of the targets that were attempted, quality control on the protein production side, 
and a lack of target optimization by the systematic truncation of floppy subunits.  
Additionally, further optimization of the crystal growth conditions using tools such as small 
molecule additive screening or temperature control could improve the diffraction resolution 
of the crystals.  The crystal optimization efforts were directly proportional to the limited 
amount of material provided for each of the targets. 
 
Our success rates of 75% for crystallization and 33% overall rate of producing diffraction-
quality crystals from purified protein are roughly double those of the PSI, which are 38% and 
18%, respectively (http://targetdb.pdb.org/statistics/TargetStatistics.html).  One must, 
however, also take into account the relatively small sample size in the present survey (N = 
12) compared to the large number (N ~ 10,000) tested by the PSI, which leads to a lower 
statistical significance in our observed rates.  To mitigate this effect protein targets were 
selected that are well above average in their crystallization difficulty; the vast majority of our 
targets failed conventional crystallization attempts.  The size of the present data set 
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notwithstanding, the evidence presented is strong enough to suggest that microfluidic 
crystallization tools should become incorporated in large-scale structural genomics efforts. 
 
In conclusion, the rational phase-diagram-based crystallization strategy presented in this 
paper was successfully used to crystallize diverse and challenging proteins.  The use of 
solubility information to design customized crystallization screens doubled the crystallization 
success rate over traditional screening techniques and increased the production of diffraction-
quality crystals.  Microfluidic devices such as these consume small amounts of protein, are 
inexpensive, and are amenable to use in high throughput crystallization efforts. 
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Chapter 3 
CRYSTAL STRUCTURE OF A HYPERACTIVE ESCHERICHIA COLI 
GLYCEROL KINASE MUTANT GLY230 → ASP OBTAINED USING 
MICROFLUIDIC CRYSTALLIZATION DEVICES 
 
Introduction 
In depth analysis of Escherichia coli metabolism over the past decades has revealed complex, 
tightly regulated metabolic networks that facilitate optimal growth under diverse 
environmental conditions.  A constraints-based in silico model of E. coli metabolism was 
recently developed and used to predict the optimal growth rates of E. coli on various 
substrates (28).  The experimental growth rate for each substrate was determined and E. coli 
grew at the predicted optimal growth rate on all of the substrates with the exception of 
glycerol.  An adaptive evolution study of E. coli growth on glycerol revealed that after 700 
generations E. coli strains evolved to reach the predicted optimal growth rate for glycerol.  
Sequence analysis of the evolved E. coli strains identified ten distinct species, eight of which 
contain mutations in the glycerol kinase gene (29, 30).   
 
Glycerol kinase (GK) is the enzyme responsible for the transfer of the γ-phosphoryl group 
from ATP to glycerol to produce glycerol-3-phosphate and is the rate-limiting step in 
glycerol metabolism (31, 32).  Under physiological conditions GK exists in a dimer-tetramer 
equilibrium where the dimer is active and the tetramer is inactive, although a series of kinetic 
studies suggest an active tetramer may also exist (33–35).  GK dimers exhibit ‘half-of-the-
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sites binding’ for glycerol and ATP substrates, in which one monomer has a high-affinity 
active site and the other has a low-affinity active site (36).  GK is a member of the ATPase 
superfamily and shares a common βββαβαβα tertiary fold and catalytic mechanism with 
actin, hexokinase, and the heat shock protein 70 (37).  GK undergoes a large conformational 
change from an open to a closed form during enzymatic activity similar to actin and 
hexokinase, although the conformational change occurs at a different stage in GK activity 
(38–41).  
 
Allosteric regulation of GK activity is necessary to prevent the accumulation of toxic levels 
of glycolytic intermediates and to promote the preferential use of glucose over glycerol 
(Figure 3.1).  GK activity is regulated by two distinct allosteric effectors; the sugar 
phosphotransferase system (PTS) phosphocarrier protein IIAGlc (42, 43) and the glycolytic 
pathway intermediate fructose 1,6-bisphosphate (FBP) (44).  The PTS protein IIAGlc inhibits 
GK activity in the presence of glucose by binding to a coil and an α-helix on the surface of 
GK and transforming the region into a 310 helix (45, 46).  One IIAGlc molecule is bound per 
GK monomer at a position near the dimer interface and opposite the tetramer interface.   
 
Feedback inhibition by FBP involves the formation and stabilization of an inactive tetrameric 
form of GK.  Two FBP molecules are bound per GK tetramer with one half of the FBP 
binding site contributed by an FBP binding loop in each monomer at the tetramer interface 
(47).  The sequence of the FBP binding loop is similar to a Walker-type nucleotide phosphate 
binding loop (residues 229–236 IGGKGGTR (48); Walker-type motif GxxGxGKT/S).  
Although Walker-type loops in ATP binding proteins are traditionally involved in nucleotide 
 35 
binding, the FBP binding loops bind to the 1- and 6-phosphate moieties of FBP (47).  FBP 
regulation of GK is dependent on tetramer formation and disruption of the GK tetramer 
interface eliminates FBP inhibition (38, 47, 49, 50).   
 
 
 
Figure 3.1: Overview of E. coli metabolism.  GK is involved in glycolysis and fatty acid 
synthesis.  Glucose is the preferred carbon source for the glycolytic pathway, and in the 
presence of glucose GK is repressed by IIAGlc binding and FBP binding.  In the absence of 
glucose, glycerol is utilized and GK is subject to feedback regulation by FBP.   
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Notably, six of the seven GK mutations identified during the above-mentioned adaptive 
evolution experiments occurred at the FBP binding site and the tetramer interface in regions 
associated with FBP regulation.  The mutation that appeared with the greatest frequency was 
located in the FBP binding loop at Gly230→Asp (GKG230D).  Kinetic investigation of 
GKG230D revealed a 12-fold increase in enzyme activity and a 33% decrease in FBP inhibition 
compared to wild-type GK (GKWT) (29).  The crystal structure of GKG230D is presented to 
investigate the increased activity and altered allosteric regulation of this hyperactive glycerol 
kinase mutant.  The crystal structure of GKG230D was obtained using a microfluidic 
crystallization platform and is the first demonstration of in situ structure determination for a 
novel crystallization target.  
 
Experimental Procedures 
 
Protein Preparation.  The Escherichia coli GKG230D protein expression and purification were 
performed as previously described with minor modifications (51, 52) and the protocols are 
outlined in Appendix D.  The purified protein was stored in standard buffer at -80 °C (20 
mM Tris·HCl (pH 7.5), 10 mM glycerol, 1 mM β-mercaptoethanol (βME)).  The activity of 
GKG230D was measured using an ADP-coupled assay (36) and compared to the activity of 
GKWT using commercially available lyophilized E. coli GKWT (Fluka).  GKG230D and GKWT 
activity was on the order of the previously published values (36, 53).  All enzyme standards 
and chemicals for the assay were purchased from Sigma-Aldrich.   
 
Size Exclusion Chromatography—Multi-Angle Laser Light Scattering (SEC-MALLS) Studies.  
A DAWN EOS (Wyatt Technology) equipped with a K5 flow cell and a 30 mW linearly 
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polarized GaAs laser of wavelength 690 nm was used in all experiments. The construction, 
principles and operation of this apparatus were previously described (54, 55).  All 
measurements were made in the in-line flow mode.  Elution buffer (standard buffer ± 1 mM 
FBP) was pumped at 0.5 ml/min through a Shimadzu DGU-14A degasser (Shimadzu Corp.) 
onto a Shodex KW-804 gel filtration column (Shoko America) and 100 ml of 2 mg/ml 
protein was injected into the system for each analysis. GKG230D was purified as described 
above and GKWT was purchased from Fluka.  Protein concentration was determined with an 
Optilab Rex refractive index detector, using a value of 0.185 ml/g for the dn/dc. Light 
scattering data was measured by 12 detectors ranging from 34.8° to 142.5°.  The detector 
responses were normalized by measuring the signal from monomeric bovine serum albumin.  
The temperature of the light scattering unit and the refractometer were maintained at 25 °C 
and the column and all external connections were at ambient temperature.   
 
Solubility Characterization and Crystallization.  A microfluidic formulator device was used 
to characterize the solubility of GKG230D and to generate phase diagrams for crystallization 
experiments.  The solubility screening was performed as previously described with minor 
modifications in the experimental setup (4, 12).  GKG230D was screened with 680 unique 
reagents produced using 17 salt solutions, 5 buffering agents, and 8 precipitating agents (see 
Appendix B for a complete list of the reagents).  GKG230D was used at a stock concentration 
of 30 mg/ml for all solubility and crystallization experiments.  Each reagent was screened at 
six different protein and precipitant concentrations while holding the salt solution and 
buffering agent at a fixed level. Protein aggregation was quantified as previously described 
and reagents that caused protein aggregation above 2 pixel intensity standard deviation units 
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were classified as crystallization reagents.  Phase diagrams were generated for a subset of the 
identified crystallization reagents as previously described (4, 12).  Each phase diagram 
screened GKG230D solubility at 64 different protein and precipitating agent combinations 
(between 5–75% of the stock concentrations) while the salt solution and buffering agent were 
held at a constant concentration.  Positions with protein aggregation above 2 pixel intensity 
standard deviation units were categorized as insoluble and positions with protein aggregation 
below 2 were categorized as soluble. 
 
Initial crystallization experiments were performed using a modified microfluidic free 
interface diffusion screening device as described in Anderson et al. (12).  Crystals formed 
after one week at ambient temperature and the best crystallization condition (0.3 M 
magnesium chloride, 0.1 M Tris·HCl (pH 8.5), and 20% PEG 1500) was transported to 
microfluidic scale-up diffraction devices.  Device fabrication and experimental setup for the 
scale-up diffraction devices were previously described (6).  Crystals appeared in the scale-up 
diffraction devices after one week at ambient temperature.  Sections of the scale-up 
diffraction device surrounding the crystals were removed from the rest of the device and 
flash-frozen for in situ diffraction analysis.  Cryoprotectant (30% ethylene glycol) was 
introduced into the diffraction devices by diffusion one hour before flash-freezing the 
crystals within the diffraction devices.  Vapor diffusion crystallization experiments were 
performed in parallel and crystals appeared after one week at ambient temperature using the 
crystallization condition 0.1 M magnesium chloride, 0.1 M Tris·HCl (pH 8.5), and 10% PEG 
1500.  The crystals were flash-frozen using 30% ethylene glycol as a cryoprotectant. 
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Data Collection and Processing.  Data sets for GKG230D crystals were collected at station 
11.3 of the Stanford Linear Accelerator Center (Stanford University) at an incident 
wavelength of 1.0 Å with a 1° oscillation.  Data sets were collected to 2.0 Å from a crystal 
grown in a scale-up diffraction device and to 3.0 Å from a vapor diffusion crystal for 
comparison.  The data sets were indexed and scaled using DENZO and SCALEPACK and 
the data set from the scale-up diffraction device was used for structure determination (56).    
 
Structural Determination and Refinement.  The phases for the diffraction data were 
determined by molecular replacement using a monomer from the PDB structure 1GLF as a 
search model.  The ‘fastdirect’ method as implemented in CNS (57) was used to search with 
one monomer at a time until eight monomers were placed within the asymmetric unit (asu).  
The asu contained two complete tetrameric species.  Non-crystallographic symmetry (NCS) 
restraints were applied such that corresponding protomers between the two tetramers were 
restrained.  The initial round of minimization and group B factor refinement resulted in a 
starting R/Rfree value of 38.7/42.3.  Simulated annealing did not improve the structure, so 
iterative rounds of manual rebuilding with O (58) and minimization/B factor refinement in 
CNS were used to further the structure refinement.   Rebuilding was focused on addressing 
the hinge motion that created a variety of positions for the second lobe (~ residues 250–500) 
of the different protomers.  Eight glycerol molecules were placed into well-defined electron 
density in each of the active sites.  NCS restraints were removed completely at this point.  
The combined effect of these changes enabled a reduction in the R/Rfree to 26.6/30.5 through 
alternating minimization and grouped B factor refinement.  The addition of 638 water 
molecules further reduced the R/Rfree values to 23.5/27.3.  Several regions of the protein did 
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not have clear electron density and were set to 0 occupancy at this point.  These regions are: 
segment XI, residues 229–234 and 501–509; segment OI residues 229–235; segment ZI 
residues 498–511; segment XII residues 229–235 and 324–327; segment YII residues 229–
235 and 324–327; segment OII residues 229–234 and residue 463; segment ZII residues 229–
235.  The correct orientation of several side chains were established by analyzing likely 
hydrogen bonding patterns (59).  TLS refinement, as implemented in REFMAC (60), was 
used in the final stages.  B factors were reset to 20 before attempting TLS and refined 
immediately following TLS as restrained individual B factors.  The X-ray/geometry weight 
was optimized to 1.0 to yield the final R/Rfree values of 21.0/25.9.  The data collection and 
refinement statistics are presented in Table 3.1. 
 
Domain Motion Analysis.  The analysis was performed with the Hingefind algorithm, as 
implemented in VMD (61).  A partition value of 1.8 Å was used for all measurements. The 
rotation axis defining the two domains in the GKG230D monomers was essentially identical to 
that found by Bystrom et al. (38).  Root-mean-square deviation (rmsd) values were calculated 
by superpositioning the Cα atoms of residues 2–499 from one monomer onto the second 
monomer. 
 
Results 
Microfluidic Crystallization Strategy for GKG230D.  The microfluidics-based crystallization 
platform for GKG230D involved a suite of microfluidic devices that characterized the solubility 
trends of GKG230D to create a rational crystallization screen, performed hundreds of parallel 
free interface diffusion crystallization experiments, transported initial crystal hits into larger 
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scale free interface diffusion experiments, and allowed for in situ data collection from 
diffraction-quality crystals.  The microfluidic crystallization platform enabled nanoliter 
volume solubility characterization and crystallization experiments and eliminated the 
necessity of crystal harvesting before data collection.   
 
The crystallization scheme began with a comprehensive characterization of GKG230D 
solubility using a microfluidic formulator device (10).  GKG230D was systematically screened 
against 680 reagents with distinct salt, buffer, and precipitant components and reagents that 
caused protein aggregation were classified as potential crystallization reagents (Figure 3.2).  
Protein phase behavior was broadly screened in response to each reagent by measuring 
GKG230D solubility at six positions on the phase diagrams.  The solubility characterization of 
GKG230D included a total of 4080 solubility experiments and 28% of the reagents were 
identified as potential crystallization reagents.  GKG230D aggregation occurred with the 
highest frequency for reagents that contained one of the following components: magnesium 
sulfate salt, sodium phosphate salt, citric acid (pH 3.5) buffer, and PEG 20000 precipitant.  
Following the broad solubility characterization, complete phase diagrams were generated for 
GKG230D with a subset of the identified crystallization reagents (Figure 3.3).  Phase diagrams 
outline the solubility regimes of a protein in combination with a reagent and are used to 
design crystallization conditions that target the solubility boundary of a protein.  Each 
complete phase diagram measured GKG230D solubility at 64 different positions and protein 
aggregation was used to map the insoluble region of the phase diagram.  The identified 
crystallization reagents and the phase behavior information were incorporated into a 
customized crystallization screen for GKG230D.   
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Figure 3.2: Solubility screening results for GKG230D.  The reagents are displayed on separate 
lines according to buffer composition, and each line is divided by precipitant composition 
and subdivided by salt composition.  The crystallization reagent used for structure 
determination is highlighted with an asterisk.  
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Figure 3.3: Complete phase diagrams for GKG230D.  (A) Reagent 0.2 M magnesium chloride, 
0.1 M Tris·HCl (pH 8.5), and PEG 1500.  (B) Reagent 0.2 M magnesium sulfate, 0.1 M 
Hepes pH 7.5.  (C) Reagent 0.2 M magnesium acetate, 0.1 M Tris·HCl (pH 8.5), and PEG 
300.  (D) Reagent 0.2 M magnesium acetate, 0.1 M citric acid (pH 4.5), and PEG 300.  Blue 
circles represent soluble positions and yellow circles represent insoluble positions.   
 
The crystallization screen for GKG230D was implemented using microfluidic free interface 
diffusion screening devices and 16% of the reagents produced crystals (4, 12).  Crystal hits 
were observed most frequently for crystallization conditions with one of the following 
components: potassium acetate salt, N-Tris(hydroxymethyl)methyl-3-aminopropanesulfonic 
acid (TAPS) (pH 9.5) buffer, and PEG 1500 precipitant.  Optimization of the best initial 
crystallization condition improved crystal size and morphology and produced rhombohedral 
crystals of dimensions 200 x 150 x 50 µm (Figure 3.4A).  The crystallization condition was 
transported to a microfluidic scale-up diffraction device (6) to produce rhombohedral crystals 
of dimensions 500 x 200 x 100 µm (Figure 3.4B). The scale-up diffraction device was 
designed to produce large crystals encapsulated within a thin layer of elastomeric material to 
allow for diffraction analysis of the crystals directly through the device.  Once crystals 
appeared in the scale-up diffraction device, a small section of the device surrounding the 
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crystal was cut out and extracted from the rest of the device.  The extracted section of the 
device formed a thin disk that was mounted onto a customized crystal cap, placed directly 
onto the goniometer head, and data was collected from the crystal through the device. The 
crystal in Figure 3.4B was used for in situ data collection through the scale-up diffraction 
device and diffracted to 2.0 Å (Figure 3.5).  The structure of GKG230D was solved using 
molecular replacement and the statistics for the refined model are reported in Table 3.1.  The 
entire process from the solubility characterization to the production of diffraction-quality 
crystals required only 31 µl of sample, corresponding to less than 1 mg of GKG230D.  
 
 
 
Figure 3.4: Crystallization results for GKG230D.  (A) Crystal plates in a free interface 
diffusion device.  (B) Rhombohedral crystal in a scale-up diffraction device.  The crystal was 
grown with the reagent 0.3 M magnesium chloride, 0.1 M Tris·HCl (pH 8.5), and 20% PEG 
1500. The scale bars represent 100 µm. 
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Figure 3.5: In situ diffraction analysis of crystals.  GKG230D crystallized in space group P21 
with a unit cell of a = 91.1 Å, b = 114.3 Å, c = 212.6 Å, and β = 91.1º, and a mosaicity of 
0.265.  The faint powder ring around 7 Å is due to X-ray scattering off of the elastomeric 
material of the scale-up diffraction device.   
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(62) 
 
Structural Overview.  GKG230D crystallized in space group P21 with two tetramers of 222 
point symmetry in the asu.  The monomers of tetramers I and II are designated OI, XI, YI, ZI, 
and OII, XII, YII, ZII, respectively, following the previously established GK notation (Figure 
Table 3.1: Data collection and refinement statistics for GKG230D 
Data collection   
   Wavelength (Å )  1 . 0  
   Space group  P21 
   Cell dimensions  
      a (Å) 91.1  
      b (Å) 114.3  
      c (Å) 212.6  
       (° )  91.1  
   Resolutiona (Å) 50-2.0 (2.1-2.0) 
   Unique observationsa 250186 (21731) 
   Redundancya 5.9 (3.4) 
   Completenessa 84.0 (73.2) 
   Mosiacity 0.265  
   I/ (I) a 36.8 (6.6) 
   Rsymb 5.9 (22.5) 
  
Refinement  
   Resolution (Å) 20-2.0 
   No. of reflections 221751 
   No. of refined protein atoms  31752  
   No. of refined solvent atoms 6 3 8  
   No. of glycerol molecul e s  8  
   Rcrystc 21.0  
   Rfreed 25.9  
   Average B-factor (Å2) 21.2  
   Bond length rmsd (Å) 0.018  
   Angle rmsd (° )  1.74  
   Ramachandran plot (% in most favored/        
      allowed/generous/disallowed regionse) 
90.7/8.8/0.3/0.2 
  a Numbers in parenthesis refer to the highest resolution shell.  b Rsym = ijj|Ii(j) - ‹I(j)›| / 
ijIi(j), where Ii(j) is the intensity of the i-th observation of reflection j, I(j) is the weighted 
mean of all meas urements of j.  c Rcryst = j|Fo(j) – Fc(j)|/ j|Fo(j)|, where Fo and Fc are the 
observed and calculated structure factors.   d Rfree = Rcryst calculated by using 10% of the 
reflection data chosen randomly and omitted fr om the start of refinement (62).       e The                       
residues in the disallowed regions were found in the active site interacting with glycerol. 
 
 47 
3.6). The tertiary structure of tetramers I and II mimics the tetramer geometry seen in an 
earlier structure of GK that is postulated to be the physiologically relevant tetrameric form of 
the protein (46).  The O-Y and X-Z monomer interfaces are identical to the functional dimer 
interface seen in GKWT and indicate the O-Y and X-Z monomers also form the functional 
dimer in GKG230D.  Each dimer has one monomer in the closed conformation and one 
monomer in the open conformation, similar to the putative active conformation of GK seen 
in the presence of glycerol and ATP analogs (38).  The FBP binding loops, located at the O-
X and Y-Z tetramer interfaces, are ordered at the YI-ZI tetramer interface in GKG230D and 
differ significantly from the GKWT FBP binding loops.  Monomer domain organization is 
identical to GKWT and has previously been described (45).  All monomers in the asu have a 
glycerol molecule bound at the cleft of the active site.     
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Figure 3.6: Tetramer structure of GKG230D.  GKG230D tetramer I is shown with the OI, XI, YI, 
and ZI monomers colored green, yellow, blue, and pink, respectively.  The XI and YI 
monomers are in the closed conformation, the OI monomer is in the open conformation, and 
the ZI monomer is in the ‘very open’ conformation.  The FBP binding sites are located at the 
top and the bottom of the tetramer in the OI-XI and YI-ZI interface loops.  The mutation 
GKG230D is circled and shown in orange using stick representation at the YI-ZI tetramer 
interface.  The IIAGlc binding sites are located at a 310 helix on each monomer near the dimer 
interface.  Glycerol is shown in a space-filling representation and indicates the location of the 
active site and the base of the hinge region in each monomer.  All structural images were 
prepared with PyMOL (63). 
 
The FBP Binding Loops.  The G230D mutation in the FBP binding loops (residues 229–236) 
is ordered at the YI-ZI tetramer interface in the GKG230D structure.  The average B factor for 
the YI-ZI FBP binding loops is 21.1 Å2, comparable to the average B factor of 21.2 Å2 for the 
overall structure.  Large conformational changes are evident between the GKG230D and GKWT 
FBP binding loops; the Y-Z loops of GKWT superposition onto the YI-ZI loops of GKG230D 
(residues 225–240) with a Cα rmsd of 2.6 Å (Figure 3.7). In GK
WT, the main chain loop 
conformations and the side chain positions are identical in monomers Y and Z, creating a 
symmetrical FBP binding site at the tetramer interface.  In GKG230D, the YI and ZI FBP 
binding loops have unique main chain conformations in each monomer and disrupt FBP 
binding by eliminating the symmetrical binding pocket for FBP at the tetramer interface.   
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The wild-type FBP binding loop conformation in GKWT is stabilized through intramolecular 
and intermolecular loop interactions.  The intramolecular loop interactions include hydrogen 
bond interactions between Oδ1 of Asn228 and the backbone amide of Gly230, and between 
the backbone oxygen of Thr235 and Nε of Arg236 (46).  Intermolecular loop hydrogen bond 
interactions also occur across the tetramer interface between Nδ2 of Asn228 and the backbone 
oxygen of Gly231, and between the backbone oxygen of Asn228 and the backbone amide of 
Gly231 in both monomers (46). 
 
 
 
Figure 3.7: Comparison of the FBP binding loop conformations in GKG230D and GKWT.  
Residues 225 to 240 of the Y-Z FBP binding site in GKWT (PDB entry 1GLF) are 
superpositioned onto the YI-ZI FBP binding site in GKG230D. 
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Intramolecular hydrogen bonding networks in the GKG230D FBP binding loops replace the 
wild-type loop interactions and hold the YI and ZI loops in two main chain conformations 
that are significantly different than in GKWT (Figure 3.8A).  In the YI monomer there are two 
hydrogen bond interactions between Oδ2 of Asp230 and the backbone amide of Thr235, and 
between the backbone oxygen of Gly231 and the backbone amide of Gly234.  In the ZI 
monomer there are two hydrogen bond interactions between Oδ1 of Asn228 and the backbone 
amide of Asp230, and between the backbone oxygen of Gly231 and the backbone amide of 
Gly234.  A simplified view of the GKWT FBP binding loops is presented for comparison with 
the GKG230D intramolecular loop interactions (Figure 3.8B).  Notably, the backbone oxygen 
atoms of Gly231 in GKWT are involved in intermolecular loop interactions, whereas the 
backbone oxygen atoms of Gly231 in GKG230D are utilized in intramolecular loop 
interactions. 
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Figure 3.8: Altered FBP binding loop conformations in GKG230D. (A) Intramolecular 
hydrogen bonding networks in the GKG230D FBP binding loops.  The YI monomer has two 
hydrogen bond interactions between Asp230 and Thr235, and between Gly231 and Gly234.  
The ZI monomer has two hydrogen bond interactions between Asn228 and Asp230, and 
between Gly231 and Gly234.  The YI and ZI monomers of GKG230D are blue and pink, 
respectively. (B) FBP binding loop conformation in GKWT at the Y-Z tetramer interface.  
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Note that GKWT is shown as it appears when aligned to the GKG230D FBP binding loops as 
displayed in (A).  
 
The FBP Binding Site.  In GKWT, residues Gly234 and Arg236 from each monomer are 
located at the tetramer interface and are required for FBP binding.  Five interactions between 
GKWT residues Gly234 and Arg236 and the phosphate moieties of FBP occur in the wild-
type regulatory binding site (47).  The majority of the interactions position the 6-phosphate 
of FBP at a central location between the two FBP binding loops (Figure 3.9A). Specifically, 
Nη1 of Arg236 in monomer Y interacts with the 6-phosphate of FBP in monomer Y, and Nη2 
of Arg236 in monomer Z interacts with the 6-phosphate of FBP.  The 6-phosphate of FBP is 
also bound by interactions with the backbone amide of Gly234 in monomers Y and Z.  
Furthermore, Nη2 of Arg236 in monomer Y interacts with the 1-phosphate of FBP and serves 
to bridge both phosphate groups of FBP.   
 
The appearance of Asp230 in the FBP binding site of GKG230D repositions the surrounding 
residues and eliminates the wild-type FBP binding site (Figure 3.9B).  The Cα of Asp230 is 
shifted from the wild-type Cα of Gly230 by 4.3 Å in the YI monomer of GK
G230D.  In 
addition, the Cα  of Lys232 in the ZI monomer is shifted by 10.3 Å from the wild-type 
position and appears at the tetramer interface in GKG230D.  To accommodate Asp230 and 
Lys232 in the FBP binding site, the FBP binding residues Gly234 and Arg236 are shifted 
away from their wild-type FBP binding positions in each of the monomers.  The Cα of 
Gly234 is shifted by 3.3 Å in the ZI monomer and the Nε of Arg236 is shifted by 9.7 Å in the 
YI monomer of GKG230D.  The repositioning of the FBP binding residues Gly234 and Arg236 
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to the outside of the FBP binding site could explain why a decrease in FBP inhibition is 
observed for GKG230D. 
 
 
 
Figure 3.9: Altered FBP binding site in GKG230D.  (A) FBP binding mechanism in GKWT at 
the Y-Z tetramer interface (PDB entry 1BO5).  FBP is positioned between the Y and Z 
monomers by a network of interactions involving Gly234 and Arg236.  FBP is shown in stick 
representation with the 1-phosphate at the bottom and the 6-phosphate at the top of the 
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image.  (B) The YI-ZI tetramer interface of GKG230D. The residues Asp230 of the YI 
monomer and Lys232 of the ZI monomer are positioned at the tetramer interface in GKG230D 
and disrupt the wild-type FBP binding site.  Note that the Arg236 side chains are shifted 
away from the FBP binding site in both monomers.  
 
The Oligomeric State of GKG230D.  To further explore the decreased FBP inhibition and 
increased activity of GKG230D, light scattering was used to compare the oligomeric states of 
GKG230D and GKWT in the presence and the absence of FBP.  In the absence of FBP, the 
GKG230D sample contained a principal dimer peak with a molecular weight of 113 ± 1 kDa 
and a secondary tetramer peak of 227 ± 16 kDa that was ~ 2% (estimated mass) of the 
principal peak (Figure 3.10).  Under the same conditions, the GKWT sample had a principal 
dimer peak with a molecular weight of 177 ± 1 kDa and a secondary peak of 391 ± 4 kDa 
that comprised ~ 9% (estimated mass) of the total sample.  The GKWT dimer peak eluted ~ 
0.3 ml later than the GKG230D dimer peak and the GKWT secondary peak was more 
predominant than in GKG230D.  The secondary peak of GKWT likely represents a tetramer 
species mixed in with some higher molecular weight species, as indicated by the sharp rise in 
the molecular weight versus volume plot.   The later elution time for the GKWT dimer peak is 
indicative of a dynamic dimer-tetramer species, in contrast to the predominantly dimeric 
species in the GKG230D sample. 
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Figure 3.10: Light scattering results in the absence of FBP.  GKG230D is shown in green and 
exists primarily as dimers with a very slight amount of tetramers in a ~ 140:1 molar ratio. 
GKWT is shown in blue and exists as a mixture of dimers and tetramers in a ~ 10:1 molar 
ratio.  The molecular weight of each species was determined on a gel filtration column using 
a light scattering setup as described in the Experimental Procedures section.  The thin 
continuous line represents the signal from the right angle scattered light and is similar to the 
UV trace usually presented for protein chromatography.  It should be noted that the scattered 
light is proportional to the square of the molecular weight, so heavier species are 
disproportionately represented on the plot.  The heavier discontinuous lines plot the 
molecular weight determinations of the protein eluting from the column at that particular 
time.   
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Figure 3.11: Light scattering results in the presence of FBP.  GKG230D remained a primarily 
dimeric species while GKWT was primarily tetrameric and contained no dimeric species.  The 
addition of FBP to the elution buffer also caused a certain degree of nonhomogenous 
aggregation for both GKG230D and GKWT, forming species with molecular weights ranging 
from ~ 400 to greater than 1000 kDa.  Note that the GKG230D dimer peak of was eluted ~ 0.7 
ml later and the GKWT tetramer peak was eluted ~ 1 ml later than the corresponding peaks 
observed in the absence of FBP. 
 
In the presence of FBP, the GKG230D sample had a principal dimer peak with a molecular 
weight of 127 ± 3 kDa and an aggregate peak with ~ 1/4th the mass that contained species 
ranging from 200–800 kDa (Figure 3.11).  The GKWT sample eluted as two peaks in the 
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presence of FBP:  one large aggregate peak just after the dead volume and a second peak that 
did not completely resolve from the aggregation peak.  The aggregate peak contained species 
in excess of 1 Mda.  The second peak had a molecular weight of 328 ± 10 kDa and is similar 
to the tetramer + aggregate peak observed in the absence of FBP.  The addition of FBP to the 
elution buffer appeared to create a certain degree of nonhomogenous aggregation for both of 
the samples.  Despite the aggregation, the GKG230D sample was primarily dimeric, whereas the 
GKWT dimeric species was completely eliminated in the presence of FBP. 
 
The IIAGlc Binding Site.  The IIAGlc binding site adopts the IIAGlc-free conformation seen in 
GKWT in all of the GKG230D monomers with the exception of the OI monomer.  In the absence 
of IIAGlc, residues 473 to 475 have a random coil conformation and residues 476 to 501 form 
the C-terminal a-helix.  In the presence of IIAGlc, residues 473 to 478 are shifted into a 310 
helix and the C-terminal a-helix begins at residue 479 (46).  A crystal contact at Arg402 in 
the OI monomer, supplied by an XI symmetry operator, alters the conformation of OI at the 
IIAGlc binding site to form the 310 helix seen when IIAGlc is present.  The crystal contact at 
Arg402 appears to be inducing the structural rearrangements that occur upon IIAGlc binding.  
 
Changes in Quaternary Structure.  The quaternary structure of GKG230D is similar to that seen 
in GKWT.  The functional dimer interfaces of OI-YI, XI-ZI, OII-YII, and XII-ZII are identical to 
the O-Y and X-Z interfaces of GKWT.  GKG230D tetramers I and II have an almost identical 
quaternary structure, verified by the low 2.0 Å Cα rmsd between the tetramers.  The GK
WT 
tetramer superpositions onto GKG230D tetramers I and II with a Ca rmsd of 3.6 and 3.3 Å, 
respectively.  The primary deviations in the quaternary structure of GKG230D and GKWT arise 
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from changes at the tetramer interface as a result of the G230D mutation at the FBP binding 
site.  It should be noted that while GKG230D crystallized as a tetramer, the light scattering 
analysis demonstrated that GKG230D exists primarily as a dimer (Figure 3.10).  The GKG230D 
structure is not the first example of a GK mutant crystallizing as a tetramer when it was 
shown to exist as a dimer in solution (38, 46). 
 
Domain Motion.  The eight monomers in the glycerol-bound GKG230D structure 
(GKG230D·glyc) exhibit a range of open and closed conformations.  The XI and YI monomers 
in GKG230D·glyc have a main chain conformation identical to the closed conformation of 
GKWT and the OI and OII monomers have a main chain conformation identical to the open 
conformation previously seen in the structure of a GK mutant with both glycerol and the non-
hydrolyzable ATP analog phosphodifluoromethylphosphonic acid-adenylate ester 
bound (GKS58W·glyc·ATF) (38).   The XII and YII monomers exist in an intermediate 
conformation between the closed and open conformation and the ZI and ZII monomers adopt 
a more open (‘very open’) conformation than is seen in the previously reported open 
conformation.   
 
Domain motion analysis of the GKS58W·glyc·ATF structure revealed a difference of ~ 6° 
between the open and closed form of the GK monomers.  The GKG230D·glyc structure 
exhibited a larger difference between the open and closed forms, with rotations between 
monomer domains I and II in the range of 10 to 18°.     The larger difference observed for the 
GKG230D·glyc open versus closed state is more in line with the ~ 12° rotation observed for the 
yeast hexokinase structure (40).  The motion in the yeast hexokinase structure was, however, 
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attributable to the binding of glucose.  The motion in the GKG230D·glyc structure cannot be 
attributed to the binding of glycerol since the large domain motion occurred with glycerol-
bound to all of the individual protomers.  Thus it appears that unlike hexokinase, the binding 
of glycerol alone to glycerol kinase does not influence the open versus closed state of the 
molecule.   
 
In contrast to the wide range of conformations observed for the binary complex 
GKG230D·glyc, the structure representing the ternary complex GKS58W·glyc·ATF was observed 
to exist within a rather narrow range of domain orientations. Apparently, glycerol kinase 
does not adopt a catalytically competent conformation until both glycerol and nucleotide are 
bound within the active site.  A comparison between the closed form, as represented by the Y 
protomer from GKS58W·glyc·ATF, and the open form as represented by the either the OII or 
ZII protomers from GKG230D·glyc, indicates that there is a ~ 14° rigid body rotation that 
occurs upon nucleotide binding (Table 3.2).  This is comparable to the value observed 
between the open and closed state of yeast hexokinase structure, suggesting that nucleotide 
triphosphate binding is the determining factor in creating the ‘closed’ state of the molecule. 
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(38) 
 
Discussion 
Use of the microfluidic crystallization platform allowed us to determine the high-resolution 
structure of GKG230D using less than 1 mg of protein, significantly less than is required using 
traditional crystallization techniques.  The solubility screening and phase diagram 
measurements consumed ~ 200 µg of protein, the crystal screening and optimization 
consumed ~ 250 µg, and the crystal scale-up consumed ~ 450 µg.  Vapor diffusion 
crystallization experiments with the same crystallization reagent were performed in parallel 
to compare the diffraction limits of crystals grown in the scale-up diffraction devices to 
crystals grown in traditional formats.  The vapor diffusion crystallization experiments 
produced rhombohedral crystals of dimensions 1000 x 500 x 500 µm that diffracted to 3.0 Å 
(with unit cell a = 91.3 Å, b = 102.9 Å, c = 222.6 Å, β = 90.6° and a mosaicity of 0.636) in 
the same space group as the diffraction device crystals.  The vapor diffusion crystals were not 
used for structure determination due to the higher quality of the crystals grown in the scale-
Table 3.2: Domain rotation for GK
G230D
 
Pair  Rotation Angl e   RMSD (Å) 
YI-OI 15.5   1.6 
XI-ZI 18.0   1.8 
YII-OII 11.3   1.0 
XII-ZII 10.0   1.5 
BWFa - YI
b  n.d.  0.5 
BWF - XII
c  7.2  0.9 
BWF - OII 14.7   1.5 
BWF - ZII 14.3   1.5 
  Used Hingefind algorithm to determine effective motion of domains.    Used a partition 
value of 1.8 Å with the VMD implementation.  Automatically determined domains were 
essentially identical to previous analysis (38).    a BWF monomer Y was used for all 
calculations.  b BWF – YI: no difference (n.d.) between BWF and YI protomer.  
c Rotation 
axis for XII is not the same as the rotation axis for OII and ZII.   
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up diffraction devices.  The higher diffraction resolution (2.0 Å) and lower mosaicity (0.265) 
of the crystals grown in the microfluidic devices can be attributed two factors: the crystal 
growth kinetics of the free interface diffusion crystallization experiments and the avoidance 
of crystal damage, a corollary of crystal harvesting, by in situ data collection from the 
diffraction devices.   
 
GKG230D provides the first structural overview of a GK variant with a mutation in the FBP 
binding site and is the first glycerol kinase structure where the FBP binding loops are ordered 
in the absence of a bound FBP or buffer molecule.  GKG230D contains an altered interaction 
network at the tetramer interface that replaces the wild-type FBP binding site.  Most notably, 
the FBP binding loops in GKG230D adopt a conformation different from what is observed in 
the wild-type enzyme.  The GKG230D FBP binding loop conformations are supported through 
a series of intramolecular hydrogen bond interactions in each of the FBP binding loops.   
Additionally, residues Asp230 and Lys232 are found at the tetramer interface in GKG230D 
whereas the wild-type FBP binding residues Gly234 and Arg236 are directed away from the 
FBP binding site.  The structural changes at the FBP binding site eliminate the wild-type FBP 
binding pocket at the tetramer interface and as a result decrease FBP inhibition in GKG230D. 
 
The existence of an active dimer form and an inactive tetramer form of GKWT shows an 
inherent link between the oligomeric state of the protein and its activity.  Since the crystal 
structure did not elucidate a reasonable explanation for the enhanced enzymatic activity 
observed for GKG230D, light scattering studies were used to probe the oligomeric state of the 
protein.  The light scattering results showed that in the absence of FBP, GKG230D exists 
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primarily as a dimer with only a trace amount of tetramer species while GKWT exists as a 
dynamic mixture of dimers and tetramers.  The dimers observed for GKWT disappeared upon 
the addition of FBP whereas the GKG230D dimer population was essentially unaffected.  Since 
GKWT FBP inhibition is dependent upon tetramer formation, the absence of a GKG230D 
tetramer species in the presence of FBP is consistent with the decreased FBP inhibition of 
GKG230D.  Furthermore, the higher proportion of GKG230D dimer species in the absence of 
FBP and the resistance of GKG230D dimers to tetramer formation in the presence of FBP 
suggest the primarily dimeric state of the enzyme is responsible for the increased activity of 
GKG230D.  Given the light scattering results, the GKG230D tetramer in the crystal structure is 
probably the result of crystal packing energetics and most likely reflects one of potentially 
multiple dimer-dimer interactions that occur.   
 
It should be noted that the functional implications of the mutation can not be completely 
established based on the ordered YI-ZI FBP binding site given the appearance of disordered 
binding sites in the structure.  The light scattering results confirmed GKG230D is primarily 
dimeric in solution and suggest GKG230D dimers form fleeting dimer-dimer interactions in 
solution that are unlikely to persist on a long timescale.  Given the transient nature of the 
dimer-dimer interactions in solution, the ordered tetramer interface most likely depicts only 
one of many dimer-dimer interactions that occur at the FBP binding site of GKG230D in 
solution. The general structural rearrangements in the GKG230D YI-ZI FBP binding loops 
reveal two ways in which the FBP binding site is altered: novel main chain loop 
conformations that disrupt the wild-type FBP binding pocket, and the repositioning of 
residues responsible for FBP binding away from the FBP binding site.  Both types of 
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structural rearrangements seen in the YI-ZI FBP binding loops provide a plausible 
explanation for the altered FBP regulation in GKG230D, and other loop interactions based on 
one or both of these structural alterations could account for other fleeting dimer-dimer 
interactions that occur between GKG230D dimers in solution.  
 
GKG230D also provides the first structural evidence of multiple GK monomer conformations 
in the presence of glycerol and the absence of a nucleotide substrate.  Previous monomer 
domain motion analysis of a GKS58W·glyc·ATF variant identified an open and closed 
conformation for GK monomers in the presence of glycerol and ATF.  The open and closed 
monomer conformations were observed in the GKG230D·glyc structure, and in addition a new 
‘very open’ conformation of the enzyme hypothesized to exist in the absence of a bound 
nucleotide was evident in monomers ZI and ZII.  The multiple GKG230D·glyc monomer 
conformations conclusively demonstrate glycerol binding does not restrict the domain motion 
of GK monomers and confirms nucleotide binding is the determining factor in locking GK 
into the closed form required for enzyme activity. 
 
In conclusion, the crystal structure of GKG230D is the first demonstration of in situ structure 
determination for a novel crystallization target using a microfluidic crystallization platform.  
The GKG230D structure revealed an altered interaction network at the tetramer interface that is 
responsible for disrupting the FBP binding site and decreasing the allosteric regulation of 
GKG230D by FBP.  The oligomeric state of GKG230D was investigated with light scattering and 
showed the increased enzymatic activity is a result of the stable dimeric quaternary state of 
GKG230D.  Lastly, domain motion analysis revealed a wide range of GKG230D monomer 
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conformations in the presence of glycerol and verified glycerol binding is not responsible for 
inducing the conformational change and locking GK into a catalytically active conformation. 
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Chapter 4 
SOLUBILITY CHARACTERIZATION AND CRYSTAL STRUCTURES OF 
ESCHERICHIA COLI GLYCEROL KINASE MUTANTS ASP72 → ALA, 
235LYS-GLY-GLY INSERT, AND MET271 → ILE 
 
Introduction 
The glycerol kinase crystallization experiments were continued using three additional GK 
mutants identified during the adaptive evolution experiments (28–30).  The first GK mutant 
is Asp72 → Ala (GKD72A), and the mutation occurs at the tetramer interface in close 
proximity to the FBP binding site.  The second GK mutant, 235Lys-Gly-Gly (GK235KGG), has 
an insertion of three residues in the FBP binding loops.  The third GK mutant is Met271 → 
Ile (GKM271I), and the mutation is buried within the GK monomer.  Notably, GKM271I is the 
only one of the seven GK mutants from the adaptive evolution experiments with a mutation 
that does not occur near the tetramer interface or the FBP binding site.  The microfluidic 
crystallization platform was used to characterize the solubility properties of each GK mutant, 
to perform free interface diffusion crystallization experiments, and to produce larger format 
crystals for in situ diffraction analysis.  The microfluidic crystallization strategy was 
successfully applied to each of the GK mutants and the structures were determined to 2.3 Å 
for GKD72A, 2.8 Å for GK235KGG, and 2.9 Å for GKM271I.  
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Experimental Procedure 
Protein Preparation. The Escherichia coli GKD72A, GK235KGG, and GKM271I protein 
expression and purification were performed as previously described with minor 
modifications (51, 52) and the protocols are presented in Appendix D.  The GKD72A and 
GK235KGG purified protein was concentrated to 10 mg/ml and the GKM271I purified protein 
was concentrated to 15 mg/ml for crystallization experiments. The purified protein was 
stored in standard buffer at -80 °C (20 mM Tris·HCl (pH 7.5), 10 mM glycerol, 1 mM β-
mercaptoethanol).  The activity of GKD72A, GK235KGG, and GKM271I were previously 
determined using an ADP-coupled assay (30). 
 
Size Exclusion Chromatography—Multi-Angle Laser Light Scattering Studies.  The 
oligomeric state of GKD72A, GK235KGG, and GKM271 was determined as described previously 
(13) (see Chapter 3 Experimental Procedures for details).    Each measurement was made 
using 100 µl of 2 mg/ml protein with elution buffer composed of standard buffer ± 1 mM 
FBP.   
 
Solubility Characterization and Crystallization.  A microfluidic formulator device was used 
to characterize the solubility of GKD72A, GK235KGG, and GKM271I for crystallization 
experiments.  The device fabrication, experimental setup, and solubility screening was 
performed as previously described (10, 13).  Each protein was screened with 765 unique 
reagents produced using 17 salt solutions, 5 buffering agents, and 9 precipitating agents (see 
Appendix B for a complete list of reagents).  Each reagent was screened at six different 
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protein and precipitating agent concentrations to generate broad phase diagrams.  Protein 
samples were used at a stock concentration of 30 mg/ml for all solubility experiments.    
 
Crystallization screening experiments were performed with the identified crystallization 
reagents using microfluidic free interface diffusion screening devices (4, 12).  The successful 
crystallization conditions were transported to microfluidic scale-up diffraction devices (6).  
Cryoprotectant (25–30% ethylene glycol) was introduced into the diffraction devices and 
crystals were frozen within the devices for diffraction analysis as previously described (6, 
12).  
 
Data Collection and Structure Determination.  Data sets for GKD72A, GK235KGG, and GKM271I 
crystals were collected at station 9.1 of the Stanford Linear Accelerator Center (Stanford 
University) at an incident wavelength of 1.0 Å with a 1° oscillation.  The data sets were 
collected to 2.3 Å, 2.8 Å, and 2.9 Å, respectively, from crystals grown in scale-up diffraction 
devices.  The data sets were indexed and scaled using DENZO and SCALEPACK (56).  The 
GKD72A data was further processed with ellipsoidal truncation and anisotropic scaling (64) 
using a F/σ(F) cutoff of 3, resulting in resolution cutoffs of a* = 2.3 Å, b* = 2.8 Å, and c* = 
2.3 Å.  
 
The structures for GKD72A and GK235KGG were determined by molecular replacement using 
GKG230D tetramer I (PDB entry 2P3R) as a search model.  The rigid body refinement method 
as implemented in CCP4 (65) was used to search with eight rigid bodies defined by dividing 
each monomer in the tetramer into two domains (residues 2–249 and residues 250–500).  The 
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starting models each had one tetramer in the asu.  The structures were refined using alternate 
cycles of manual rebuilding with COOT (66) and refinement with REFMAC5 (67).   Four 
glycerol molecules were placed into well-defined electron density in each of the active sites, 
and water molecules were automatically picked using COOT.  Residues 229–235, which 
were missing in the O and X monomers in the 2P3R search model, were built into GKD72A 
using real-space protein model completion software (68).  Three alternate side chain 
conformations were placed into well-defined electron density for GKD72A: monomer O 
residue 271, monomer X residue 147, and monomer Y residue 21.  Regions of the models 
without clear electron density were set to zero occupancy.  The regions set to zero occupancy 
for GKD72A were monomer Y residues 230–233 and monomer Z residues 230–234.  The 
regions set to zero occupancy for GK235KGG were monomer O residues 231–237, monomer X 
residues 230–236, monomer Y residues 232–235, and monomer Z residues 232–236 and 503.   
 
The structure for GKM271I was determined by molecular replacement using GKD72A as a 
search model.  The rigid body refinement as implemented in PHENIX (69) was used to 
search with eight rigid bodies as described above.  The starting model contained one tetramer 
in the asu.  The structure was refined using alternate cycles of manual rebuilding with COOT 
(66) and refinement with REFMAC5 (67).   Four glycerol molecules were placed into well-
defined electron density in each of the active sites.  The following regions of the model did 
not have clear electron density and were set to zero occupancy: monomer O residues 230–
233, 322–327, 346–351, 358–361, 462–464, and 492–500; monomer X residues 231–233, 
324–326, and 500; monomer Y residues 230–233, 323–327, and 493–500; and monomer Z 
 70 
residues 158–159, 230–234, and 498–500.  GKD72A, GK235KGG, and GKM271I data collection 
and refinement statistics are summarized in Table 4.1.    
 
Domain Motion Analysis.  Effective domain motion analysis was determined using the VMD 
implementation of the Hingefind algorithm (61).  A partition value of 1.8 Å was used for all 
measurements.  The rotation axis defining the two domains in the monomers was identical to 
the previously reported rotation axis (38).  The domain rotation angles for GKD72A, 
GK235KGG, and GKM271I were computed between the monomers in each dimer and between 
each monomer and the previously reported closed conformation of GK (PDB entry 1BWF, 
monomer Y) (38). 
 
Results 
Solubility Characterization and Crystallization.  The crystallization strategy for GKD72A, 
GK235KGG and GKM271I began with a complete solubility characterization using 765 unique 
reagents composed of diverse salt solutions, buffering agents, and precipitating agents.  A 
microfluidic formulator device (10) systematically combined nanoliter volumes of GKD72A, 
GK235KGG and GKM271I with each reagent and broadly screened protein solubility across the 
associated phase diagram for a total of 13,770 solubility experiments (Figure 4.1).  Reagents 
that caused protein aggregation at any point on the phase diagrams were identified as 
potential crystallization reagents and the broad phase diagrams were used to create individual 
crystallization screens for GKD72A, GK235KGG and GKM271I.  The GK235KGG sample aggregated 
the most frequently of the three samples; 30% of the reagents screened were identified as 
potential crystallization reagents for GK235KGG.  On the other hand, only 17% of the reagents 
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screened for GKD72A were identified as crystallization reagents.  GKM271I was in between the 
two samples and aggregated in response to 22% of the reagents screened.  For comparison, 
the GKG230D sample described in Chapter 3 aggregated in response to 34% of the 765 
reagents screened for GKD72A, GK235KGG, and GKM271I.   
 
 
 
Figure 4.1: Solubility characterization of GKD72A, GK235KGG, and GKM271I.  The solubility 
screening results are grouped by precipitant composition and subdivided by buffer and salt 
composition, respectively.  A total of 4590 solubility experiments were performed for each 
protein.  The solubility characterization of GKG230D described in Chapter 3 is also included 
for reference.  Pixel intensity standard deviation represents the amount of protein aggregation 
observed in combination with each reagent; reagents that caused protein aggregation above 1 
pixel intensity standard deviation unit were classified as crystallization reagents.   
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Although the GK mutants are identical except for single point mutations, the solubility 
characterization revealed unique solubility trends for each of the four GK mutants.  The 
effect of each of the reagent components on protein solubility for the GK mutants was 
examined (Figure 4.2).  Overall, the precipitating agent had the greatest effect on protein 
solubility and larger precipitating agents with longer PEG polymer chain lengths caused 
higher rates of aggregation (Figure 4.2A).  For GKG230D and GKM271I, aggregation occurred 
most frequently for reagents containing the largest precipitating agent PEG 20000.  For 
GKD72A and GK235KGG, aggregation occurred at the highest rate for reagents containing the 
precipitating agent PEG 8000.  Additionally, the GKG230D sample aggregated at a 
significantly higher rate for the smaller precipitating agents PEG 300, PEG 1500, and PEG 
3350 than the other samples.  One common trend for all of the GK mutants was a low rate of 
aggregation in response to the ionic precipitating agents. 
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Figure 4.2: Solubility trends for GK mutants.  (A) Classification of identified reagents for 
each mutant by the molecular weight of the precipitating agent.  (B) Classification of 
identified reagents by the ionic strength of the reagent.  (C) Classification of the identified 
reagents by the cation component of the salt solution.  (D) Classification of the identified 
reagents by the anion component of the salt solution.  The anions formate, acetate, and 
thiosulfate are abbreviated as For, Ace, and Thio, respectively.  (E) Classification of 
identified reagents by the deviation from the 5.36 pI of glycerol kinase.  For (A–E), the 
percentage of identified reagents is normalized by the number of reagents screened in each 
category. 
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Variations were also seen in the ionic strength and composition of the reagents identified for 
each of the GK mutants.  The GKG230D and GKM271I samples aggregated most frequently for 
reagents with an ionic strength of 0.8, the GK235KGG sample aggregated most often for 
reagents with an ionic strength of 0.7, and the GKD72A sample aggregated most frequently for 
reagents with an ionic strength of 1.2 (Figure 4.2B).  Notably, the GKM271I and GKG230D 
samples aggregated most often for reagents with the same precipitating agent composition 
and for reagents with the same ionic strength.  The cation that occurred most frequently in 
the identified reagents for GKG230D, GK235KGG, and GKM271I was magnesium (Figure 4.2C).  
For GKD72A, the aggregation occurred most often for reagents containing sodium or 
magnesium cations.  The anion that occurred most frequently in the reagents identified for 
GKD72A, GK235KGG, and GKM271I was nitrate (Figure 4.2D).  On the other hand, the GKG230D 
sample aggregated most often for reagents containing phosphate or sulfate anions. 
 
Lastly, the buffering agent composition had contrasting effects on the solubility responses of 
different GK mutants (Figure 4.2E).  The GKD72A and GKM271I samples aggregated most 
often for reagents at the isoelectric point of GK.  Alternatively, the GKG230D and GK235KGG 
samples aggregated most frequently for reagents far away from the pI of GK. The unique 
solubility properties exhibited within a series of four closely related point mutants highlights 
the potential limitations of using a generalized set of crystallization conditions for multiple 
proteins. 
 
Following the solubility characterization, microfluidic free interface diffusion screening 
devices (4, 12) were used to screen the unique crystallization reagents identified for GKD72A, 
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GK235KGG, and GKM271I.  The best crystal hits were optimized using additional free interface 
diffusion screening devices until the crystals were of sufficient quality for larger format 
crystallization experiments (Figure 4.3).  The GKM271I sample had the highest crystallization 
rate and crystallized with 47% of the reagents screened.  The other two GK mutants also had 
high crystallization success rates; GK235KGG produced crystals with 38% of the reagents 
screened, and GKD72A crystallized with 37% of the reagents screened.  These crystallization 
success rates are much higher than the 16% crystallization success rate observed for the 
GKG230D sample. 
 
 
 
Figure 4.3: Crystallization of GKD72A, GK235KGG, and GKM271I.  (A) GKD72A was crystallized 
with the reagent 0.2 M magnesium acetate, 0.1 M Hepes (pH 7.5), and 60% PEG 300.  (B) 
GK235KGG was crystallized with 0.75 M sodium chloride, 0.1 M TAPS (pH 9.5), and 24% 
PEG 3350.  (C) GKM271I was crystallized with 0.2 M magnesium chloride, 0.1 M Tris·HCl 
(pH 8.5), and 30% PEG 5000 MME.  The scale bars represent 100 µm. 
 
Similar to the unique solubility properties of the GK mutants, a distinct set of crystallization 
reagents produced crystals for each of the GK mutants.  The crystallization reagents for each 
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of the GK mutants were compared and the effect of each of the reagent components on 
crystallization was examined (Figure 4.4).  A different precipitating agent produced the 
highest percentage of crystal hits for each of the GK mutants (Figure 4.4A).  For GKM271I the 
smallest polymer precipitating agent, PEG 300, had the highest crystallization rate.  For 
GKD72A and GK235KGG, chemically modified PEG MME precipitating agents had the highest 
crystallization rates.  For GKG230D, the largest percentage of crystal hits was observed with 
the precipitating agent PEG 1500.  Notably, the larger precipitating agents that caused 
protein aggregation most frequently were not the reagents that produced the highest 
percentage of crystal hits.   
 
The ionic strength of the reagents that produced the highest percentage of crystal hits was 
different for each of the GK mutants (Figure 4.4B).  The highest percentage of crystal hits 
appeared for reagents with ionic strengths of 0.4, 0.7, 0.8, and 1.2 for samples GKM271I, 
GKD72A, GKG230D, and GK235KGG, respectively. Notably, the crystallization trends for GKM271I 
favor reagents with a low ionic strength whereas the solubility trends showed protein 
aggregation occurred most frequently for reagents with a high ionic strength.  Two cations 
were implicated in the highest percentage of crystal hits for the GK samples.  Magnesium 
was the most frequent cation for GKD72A and GK235KGG crystallization and potassium 
appeared most often in the GKG230D and GKM271I crystallization reagents (Figure 4.4C).  The 
anion that caused the most crystal hits for GKD72A and GK235KGG was formate (Figure 4.4D).  
For the GKD72A sample, thiosulfate caused the highest percentage of crystal hits.  For the 
GK235KGG sample, nitrate and phosphate caused the highest percentage of crystal hits.  Notice 
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that the same ionic components were identified for the GKD72A and GK235KGG reagents with 
the highest percentage of crystal hits.   
 
 
 
Figure 4.4: Crystallization trends for GK mutants.  (A) Classification of crystal hits by the 
molecular weight of the precipitating agent.  (B) Classification of crystal hits by the ionic 
strength of the reagent.  (C) Classification of crystal hits by the cation component of the salt 
solution.  (D) Classification of crystal hits by the anion component of the salt solution.  (E) 
Classification of crystal hits by the deviation from the 5.36 pI of glycerol kinase.  For (A–E), 
the percentage of crystal hits is normalized by the number of crystallization conditions 
screened in each category. 
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The buffering agent component of the crystallization reagents revealed that reagents with 
buffering agents far away from the pI of GK produce more crystals than reagents near the pI 
(Figure 4.4E).  For GK235KGG and GKM271I, the most crystals were produced using reagents 
with buffering agents three units away from the pI of GK.  For GKD72A and GKG230D, the most 
crystals were produced using reagents with buffering agents four units away from the pI of 
GK.  Notice that the crystallization trends for GKD72A and GKM271I favor reagents far from the 
pI whereas the solubility trends showed protein aggregation occurs most frequently for 
reagents near the pI.   
 
The best crystallization condition for each protein was transported to microfluidic scale-up 
diffraction devices (6).  GK235KGG and GKM271I formed rhombohedral crystals, and GKD72A 
formed rectangular prism crystals in the scale-up diffraction devices (Figure 4.5).  The 
crystals were flash-frozen within the scale-up diffraction device for in situ diffraction 
analysis.  The GKD72A, GK235KGG, and GKM271I crystals diffracted to 2.3 Å, 2.8 Å, and 2.9 Å 
resolution, respectively, and the structures were solved using molecular replacement.  Data 
collection and refinement statistics for each model are presented in Table 4.1. 
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Figure 4.5: Larger format crystals in diffraction devices.  (A) GKD72A rectangular prism 
crystals, (B) GK235KGG rhombohedral crystals, and (C) GKM271I rhombohedral crystals were 
grown in scale-up diffraction devices for in situ data collection.  The scale bars represent 100 
µm. 
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(62) 
 
Table 4.1:  Data collection and refinement statistics 
    GKD72A GK235KGG GKM271I 
Data collection 
   wavelength (Å) 1.0 1.0 1.0 
   space group P212121 P21 P21 
   cell dimensions    
      a (Å) 91.3 90.5 95.2 
      b (Å) 119.6 110.5 97.6 
      c (Å) 211.5 116.7 118.1 
       (° ) 90 92.8 113.0 
   resolutiona (Å) 50-2.3 (2.4-2.3) 50-2.8 (2.9-2.8) 50-2.9 (3.0-2.9) 
   unique observationsa 97883 (9076) 56144(5620) 42813 (4333) 
   redundancya 16.7 (9.9) 12.1 (6.4) 8.6 (5.5) 
   completenessa 85.6 (27.4),f 99.8 (99.7) 97.4 (94.8) 
   I/ (I) a 13.7 (1.6) 17.7 (2.5) 23.1 (1.9) 
   Rsymb 19.1 (96.7)f 14.4 (70.8) 11.0 (76.2) 
    
 Refinement    
   resolution (Å) 20-2.3 20-2.8 20-2.9 
   no. of reflections 80355 53010 40468 
   no. of refined protein atoms 15698 15652 15169 
   no. of refined solvent atoms 470 334 0 
   no. of glycerol molecules 4 4 4 
   Rcrystc 21.1 18.2 22.9 
   Rfreed 29.1 26.5 32.2 
   average B-factor (Å2) 37.0 45.2 62.6 
   bond length rmsd (Å) 0.017 0.015 0.013 
   angle rmsd ( ° ) 1.61 1.55 1.45 
     Ramachandran plot (% in most 
favored/allowed/generous/ 
   disallowed regionse) 
89.7/9.8/0.3/0.2 86.4/13.2/0.2/0.2 83.8 /15.5/0.5/0.2 
   a  Numbers in parenthesis refer to the highest resolution shell.  b  Rsym = ij|Ii(j) - ‹I(j)›| / 
ijIi(j), where Ii(j) is the intensity of the ith observation of reflection j,   I(j) is the weighted   
mean of all measurements of j.  c  Rcryst = j|Fo(j) – Fc(j)|/ j|Fo(j)|, where Fo and Fc are the 
observed and calcu lated structure factors.     d  Rfree = Rcryst calculated by using 5% of the  
reflection data chosen randomly and omitted  from the start of refinement (62).  e  The 
residues in the disallowed regions were found in the active site interacting with glycerol.      f 
The limited completeness and high Rsym values are due to the anisotropic processing of the 
data. 
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Structure Overviews.  GKD72A, GK235KGG, and GKM271I crystallized as tetramers in space 
groups P212121, P21, and P21, respectively, with a glycerol molecule bound in the active site 
of each monomer (Figure 4.6).  Each tetramer is composed of monomers O, X, Y, and Z, 
with the O-Y and X-Z monomers forming the functional dimers.  The domain organization of 
each monomer and the O-Y and X-Z dimer interfaces are equivalent to that seen in GKWT 
(45, 46).   The tetramer interface is formed at the O-X and the Y-Z monomer interfaces.  The 
quaternary structures of GKD72A and GK235KGG are similar to the physiologically relevant 
tetramer geometry of GK where the tetramer is composed of two identical dimers with one 
monomer in the closed conformation and one monomer in the open conformation (46).  The 
GKD72A and GK235KGG X and Y monomers are in the closed conformation and the O and Z 
monomers are in the open conformation.  Alternatively, the GKM271I tetramer has a novel 
quaternary structure where every monomer in the tetramer exists in an open conformation.  
The IIAGlc binding site, located at the C-terminal end of each monomer, retains the IIAGlc-
free conformation (46) in all of the structures with the exception of monomer X in GKM271I.  
In GKM271I, the IIAGlc-bound conformation (45) occurs in monomer X as a result of a crystal 
contact between Glu475 and a monomer X symmetry operator.  The FBP binding loops are 
located at the O-X and Y-Z tetramer interfaces and are ordered at the GKD72A O-X tetramer 
interface. 
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Figure 4.6: Tetramer structures of four GK mutants.  (A) The GKD72A tetramer structure.  
The gold X and Y monomers are in the wild-type closed conformation, and the blue O and Z 
monomers are in a more open conformation than in GKWT.  Ala72 is circled at the tetramer 
interfaces.  (B) The GK235KGG tetramer structure.  The silver X and Y monomers are in the 
closed conformation, and the green O and Z monomers mimic the GKD72A open 
conformation.  The disordered location of the 235Lys-Gly-Gly insert in the FBP binding 
loops is circled at the tetramer interfaces.  (C) The GKM271I tetramer structure.  The pink X 
and Y monomers and the magenta O and Z monomers all display a novel open conformation.  
Met271 is circled in each monomer.  (D) The GKG230D tetramer structure (PDB entry 2P3R) 
described in Chapter 3.  The light blue XI and YI monomers are in the wild-type closed 
conformation, the teal OI monomer is in the wild-type open conformation, and the teal ZI 
monomer is in a more open conformation than in GKWT.  The FBP binding sites and the 
IIAGlc binding sites are highlighted and glycerol is shown in the hinge region of each 
monomer. 
 
GKD72A Tetramer Interface.  The tetramer interface is comprised of an α-helix (residues 49–
67) that packs in an antiparallel manner between the O-X and the Y-Z monomers and the 
FBP binding loops (residues 229–236) that associate to form the FBP binding sites (Figure 
4.7).  Within each monomer, the interface helix and the FBP binding loop are bridged by a 
short α-helix (residues 70–73) that includes the Asp72 → Ala mutation in GKD72A.  The 
helical interface is similar in GKWT and GKD72A, with the Cα backbone of the GK
WT O-X 
interface helices superpositioning on the GKD72A helices with a rmsd of 0.4 Å.  Conversely, 
the absence of Asp72 in the bridging helix of GKD72A creates an open region between the 
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helix and the FBP binding loops and allows for a higher degree of conformational flexibility 
in the FBP binding loops.  The Cα backbone of the O-X FBP binding loops of GK
WT are 
superpositioned on the GKD72A FBP binding loops with an rmsd of 4.0 Å.  
 
 
 
Figure 4.7: Overview of the GKD72A tetramer interfaces.  Residues 48 to 78 and 229 to 236 
of the O-X tetramer interface of GKWT (PDB entry 1GLF) are superpositioned on the O-X 
tetramer interface of GKD72A.  The FBP binding loops are located above the antiparallel α-
helices.  The O and X monomers of GKD72A are blue and gold, respectively, Ala72 is green, 
and the O and X monomers of GKWT are silver.    
 
The GKWT interaction network around Asp72 supports the main chain conformation of the 
bridging helix and positions Asp72 in the direction of the FBP binding loop (Figure 4.8A).  
Two hydrogen-bond interactions occur in GKWT monomer X between the backbone oxygen 
of Ser70 and the backbone amide of Gln73 and between Oγ of Ser70 and Nε2 of Gln73.  The 
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interaction networks in the O and X monomers are equivalent in GKWT.  The presence of the 
Asp72 side chain above the bridging helix prevents residues 232 to 235 of the FBP binding 
loop from coming within close proximity of the bridging helix. 
 
 
 
Figure 4.8: Comparison of the GKD72A and GKWT tetramer interfaces. (A) GKWT hydrogen-
bonding networks near Asp72 at the tetramer interface of monomer X.  There are two 
hydrogen-bond interactions between Ser70 and Gln73.  (B) Hydrogen-bonding networks in 
GKD72A monomer X at the Ala72 mutation site.  The X monomer has two hydrogen-bond 
interactions between Ser70 and Gln73 and one water-mediated interaction between Ser71 
and Lys232.  (C) Hydrogen-bonding networks in the GKD72A monomer O at the Ala72 
mutation site.  The O monomer has two hydrogen-bond interactions between Ser70 and 
Gln73 and one hydrogen-bond interaction between Thr235 and a water molecule.  
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The GKD72A interaction network around Ala72 deviates from the wild-type interaction 
network and also varies between monomers.  The monomer X interaction network involves 
water-mediated contacts between the bridging helix and the FBP binding loop in addition to 
the hydrogen-bond interactions within the bridging helix (Figure 4.8B).  The monomer X 
bridging helix main chain conformation is supported by two hydrogen bond interactions 
between the backbone amide of Ser70 and Oε1 of Gln73 and between the backbone oxygen of 
Ser70 and the backbone amide of Gln73.  The Gln73 side chain is flipped 180° in GKD72A 
and results in a main chain interaction with Ser70 instead of the side chain interaction with 
Ser70 in GKWT.  A water-mediated interaction also occurs in monomer X between Oγ of 
Ser71 and the backbone oxygen of Lys232.  The GKD72A monomer X water-mediated 
interaction is the only interaction observed between the bridging helix and the FBP binding 
loop in either GKD72A or GKWT.  The closest residue in the FBP binding loop in monomer X 
to Ala72 is Lys232, whereas Thr235 is the closest residue to Asp72 in GKWT and to Ala72 in 
monomer O of GKD72A.   
 
In monomer O of GKD72A there are two hydrogen-bond interactions near Ala72 between the 
backbone oxygen of Ser70 and the backbone amide of Gln73 and between the backbone 
oxygen of Ser70 and Oε1 of Gln73 (Figure 4.8C).  A third interaction occurs between Oγ1 of 
Thr235 in the FBP binding loop and a water molecule.  The Gln73 side chain is also flipped 
180° in monomer O of GKD72A compared to GKWT.  The other notable difference in the 
monomer O tetramer interface is the repositioning of Lys232 in the FBP binding loop away 
from the bridging helix; the Cβ of Ala72 and the Cβ of Lys232 are 11.0 Å apart in monomer 
O, compared to 6.4 Å in monomer X and 6.0 Å in GKWT.  Overall, the absence of Asp72 in 
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the bridging helix of GKD72A enables large conformational changes at the tetramer interface 
FBP binding loops. 
 
GKD72A FBP Binding Site.  The FBP binding site in GKD72A consists of two unique FBP 
binding loops with main chain loop conformations unlike the wild-type loop conformations 
(Figure 4.7). The ordered FBP binding site at the O-X tetramer interface in GKD72A has an 
average B factor of 32.9 Å2.  The wild-type FBP binding site is formed by two identical FBP 
binding loops that come together at the tetramer interface to create a symmetrical binding 
pocket for the phosphate groups of FBP.  Alternatively, the GKD72A FBP binding loops are 
dissimilar in each monomer and are not symmetrically positioned at the tetramer interface to 
create the FBP binding site.  
 
FBP molecules bind to the GKWT tetramer interface through a series of interactions with 
Gly234 and Arg236 on each monomer (Figure 4.9A).  Arg236 was previously shown to be 
required for FBP binding and is involved in most of the interactions with FBP (47).  The 6-
phosphate of FBP is centered in the FBP binding site through four interactions with Nη2 of 
Arg236 on monomer O, Nη1 of Arg236 on monomer X, and the backbone amides of Gly234 
on monomers O and X.  The 1-phosphate of FBP has one interaction with Nη2 of Arg236 on 
monomer X.  In addition to the direct interactions with FBP, several intramolecular and 
intermolecular interactions support the symmetrical FBP binding loop conformations in 
GKWT (46).  Specifically, intermolecular loop hydrogen-bond interactions occur between the 
backbone oxygen of Asn228 and the backbone amide of Gly231, and between Nδ2 of Asn228 
and the backbone oxygen of Gly231.  Intramolecular hydrogen-bond interactions occur 
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between Oδ1 of Asn228 and the backbone amide of Gly230, and between the backbone 
oxygen of Thr235 and Nε of Arg236.   
 
The intermolecular loop interactions positioning the GKWT FBP binding loops symmetrically 
across the tetramer interface are missing in GKD72A.  Instead, the GKD72A FBP binding loops 
are held in unique conformations at the tetramer interface through different intramolecular 
interaction networks in each monomer (Figure 4.9B).  One hydrogen-bond interaction exists 
in monomer X between Oδ1 of Asn228 and the backbone amide of Gly230.  In contrast, the 
main chain conformation of monomer O is supported through four hydrogen-bond 
interactions between the backbone oxygen of Asn228 and the backbone amide of Gly230, 
Nδ2 of Asn228 and the backbone oxygen of Lys232, Oδ1 of Asn228 and Nε of Arg236, and the 
backbone oxygen of Gly230 and the backbone amide Lys232.  The asymmetry in the number 
of intramolecular loop interactions between the O and X monomers of GKD72A is consistent 
with the diverging main chain loop conformations in each monomer. 
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Figure 4.9: GKD72A and GKWT FBP binding sites. (A) GKWT FBP binding site with bound 
phosphate molecule.  Gly234 and Arg236 are centered in the symmetrical FBP binding loops 
and position the FBP molecule between the two monomers.  The orange phosphate molecule 
binds in the location of the 6-phosphate group of FBP.  (B) Intramolecular hydrogen-bonding 
networks in the GKD72A FBP binding loops.  The O monomer has four hydrogen-bond 
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interactions between Asn228 and Gly230, Asn228 and Lys232, Asn228 and Arg236, and 
between Gly230 and Lys232.  The X monomer has one hydrogen-bond interaction between 
Asn228 and Gly230.   
 
In GKD72A, residues Gly234 and Arg236 are significantly altered from their wild-type 
positions and are no longer at the center of the tetramer interface.  Arg236 in monomer O is 
involved in an intramolecular loop interaction that shifts Nε of the side chain 4.4 Å away 
from the wild-type position in the FBP binding site and towards the outside of the FBP 
binding loop.  The side chain of Arg236 in monomer X is also directed away from the 
tetramer interface, although this appears to be due in part to a crystal contact with a monomer 
Z symmetry operator.  Furthermore, the Cα of Gly234 in monomer X is 6.4 Å from the GK
WT 
position at the tetramer interface.  One other disparity in the main chain loop conformations 
of GKD72A and GKWT monomer O is the position of Gly233; the Cα of Gly233 is 4.2 Å from 
the GKWT position and appears directly in between the 6-phosphate binding site in GKWT and 
Nη2 of Arg236 that is responsible for FBP binding.  The Cα of Gly233 is 1.7 Å from O1 of the 
6-phosphate molecule and 1.2 Å from Nη2 of Arg236 in GK
WT.  The appearance of Gly233 in 
close proximity of the wild-type 6-phosphate binding site is likely to disrupt FBP binding.  
The combination of conformational changes in the GKD72A FBP binding loops that disrupt 
the FBP binding site and the intramolecular loop interaction networks sustaining the unique 
loop conformations correlates well with the decreased FBP inhibition in GKD72A.   
 
Domain Motion of GK Mutants.  The physiologically active form of GKWT is a dimer with 
one monomer in a closed conformation and one monomer in an open conformation.  The 
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GKWT active form was identified using a Ser58 → Trp dimer mutant with glycerol and ATF 
bound (GKS58W·glyc·ATF) in the active site of each monomer (38).  The GKS58W·glyc·ATF 
structure revealed the catalytically competent form of GKWT has a ~ 6° rotation between 
domains I and II in the closed and open conformations.  A second form of GK appeared in 
the GKG230D structure: the GKG230D·glyc dimers contain a closed conformation and an open 
conformation monomer with domain rotations of 10 to 18° (13).  The increased domain 
motion in the GKG230D·glyc open conformation monomer verified nucleotide triphosphate 
binding is required to achieve the catalytically competent dimeric form of GK.  
 
Another form of GK is evident in the glycerol-bound GK235KGG and GKD72A (GK235KGG·glyc 
and GKD72A·glyc) structures.  The X and Y monomers of GK235KGG·glyc have a main chain 
conformation identical to the closed conformation of GKWT and the O and Z monomers have 
a more open conformation than the GKG230D·glyc open conformation.  The GKD72A·glyc 
monomer conformations are equivalent to the GK235KGG·glyc monomer conformations.  As 
expected, none of the monomers exhibit the wild-type catalytically competent open structure 
of GKS58W·glyc·ATF, since nucleotide triphosphate is not present in the active sites of 
GK235KGG and GKD72A.  The domain II rotation between the closed and open monomers is 18 
to 20° in GK235KGG·glyc and 18 to 19° in GKD72A·glyc (Table 4.2).  The increased domain 
motion in GK235KGG·glyc and GKD72A·glyc reveals a greater degree of conformational 
flexibility in GK monomers in the absence of bound nucleotide triphosphate than was 
previously reported (13). 
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In contrast to both the limited domain motion in GKWT monomers and the considerable 
domain motion in GK235KGG·glyc monomers, every monomer in the glycerol-bound GKM271I 
(GKM271I·glyc) structure has an equivalent conformation with no perceptible domain motion.  
Each GKM271I·glyc monomer exists in an open conformation greater than the GKWT open 
conformation and similar to the GKG230D·glyc open conformation.  A comparison between 
the GKM271I·glyc monomers and the GKWT closed monomer conformation revealed a domain 
rotation of 14 to 17° (Table 4.2).  The GKM271I·glyc structure is the first demonstration of GK 
dimers that do not contain at least one monomer in the closed conformation.  The Met271 → 
Ile mutation in the domain II hinge region of GKM271I appears to prevent the wild-type 
Table 4.2: Domain rotation statistics 
Mutant Pair Rotation Angle RMSD (Å) 
GKD72A Y - O 19.3 0.7 
 X - Z 17.8 0.6 
 1BWFa- Y  n.d.b  
 1BWF - X n.d.  
 1BWF - O 18.6 0.7 
 1BWF - Z 16.8 0.7 
GK235KGG Y - O 17.6 0.8 
 X - Z 19.5 0.8 
 1BWF - Y n.d.  
 1BWF - X n.d.  
 1BWF - O 17.8 0.7 
 1BWF - Z 18.4 0.7 
GKM271I Y - O n.d.  
 X - Z n.d.  
 1BWF - Y 15.1 0.9 
 1BWF - X 15 .2  0.8 
 1BWF - O 16 .9  1.1 
 1BWF - Z 13 .7  1.1 
   Domain rotation was  determined using the Hingefind algorithm.   The automatically 
determined domains for each mutant agreed with the previously determined domains (38).  
a 1BWF monomer Y  was used for all calculations.  b No difference (n.d) in the rotation 
angles of the pair. 
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domain motion in GKM271I·glyc and to obstruct the formation of the GKWT closed 
conformation. 
 
GKM271I Quaternary Structure.  A novel quaternary structure is evident in GKM271I as a result 
of the exclusively open monomer conformation in GKM271I dimers rather than the open and 
closed monomer conformations in GKWT dimers.  GKM271I is the first structure where the 
mutation is buried within the monomer and not on the surface of the monomer at either the 
tetramer interface or the IIAGlc binding site. The Met271 → Ile mutation is located at the 
beginning of GKM271I domain II on a β-strand (residues 269–276) in the middle of a β-sheet 
in the domain II hinge region (Figure 4.10).  Residue 271 is buried at the base of the domain 
II region and a large α-helix (residues 373–399) forms the closest contact with the β-sheet 
containing Ile271. 
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Figure 4.10: Overview of the GKM271I domain II region.  Residues 250 to 290 surrounding 
Met271 in monomer O of GKWT (PDB entry 1GLF) are superpositioned on the 
corresponding residues in monomer Y of GKM271I.  Ile271 is magenta at the base of the 
domain II hinge region, domain II of GKM271I is pink, and domain II of GKWT is silver.   
 
GKWT contains a cluster of Methionine residues at the base of the domain II region with 
Met271 on one end of the cluster (Figure 4.11A).  Met271 and Met273 are situated on the β-
sheet with side chains directed towards the adjacent α-helix, and Met395 is located on the α-
helix between Met271 and Met273 with the side chain pointed towards the β-sheet.  The 
sulfur atoms in the Methionine side chains are loosely centered between the β-sheet and the 
α-helix, forming a line approximately parallel to the secondary structural elements.  
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Additionally, Leu392 on the α-helix in GKWT is positioned away from the β-sheet owing to 
the close proximity of the Met271 side chain.   
 
 
 
Figure 4.11: Comparison of GKM271I and GKWT Methionine network.  (A) GKWT monomer 
O Methionine network near Met271.  Met 271, Met395, and Met273 are aligned between an 
α-helix and β-strand interface and position Leu392 away from Met271.  (B) GKM271I 
monomer Y altered Methionine network near Ile271.  Ile271 is positioned away from Met273 
and Met395, allowing Leu392 to reposition in between Ile271 and Met395.  Note that the 
region surrounding Ile271 is similar in all GKM271I monomers. 
 
In GKM271I, the removal of Met271 from the Methionine cluster enables side chain 
rearrangements and secondary structure shifts at the α-helix and β-sheet interface (Figure 
4.11B). The primary alteration in GKM271I is the repositioning of Leu392 into the region 
previously occupied by Met271.  The Cγ of Leu392 is shifted 2.8 Å towards the β-sheet in 
GKM271I and is only 2.1 Å from the wild-type position of Sδ in Met271.  A 1.6 Å rotation in 
the α-helix at Leu392 is also responsible for directing Leu392 closer to the β-sheet.  The 
repositioning of Leu392 is supported by the relocation of Ile271 away from the center of the 
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α-helix and β-sheet interface; the Cδ1 of Ile271 in GK
M271I is shifted 3.2 Å from Sδ in Met271 
of GKWT.  In contrast to Leu392, Met273 and Met395 are similarly positioned in GKWT and 
GKM271I with the sulfur atoms still loosely centered between the β-sheet and the α-helix.  
Overall, the shift in the α-helix to position Leu392 closer to the β-sheet appears to support 
the GKM271I open monomer conformation, as no other significant structural rearrangements 
occur in GKM271I. 
 
The Oligomeric State of GKD72A, GK235KGG, and GKM271I.  The oligomeric states of GKD72A, 
GK235KGG, and GKM271I in the presence and absence of FBP were established using light 
scattering experiments.  In the absence of FBP, GKD72A, GK235KGG, and GKM271I exist as 
dimers in solution.  In the presence of FBP, GK235KGG and GKM271I exist as dimers in solution 
while GKD72A exists as tetramers in solution.  For comparison, in the absence of FBP, GKWT 
exists primarily as a dimer in solution with a small amount of tetramers detectable, and in the 
presence of FBP, GKWT is transformed completely into tetramers (13). 
 
Discussion 
High-quality crystals were obtained for GKD72A, GK235KGG, and GKM271I using a 
microfluidics-based crystallization strategy.  An initial solubility characterization for the GK 
mutants revealed that each of the GK mutants had unique solubility behavior.  Given the 
single point mutations that differentiate the GK samples from each other, it is interesting that 
the aggregation responses to the same chemicals were so varied for the four samples.  In 
particular, only three residues separate the GKG230D and GK235KGG mutations and both occur 
within the FBP binding loops, and still the solubility trends varied considerably between the 
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samples.  The most surprising result of the solubility characterization was the bimodal effect 
of pH on protein solubility: two of the mutants aggregated most frequently at the GK pI and 
the other two mutants aggregated most often far away from the pI.  This result emphasizes 
the importance of a complete exploration of reagent pH levels for all crystallization samples 
to find the optimal pH level to drive protein aggregation.  The solubility characterization also 
revealed that the ionic composition of the reagent has a relatively minor effect on protein 
solubility and might be left as a secondary parameter in the identification of potential 
crystallization reagents.  The diverse results obtained from a complete solubility 
characterization of closely related protein samples demonstrates the significant effect minor 
changes can make on protein solubility behavior.  Furthermore, these results suggest 
solubility characterization might be a useful precursor to crystallization in order to design 
crystallization experiments guaranteed to target the solubility boundary of the crystallization 
sample.  
 
Crystallization experiments using the unique set of identified reagents for each of the GK 
mutants produced crystal hits for a large percentage of the reagents screened.  The high 
crystallization success rates for each of the GK mutants allowed for multiple crystal 
morphologies to be pursued simultaneously in order to identify the crystal form with the 
highest diffraction limit.  The crystallization experiments also revealed slight deviations 
between the reagents that frequently caused protein aggregation and the reagents that 
promoted crystal formation.  The crystallization results emphasize the importance of 
exploring all potential crystallization reagents for a target in order to ensure the optimal 
crystallization condition is discovered.  Overall, the customized crystallization strategy for 
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each GK mutant resulted in high crystallization rates and also allowed for in situ diffraction 
analysis of the crystals. 
 
GKD72A is the first glycerol kinase structure with a mutation in the short helix bridging the 
tetramer interface and the FBP binding site and establishes the inherent link between the 
bridging helix and the FBP binding loop conformation.  The removal of the bulky side chain 
group of Asp72 that is directed towards the FBP binding site in GKWT creates an open pocket 
of space below the FBP binding loops and enables a greater degree of conformational 
flexibility in the GKD72A FBP binding loops.  As a result, two unique main chain 
conformations appear in the FBP binding loops that are supported through altered 
intramolecular interaction networks that replace the wild-type intramolecular and 
intermolecular FBP loop interaction networks.  The altered intramolecular interactions are 
responsible for repositioning the residues involved in FBP binding away from the tetramer 
interface and holding the FBP binding loops in conformations that directly interfere with the 
wild-type FBP binding pocket in order to decrease the FBP inhibition in GKD72A.  Therefore, 
the appearance of novel FBP binding loop conformations in the GKD72A structure reveals the 
necessity of Asp72 in maintaining the wild-type FBP binding loop conformations and the 
integrity of the FBP binding site.   
 
Notably, light scattering experiments investigating the oligomeric state of GKD72A showed 
GKD72A exists as a dimer in solution in contrast to the tetramer form of the enzyme in the 
crystal structure.  This is not the first example of a tetramer structure resulting from a GK 
dimer solution and is most likely due to the high concentrations of GK required for 
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crystallization.  Thus, the FBP binding loop conformations in the GKD72A structure probably 
represent one of the multiple interactions that occur between dimers in solution.  A second 
round of light scattering experiments confirmed the GKD72A dimers are converted into 
tetramers in the presence of FBP, mimicking the wild-type response to FBP.  The ability of 
GKD72A dimers to form tetramers in the presence of FBP was unexpected due to the 
decreased FBP inhibition of GKD72A compared to GKWT.  Additional structural studies of 
GKD72A in the presence of FBP are needed to reconcile the existence of an inactive FBP-
bound tetramer form of GKD72A given the structural rearrangements in the FBP binding loops 
that disrupt the FBP binding site in the current GKD72A structure. 
 
The decreased FBP inhibition in GK235KGG and GKM271I is more apparent based on the 
resistance of both mutants to tetramer formation in the presence and absence of FBP.  The 
inability of FBP to convert the GK235KGG dimers into tetramers is in agreement with the 
primarily dimeric form of another GK FBP binding site mutant GKG230D in the presence of 
FBP.  The increased length of the FBP binding loops in GK235KGG could enhance the 
flexibility of the FBP binding loops and prevent the formation of an ordered FBP binding 
site, thereby decreasing the FBP inhibition.  The GK235KGG dimers also exhibit a larger 
degree of domain motion in the presence of bound glycerol and in the absence of bound 
nucleotide than has been previously observed for any GK variant.  The increased domain 
motion in the GK235KGG monomers in the absence of bound nucleotide corresponds with the 
earlier hypothesis of nucleotide binding being the rate-limiting step in creating the 
catalytically competent form of GK.  
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A novel quaternary form of glycerol kinase was identified in the GKM271I structure where 
every monomer exists in an open conformation.  The inherent asymmetry of the wild-type 
GK dimers with one closed conformation monomer and one open conformation monomer is 
lost in the GKM271I dimers.  Furthermore, the open conformation exhibited in every GKM271I 
monomer demonstrates a larger degree of domain motion when compared to the GKWT open 
conformation, although the domain motion is less than the GK235KGG open conformation.  
The GKM271I monomers are each held in the open conformation due to the Ile271 mutation in 
the hinge region that obstructs the normal domain motion between domains I and II.  The 
inflexible nature of the GKM271I monomer conformation could also be responsible for 
preventing the GKM271I dimers from forming tetramers in the presence of FBP and thus 
reducing FBP inhibition. 
 
In conclusion, the GKD72A, GK235KGG, and GKM271I crystal structures provide an overview of 
several mutations that evolved in glycerol kinase as a result of the selection pressure of E. 
coli growth on glycerol.  The GKD72A structure revealed novel FBP binding loop 
conformations supported by altered intramolecular interaction networks.  The novel FBP 
binding loops in GKD72A in turn disrupt the wild-type FBP binding site.  The monomers in 
the GK235KGG structure displayed an increased range of monomer conformations compared to 
previous structures.  Also, the resistance of GK235KGG and GKM271I dimers to tetramer 
formation in the presence of FBP explains the decreased FBP inhibition compared to wild-
type GK.  Lastly, a novel quaternary structure consisting exclusively of open conformation 
monomers was revealed in the GKM271I structure.  
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Chapter 5 
MICROFLUIDIC DIALYSIS DEVICE FOR MEMBRANE PROTEIN 
CRYSTALLIZATION  
 
Introduction 
High-resolution structure determination for integral membrane proteins remains a 
challenging task for crystallographers owing to the difficulty of producing well-ordered 
membrane protein crystals.  While approximately 30% of the proteins encoded by an 
organism’s genome are integral membrane proteins (70, 71), less than 2% of the structures in 
the RCSB Protein Data Bank are membrane proteins (72).  Integral membrane proteins are 
involved in several fundamental biological processes including the active transport of ions 
and metabolites across membranes, forming junctions between cells, and are responsible for 
the non-selective permeability of membranes to small molecules.  Integral membrane 
proteins are also of great therapeutic interest for the biotechnology industry and comprise the 
majority of current drug targets (73, 74).  The first three-dimensional membrane protein 
crystals were obtained for bacteriorhodopsin and matrix porin in 1980 (75, 76) and laid the 
foundation for the field of membrane protein crystallography.   
 
The amphiphilic nature of membrane proteins requires the use of amphipathic detergents for 
the isolation, purification, and crystallization of membrane proteins (77, 78).  The 
hydrophobic tails of detergent monomers coalesce around the hydrophobic core of membrane 
proteins to form a micelle belt, replacing the native lipid bilayer and leaving only the 
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hydrophilic regions of the membrane proteins exposed to the aqueous solution.  
Crystallization experiments with protein-detergent micelles can produce either two-
dimensional or three-dimensional crystals (Figure 5.1).  Two-dimensional crystals involve 
hydrophobic interactions between the hydrophobic surfaces of membrane proteins to form 
thin sheet crystals for electron microscopy experiments (79).  Alternatively, three-
dimensional crystals are supported largely through hydrophilic interactions and are used for 
X-ray diffraction experiments (80).  Type I three-dimensional crystals consist of stacked two-
dimensional crystals held together through hydrophilic contacts between membrane proteins 
in different sheets.  Type II three-dimensional crystals involve hydrophilic interactions 
between the polar regions of the membrane proteins and detergent micelle interactions.  The 
type II crystals are similar to soluble protein crystals and most membrane protein structures 
are generated from type II crystals (81). 
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Figure 5.1: Crystallization of protein-detergent micelle solutions.  Protein-detergent micelles 
can form three types of crystals: two-dimensional sheet crystals, type I three-dimensional 
stacked sheet crystals, and type II three-dimensional crystals.  The hydrophobic core of the 
membrane protein is yellow and the hydrophilic ends are red.  The blue detergent monomers 
interact with the hydrophobic region of the protein.  Figure was adapted from (82). 
 
Although protein-detergent micelle solutions can be crystallized, the removal of membrane 
proteins from their native lipid environments may not be the best strategy for membrane 
crystallization.  The lipid bilayer was shown to be critical for maintaining membrane protein 
structure and activity (83, 84), and the physical forces exerted on a protein molecule in a 
detergent micelle are different than in a phospholipid bilayer.  As a result, a number of 
crystallization methods were developed to crystallize membrane proteins in a lipid 
environment that more closely resembles the native membrane.  The in cubo crystallization 
method involves embedding membrane proteins in a three-dimensional lipid cubic phase 
bilayer and adding precipitating agents to promote crystallization (85).  A second method 
entails the formation of three-dimensional crystals by driving vesicle fusion of 
bacteriorhodopsin membranes with small amounts of detergent and precipitating agents (86).  
Lastly, a bicelle crystallization method involves mixing membrane proteins with a lipid-
amphiphile mixture and adding precipitants to form three-dimensional bicelle crystals (81).  
While these methods have been used successfully to determine structures for bacterial 
membrane proteins (87–105), the more general utilization of these methods for challenging 
membrane protein targets has not been realized.  Therefore, a crystallization platform 
enabling the use of a broader range of detergent-solubilized membrane protein samples in 
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lipid crystallization experiments would have great utility for membrane protein 
crystallization. 
 
A microfluidic dialysis device for membrane protein crystallization is presented that was 
designed to perform multiple crystallization experiments in a lipid environment using 
detergent-solubilized membrane protein samples.  The microfluidic device incorporates a 
dialysis platform for the removal of detergent monomers from protein-detergent-lipid 
solutions with a free interface diffusion crystallization platform.  Dialysis is an ideal 
technique for the removal of detergents from protein-detergent-lipid solutions since detergent 
monomers are free to diffuse across the dialysis membrane, whereas phospholipids are 
trapped in lipid bilayers and are not involved in the dialysis experiment.  Dialysis 
experiments are currently used to remove excess detergent monomers from detergent-
solubilized membrane protein samples for two-dimensional crystallization experiments (79). 
The dialysis platform alleviates any restrictions on detergent use for sample preparation, 
since the detergent monomers will be subsequently removed, and broadens the range of 
membrane protein targets available for lipid crystallization experiments.   
 
A detergent-solubilized Streptomyces lividans KcsA potassium channel is used to 
demonstrate the utility of the microfluidic dialysis device for membrane protein 
crystallization.  Previous structural and functional analysis of the KcsA potassium channel 
established phospholipids are required for the correct folding and activity of KcsA (106), 
making KcsA an ideal sample for crystallization experiments in a lipid environment.  A 
modified lipid cubic phase crystallization strategy and a bicelle crystallization strategy were 
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designed and implemented for the KcsA channel to explore the full capabilities of the 
microfluidic dialysis device. 
 
Experimental Procedures 
Device Fabrication and Experimental Setup.  The microfluidic dialysis device for membrane 
protein crystallization was fabricated using multilayer soft lithography (7) and a detailed 
fabrication protocol is presented in Appendix A.  The dialysis membrane used within each 
device is a single sheet of dry cellulose membrane (Spectra/Por 132680, 12–14 kDa 
molecular weight cutoff, 20 µm thick) of dimensions 5.22 x 1.90 cm.  The fabrication 
protocol for the control version of the dialysis device without dialysis membrane is also 
presented in Appendix A. 
 
The experimental setup for the dialysis devices began by filling each of the dialysis 
reservoirs with 150 µl of dialysis reagent and waiting five minutes to prime the dialysis 
membrane.  Next, the interface control line and the containment control lines were primed 
with Poly(3,3,3-trifluoropropylmethylsiloxan) (FMS) oil (Hampton Research) and the 
interface control line was actuated at 20 psi.  Once all of the interface valves were closed, gel 
loading tips with 6 µl of crystallization reagent and 6 µl of protein sample were inserted into 
opposite sides of the device and pressurized to 5 psi to load the solutions onto the device.  
When all of the chambers were finished dead-end filling, the containment control lines were 
actuated at 20 psi.  Finally, the pressure on the interface control line was released and each of 
the free interface diffusion experiments was initiated.  Dialysis devices were incubated at 
 106 
room temperature for up to two weeks and cryoprotectant can be introduced by diffusion 
through the dialysis reservoirs an hour before crystal harvesting. 
 
Protein Preparation.  The Streptomyces lividans KcsA detergent-solubilized protein sample 
was provided by Roderick MacKinnon at Rockefeller University.  The KcsA sample was 
stored at 1.6 mg/ml in storage buffer at 4 °C (150 mM potassium chloride, 20 mM Tris·HCl 
(pH 7.5), and 10 mM n-decyl-β-D-maltoside (DM)).  The KcsA dialysis buffer used in the 
dialysis devices was the storage buffer without detergent (150 mM potassium chloride, 20 
mM Tris·HCl (pH 7.5)).  The KcsA sample was used at 1.6 mg/ml for bicelle preparation, 
vesicle preparation, and for the initial crystallization experiments performed in the absence of 
lipids.  A portion of the sample was concentrated to 8 mg/ml using a microcentrifuge device 
with a 10 kDa molecular weight cutoff for additional crystallization experiments. 
 
Bicelle Preparation.  A 1,2-dimyristoyl-sn-glycero-3-phosphocholine/3-
[(Cholamidopropyl)dimethylammonio]-1-propane-sulfonate (DMPC/CHAPS) lipid/detergent 
bicelle solution was prepared  as previously reported with minor modifications (81).  Briefly, 
a 40% 3:1 (DMPC:CHAPS) molar ratio bicelle mixture was created by combining 30 mg of 
room temperature DMPC and 10 mg of CHAPS in 100 µl of water and mixing on ice.  Next, 
the bicelle mixture was combined with KcsA at a 4:1 (KcsA:bicelle) volume ratio and mixed 
on ice to create the protein/bicelle mixture.  The final bicelle preparation contained a 1.3 
mg/ml KcsA (with 8 mM DM)/8% bicelle mixture.  The bicelle preparation was stored at 4 
°C to keep the solution in liquid form for crystallization experiments.  DMPC powder was 
purchased from Avanti Polar Lipids and CHAPS powder was purchased from Anatrace. 
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Vesicle Preparation.  DMPC vesicle preparation was modified from a previously reported 
method (107).  The DMPC vesicles were prepared by mixing 4 mg of room temperature 
DMPC in 200 µl of KcsA storage buffer without detergent (150 mM potassium chloride, 20 
mM Tris·HCl (pH 7.5)).  The lipid solution was sonicated for one hour in 20-minute 
increments until the solution became clear.  Next, the lipid vesicle mixture was combined 
with KcsA at a 20:1 (KcsA:vesicle) volume ratio and sonicated for an additional 10 minutes.  
The final vesicle preparation contained a 1.5 mg/ml KcsA (with 9.5 mM DM)/1 mg/ml 
vesicle mixture.  The vesicle preparation was stored at 4 °C for crystallization experiments.  
 
Crystallization Experiments.  Initial crystallization experiments were performed using 
nanoliter volume microfluidic free interface diffusion screening devices as previously 
described (4, 12).  The crystallization experiments were designed around the previously 
reported crystallization conditions for KcsA-Fab complex structures (108–110). The initial 
crystallization screen was implemented with four samples: KcsA at 1.6 mg/ml, KcsA at 8 
mg/ml, KcsA bicelle preparation at 1.3 mg/ml, and the KcsA vesicle preparation at 1.5 
mg/ml.  All crystallization experiments were performed at room temperature for up to two 
weeks.  The optimal crystallization conditions for each sample were transported to 
microfluidic scale-up diffraction devices for diffraction analysis (6).  The crystallization 
conditions were subsequently transported to the microfluidic dialysis device.  Crystals grown 
in the dialysis device can be harvested for in situ diffraction analysis as previously described 
for a microfluidic scale-up diffraction device (6). 
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Diffraction Analysis.  Diffraction data for KcsA was collected at station 8.3.1 of the 
Advanced Light Source (Lawrence Berkeley National Laboratory), at an incident wavelength 
of 1.0 Å with a 30 second exposure and 1º oscillation.  All diffraction data was collected at 
room temperature from crystals within scale-up diffraction devices. 
 
Crystallization Results 
Design of Microfluidic Dialysis Device.  The microfluidic dialysis device for membrane 
protein crystallization simultaneously performs large-scale free interface diffusion 
crystallization experiments and dialysis experiments for detergent removal.  The free 
interface diffusion design in the dialysis device was modified from a microfluidic scale-up 
diffraction device that was successfully used for in situ structure determination of novel 
proteins (6, 13).  Each dialysis device performs 25 unique free interface diffusion 
experiments utilizing one crystallization reagent and one protein sample.  The dialysis device 
contains five individually addressable dialysis reservoirs (labeled A–E) and each dialysis 
reservoir covers five free interface diffusion experiments (Figure 5.2).  The protein:reagent 
chamber ratios used in the five experiments are 3:1, 3:2, 1:1, 2:3, and 1:3, with a total 
reaction volume of 180 nl per free interface diffusion experiment.  The free interface 
diffusion path length between the protein and reagent chambers varies in each of the dialysis 
reservoirs, ranging from 0.7 cm in reservoir A to 0.5 cm in reservoir E.  The multiple 
chamber ratios and path lengths in each dialysis device allow for a systematic investigation 
of parameters to determine which combination promotes optimal crystal growth for each 
reagent.  Additional versions of the dialysis device were designed utilizing one of the five 
protein:reagent chamber ratios and multiple free interface diffusion path lengths to allow for 
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detailed dialysis reagent screening.  The development of a successful fabrication procedure 
for the dialysis device is presented below in the Dialysis Device Fabrication Results section.  
 
 
 
Figure 5.2:  Microfluidic dialysis device for membrane protein crystallization.  The gold 
protein and reagent chambers are at the top and bottom of the device, respectively, and are 
connected by the blue flow channels.  The red interface control line is in the center of the 
device and the red containment control lines are at the top and bottom of the device.  The 
green dialysis membrane is incorporated over the functional features of the device, and the 
grey circular dialysis reservoirs are centered over the protein chambers.  Notice that all of the 
input connections are outside of the membrane border to prevent membrane tearing when 
punching the input ports during device assembly. 
 
Initial Crystallization Experiments.  A series of positive control crystallization experiments 
were initially performed in the dialysis device using two crystallization targets previously 
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crystallized with microfluidic devices (6, 13).  Since the crystallization targets were soluble 
samples, no detergent was present in either sample to dialyze out of solution and the sample 
storage buffers were used for dialysis reagents.  A large rhombohedral lysozyme crystal 
appeared after one day in the dialysis device and crystal growth continued for several days in 
the presence of the dialysis reagent (Figure 5.3A–B).   Additionally, GKG230D cubic crystals 
formed in the dialysis device after three days (Figure 5.3C).  The crystallization reagent used 
to produce the cubic crystals for GKG230D in the dialysis device was the same reagent that 
produced a large rhombohedral crystal in the scale-up diffraction device (see Figure 3.4B for 
comparison).  The initial crystallization experiments demonstrate the dialysis devices can be 
successfully used for protein crystallization in the presence of a dialysis reagent. 
 
 
 
Figure 5.3:  Dialysis device validation crystallization experiments.  (A) Lysozyme 
rhombohedral crystal grown in 0.6 M sodium chloride and 100 mM sodium acetate (pH 4.5) 
after one day of dialysis.  The lysozyme was used at 165 mg/ml in storage buffer (100 mM 
sodium acetate (pH 4.5)) and the dialysis reagent used in the crystallization experiment was 
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the lysozyme storage buffer.  (B) The same lysozyme crystallization experiment after five 
days of dialysis.  (C) GKG230D cubic crystals grown in 300 mM magnesium chloride, 100 mM 
Tris·HCl (pH 8.5), and 20% PEG 1500.  GKG230D was used at 30 mg/ml in standard buffer 
(20 mM Tris·HCl (pH 7.5), 10 mM glycerol, and 1 mM βME).  The dialysis reagent used in 
the crystallization experiment was the GKG230D standard buffer.  The scale bars represent 200 
µm. 
 
Crystallization Strategy for KcsA.  A crystallization strategy for the detergent-solubilized 
KcsA potassium channel sample was developed to incorporate the dialysis device for 
membrane protein crystallization into the existing microfluidics-based crystallization 
platform.  Four distinct KcsA samples were utilized in the crystallization strategy: 1.6 mg/ml 
detergent-solubilized KcsA in the absence of lipids, 8 mg/ml detergent-solubilized KcsA in 
the absence of lipids, a KcsA bicelle mixture, and a KcsA vesicle mixture.  The detergent-
solubilized KcsA samples were used to investigate the combined effects of free interface 
diffusion crystallization experiments and removal of excess detergent through dialysis on 
membrane protein crystallization.  The KcsA bicelle mixture was used to test the utility of 
detergent removal from a protein bicelle solution to promote bicelle crystallization.  Lastly, 
the KcsA vesicle mixture was used to investigate whether detergent removal from a protein 
vesicle solution induces lipid cubic phase crystallization. 
 
To begin, the KcsA samples were screened using microfluidic free interface diffusion 
screening devices to identify the optimal crystallization reagents for each sample (4, 12).   
The 1.6 mg/ml KcsA sample formed hexagonal crystals with numerous crystallization 
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reagents in the screening device (Figure 5.4A).  Similar crystallization reagents also 
produced hexagonal crystals from the 8 mg/ml KcsA sample (Figure 5.4B).  In general, the 
hexagonal crystals formed using the 8 mg/ml KcsA sample were larger than the hexagonal 
crystals grown using the 1.6 mg/ml KcsA sample.  The KcsA bicelle mixture formed small 
crystals in the presence of multiple crystallization reagents (Figure 5.4C), none of which 
compared to the hexagonal crystals grown in the absence of bicelles.  On the other hand, 
several successful crystallization reagents were identified for the KcsA vesicle mixture.  The 
KcsA vesicle mixture formed large well-defined hexagonal crystals with one crystallization 
reagent (Figure 5.4D) and cubic crystals with two additional crystallization reagents (Figure 
5.4E–F).  Overall, crystallization reagents were identified for each of the KcsA samples using 
the microfluidic screening devices and the best crystal hits were observed for the KcsA 
vesicle mixture. 
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Figure 5.4:  KcsA crystals in free interface diffusion screening devices.  (A) KcsA 
hexagonal crystals grown in 150 mM calcium chloride, 100 mM Hepes (pH 7.5), and 52% 
PEG 400.  KcsA was used at 1.6 mg/ml in storage buffer.  (B) KcsA hexagonal crystals 
grown in 200 mM calcium chloride, 100 mM Hepes (pH 7.5), and 50% PEG 400.  KcsA was 
used at 8 mg/ml in storage buffer.  (C) KcsA bicelle crystals grown in 50 mM magnesium 
acetate, 100 mM sodium acetate (pH 5.4), and 21% PEG 400.  (D) KcsA vesicle hexagonal 
crystal grown in 50 mM magnesium acetate, 100 mM sodium acetate (pH 5.2), and 24% PEG 
400.  (E) KcsA vesicle cubic crystals grown in 50 mM magnesium acetate, 100 mM sodium 
acetate (pH 5.4), and 18% PEG 400.  (F) KcsA vesicle cubic crystals grown in 50 mM 
magnesium acetate, 100 mM sodium acetate (pH 5.4), and 24% PEG 400.  The scale bars 
represent 100 µm. 
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The best crystallization reagents for each KcsA sample were transported to two larger format 
free interface diffusion crystallization devices.  The first larger format crystallization device 
is a control version of the dialysis device where the dialysis membrane is replaced with a 
solid layer of PDMS elastomer.  Crystallization experiments were performed in the control 
version of the dialysis device to observe the scaled-up free interface diffusion crystallization 
results in the absence of dialysis and to observe the best mixing ratios for crystal formation.  
The 1.6 mg/ml KcsA sample formed rhombohedral crystals with two crystallization reagents 
(Figure 5.5A–B).  A combination of hexagonal and cubic crystals also formed with a third 
crystallization reagent (Figure 5.5C–D).  The KcsA vesicle sample formed rhombohedral 
crystals of various sizes with multiple crystallization conditions (Figure 5.5E–G).  The KcsA 
bicelle sample did not crystallize in the larger format crystallization devices.  This was not 
surprising since a previous crystallization survey demonstrated the translation of crystal hits 
to larger formats depends upon the crystal quality achieved in the smaller format experiments 
(12).    
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Figure 5.5:  Larger format KcsA crystallization experiments. A control version of the 
dialysis device without dialysis membrane was used for the larger format crystallization 
experiments.  (A) KcsA rhombohedral crystals grown in 250 mM calcium chloride, 100 mM 
Hepes (pH 7.5), and 44% PEG 400.  KcsA was used at 1.6 mg/ml in storage buffer.  (B) 
KcsA rhombohedral crystals grown in 50 mM magnesium acetate, 100 mM sodium acetate 
(pH 5.6), and 26% PEG 400.  KcsA was used at 1.6 mg/ml in storage buffer.  (C–D) KcsA 
hexagonal and cubic crystals grown in 150 mM calcium chloride, 100 mM Hepes (pH 7.5), 
and 52% PEG 400.  KcsA was used at 1.6 mg/ml in storage buffer.  (E) KcsA vesicle 
rhombohedral crystals grown in 50 mM magnesium acetate, 100 mM sodium acetate (pH 
5.4), and 22% PEG 400.  (F–G) KcsA vesicle rhombohedral crystals grown in 50 mM 
magnesium acetate, 100 mM sodium acetate (pH 5.2), and 20% PEG 400.  The scale bars 
represent 200 µm. 
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Diffraction Analysis.  The crystallization conditions were also transported to scale-up 
diffraction devices for diffraction analysis of the crystal hits for different KcsA samples (6). 
The 1.6 mg/ml KcsA sample formed rhombohedral crystals of dimensions 100 µm x 100 µm 
x 100 µm with multiple reagents.  The 8 mg/ml KcsA sample also formed rhombohedral 
crystals of dimensions 100 µm x 100 µm x 150 µm.  Numerous crystals grown from the 1.6 
mg/ml and 8 mg/ml KcsA samples were screened and no diffraction patterns were observed 
for any of the crystals.  All diffraction data collection was done at room temperature to avoid 
altering the diffraction resolution of the crystals by using cryoprotectants.  Since the initial 
KcsA structures were produced using a truncated KcsA sample and a KcsA-Fab complex 
(108–110), the diffraction limit of the full-length KcsA sample alone has not been 
established.  The KcsA vesicle sample formed cubic crystals of dimensions 150 µm x 150 
µm x 150 µm that diffracted to 17 Å (Figure 5.6).  The appearance of a diffraction pattern for 
the lipid vesicle sample demonstrates that the lipid cubic phase crystallization technique 
improves the crystal quality for KcsA compared to crystals grown using detergent-
solubilized KcsA in the absence of lipids. 
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Figure 5.6: In situ diffraction analysis of larger format crystals.  The KcsA vesicle crystal 
was grown in 50 mM magnesium acetate, 100 mM sodium citrate, and 18% PEG 400.  A 150 
µm x 150 µm x 150 µm cubic crystal diffracted to 17 Å. 
 
Finally, the KcsA samples were transported to the dialysis device for crystallization.  The 1.6 
mg/ml KcsA sample formed microcrystals when a dialysis reagent composed of a 1:1 
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mixture of the KcsA dialysis buffer and the crystallization reagent was used for the dialysis 
experiment (Figure 5.7A).  Parallel experiments using only KcsA dialysis buffer for the 
dialysis reagent did not produce any crystals.  Decreasing the concentration of precipitating 
agent in the crystallization condition eliminated the microcrystals and instead produced a 
small crystal surrounded by light protein aggregation (Figure 5.7B).  Once again, the crystal 
only formed when a 1:1 mixture of KcsA dialysis buffer and crystallization reagent was used 
for the dialysis reagent.  Alternatively, the 1.6 mg/ml KcsA sample formed a larger crystal 
with a third crystallization reagent when KcsA dialysis buffer was used for the dialysis 
reagent (Figure 5.7C).  The same crystallization experiment with the 8 mg/ml KcsA sample 
also produced crystals (Figure 5.7D).  
 
Several dialysis devices were assembled with the KcsA vesicle sample and the KcsA bicelle 
sample, and crystals were produced using the KcsA vesicle sample.  The KcsA vesicle 
sample formed single crystals with multiple crystallization reagents when the KcsA dialysis 
buffer was used for the dialysis reagent (Figure 5.7E–G).  For reference, the KcsA vesicle 
crystals shown in Figure 5.7F–G were grown using the same condition as the lipid-free KcsA 
crystals in Figure 5.7C–D.  The inability of the KcsA bicelle sample to crystallize in the 
dialysis devices was expected since the no crystals formed in the larger format control 
devices.  The crystallization results for the KcsA samples are summarized in Table 5.1. 
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Figure 5.7:  KcsA crystals in dialysis devices.  (A) KcsA microcrystals grown in 50 mM 
magnesium acetate, 100 mM sodium acetate (pH 5.6), and 26% PEG 400.  KcsA was used at 
1.6 mg/ml.  (B) KcsA crystal grown in 50 mM magnesium acetate, 100 mM sodium acetate 
(pH 5.0), and 20% PEG 400.  KcsA was used at 1.6 mg/ml.  (C) KcsA crystal grown in 250 
mM calcium chloride, 100 mM Hepes (pH 7.5), and 44% PEG 400.  KcsA was used at 1.6 
mg/ml.  (D) KcsA crystals grown in the same reagent as in (C) and KcsA was used at 8 
mg/ml.  (E) KcsA vesicle crystals grown in 50 mM magnesium acetate, 100 mM sodium 
acetate (pH 5.0), and 23% PEG 400.  (F–G) KcsA vesicle crystals grown in the same reagent 
as in (C) and (D).  The dialysis reagent used for (A) and (B) was a 1:1 mixture of the KcsA 
dialysis buffer (150 mM potassium chloride and 20 mM Tris·HCl (pH 7.5)) and the 
corresponding crystallization reagent.  The dialysis reagent used for (C–G) was the KcsA 
dialysis.  The scale bars represent 200 µm. 
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Comparison of the crystallization results in the larger format crystallization devices and in 
the dialysis device demonstrate that crystal quality is affected by the incorporation of the 
dialysis platform into the free interface diffusion crystallization experiment. When the 
crystallization reagent diffuses across the free interface diffusion channel into the protein 
reaction chamber two processes can occur: the reagent can diffuse into the protein solution to 
initiate crystal nucleation, and the reagent can diffuse across the dialysis membrane into the 
dialysis reservoir.  Since the crystallization reagent is composed of small molecules with 
radii on the order of 1 Å and the dialysis membrane has a molecular weight cutoff of 12 kDa, 
the pores in the dialysis membrane are so large that the small molecules are essentially free to 
immediately diffuse into the dialysis reservoir.  The diffusion of the small molecules into the 
dialysis reservoir is problematic since it occurs at a faster rate than crystal nucleation: by the 
Stokes-Einstein equation, small molecules with 1 Å radius have a diffusion constant on the 
Table 5.1: KcsA crystallization results 
 Experiment Sample Crystals  Diffraction 
1. Screening device KcsA no lipids—1.6 mg/ml Hexagonal crystals Not tested 
  KcsA no lipids—8 mg/ml Hexagonal crystals Not tested 
  KcsA bicelles Microcrystals Not tested 
  
KcsA vesicles Hexagonal and cubic 
crystals 
Not tested 
2. Scale-up diffraction KcsA no lipids—1.6 mg/ml Rhombohedral crystals No 
 device KcsA no lipids—8 mg/ml Rhombohedral crystals No 
  KcsA bicelles No  
  KcsA vesicles Cubic crystals 17 Å 
3. Control dialysis  KcsA no lipids—1.6 mg/ml Rhombohedral crystals Not tested 
 device KcsA vesicles Rhombohedral crystals Not tested 
  KcsA bicelles No  
4. Dialysis device KcsA no lipids—1.6 mg/ml Small crystal Not tested 
  KcsA no lipids—8 mg/ml Small crystal Not tested 
  KcsA bicelles Microcrystals Not tested 
  KcsA vesicles Small crystal Not tested 
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order of 1000 µm2/s in water (111), whereas crystal nucleation occurs on the order of 
minutes to hours.  Additionally, the volumetric difference between the dialysis reservoir and 
the crystallization chamber is problematic; the 150 µm dialysis reservoir is 1600 times as 
large as the 90 nl crystallization chamber volume.  Thus, equilibration of the crystallization 
reagents across the dialysis membrane causes over a thousandfold dilution of the 
crystallization reagent and essentially removes the reagent from the free interface diffusion 
experiment.  
 
The successful crystallization experiments using 50% crystallization reagent in the dialysis 
reservoir overcame the volumetric difference by reducing the dilution of crystallization 
reagent during equilibration down to twofold, leaving half of the crystallization reagent in the 
reaction chamber for crystal nucleation.  Therefore, the most straightforward solution to 
improve crystal growth in the dialysis device would be to increase the amount of 
crystallization reagent in the dialysis reservoir to completely eliminate the dialysis of the 
crystallization reagent from the free interface diffusion experiment.  Additionally, the 
dialysis reservoir could be sealed with a layer of FMS oil at the beginning of the free 
interface diffusion experiment to allow crystal nucleation to initiate before replacing the oil 
with dialysis reagent for detergent removal.     
 
Overall, the crystallization strategy for KcsA was successfully implemented to produce KcsA 
crystals in a lipid cubic phase environment.  The lipid cubic phase crystallization method was 
a more successful crystallization method in the dialysis devices than the bicelle 
crystallization strategy.  Future experiments to optimize the dialysis reagent composition 
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could improve the size and quality of the KcsA lipid cubic crystals grown in the dialysis 
device. 
 
Dialysis Device Fabrication Results 
The procedure for constructing the dialysis device is outlined below.  All of the fabrication 
challenges encountered during device fabrication are discussed in detail. 
 
Membrane Integration in the Dialysis Device.  A dialysis membrane forms the interface 
between the free interface diffusion crystallization chambers and the large dialysis reservoirs 
in the dialysis device.  Incorporation of the dialysis membrane within the device requires 
complete bonding between the cellulose dialysis membrane and the elastomeric 
polydimethylsiloxane (PDMS) material of the device.  If not, leaking will occur between the 
two materials when fluids are introduced into the device.  Two techniques are currently used 
for membrane bonding to PDMS: placing a membrane between two oxygen plasma-treated 
layers of PDMS for irreversible bonding (112, 113), and a stamping procedure using a thin 
layer of uncured PDMS prepolymer to adhesively bond a piece of membrane between two 
layers of PDMS (114).   
 
Initial attempts at membrane incorporation using oxygen plasma-treatment were unsuccessful 
in the dialysis device due to the 20 µm thickness of the membrane. When a membrane 
section is placed between two layers of PDMS an air pocket forms around the border of the 
membrane to accommodate the membrane thickness.  Plasma-treatment of the device 
minimizes but does not eliminate the air pocket around the membrane border.  Consequently, 
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the membrane edges are not completely bonded to the PDMS in plasma treated devices and 
fluid leaks around the membrane border into the air pocket when the devices are loaded.  The 
previous plasma treatment procedure used 6 µm thick nanoporous membrane (115), less than 
one third as thick as the membrane required for dialysis experiments in the dialysis device.  
One possible solution for the incomplete bonding would be to incorporate a section of 
membrane with the same dimensions as the dialysis device to eliminate any membrane 
border within the device.  Unfortunately, this solution was not viable since the punching 
process to create the input/output (I/O) fluid ports in the completed device caused membrane 
tearing.  Therefore, I/O port punching in the dialysis device requires that the membrane is 
completely encompassed within the device and plasma-treatment does not appear to be the 
optimal technique for dialysis membrane integration in the device. 
 
The stamping technique for adhesive membrane bonding was subsequently examined and a 
modified stamping procedure was developed for the dialysis device.  The stamping procedure 
involves stamping each of the following components in a thin layer of PDMS prepolymer: 
the dialysis reservoir PDMS layer, the crystallization experiment PDMS layer (crystallization 
chamber side down), and the four edges of the dialysis membrane (see Figure 2 in (114) and 
Figure 5.9E for  details).  Once all of the components are covered in a thin film of 
prepolymer, the membrane is placed on the stamped side of dialysis reservoir layer and the 
stamped side of the crystallization experiment layer is aligned on top of the membrane, 
completely encapsulating the dialysis membrane within the device.  The prepolymer acts like 
glue between the PDMS layers and the membrane, and the prepolymer is fully incorporated 
into the device when the assembled device is cured.  The prepolymer also forms a leakage-
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free barrier around the membrane edge, thereby eliminating the air pocket around the 
membrane border that appeared during plasma-treatment membrane incorporation.  
 
The major modification to the stamping procedure for the dialysis device membrane 
integration was the composition and production of the PDMS prepolymer layers.  The 
original stamping procedure involved diluting uncured PDMS prepolymer with different 
ratios of toluene solvent and spinning each mixture onto a glass slide at a uniform speed to 
achieve different prepolymer thicknesses (114).  While this method was effectively used to 
produce prepolymer films as thin as 1 µm, toluene is a volatile and hazardous solvent that is 
difficult to work with and requires all stamping procedures and subsequent device fabrication 
steps be performed inside a fume hood.  Alternatively, pure PDMS prepolymer was used in 
the dialysis device stamping procedure and a range of prepolymer thicknesses were created 
by spinning prepolymer onto silicon wafers using different spin speeds.  A complete 
characterization of PDMS thicknesses across a range of spin speeds verified PDMS 
prepolymer films as thin as 2 µm were attainable using maximal spin speeds (Figure 5.8). 
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Figure 5.8: Plot of PDMS elastomer thickness versus spin speed.  For all spin speeds, PDMS 
elastomer (General Electrics RTV 615; 10 parts A: 1 part B) was spun onto a blank silicon 
wafer for 60 seconds and cured at 80 °C for three hours to completely cure the polymer.  
Film thicknesses were measured using a profilometer after a small section of the cured 
polymer was removed from each silicon wafer with a scalpel.    
 
It is critical to use the correct prepolymer thickness in the stamping procedure to avoid 
damaging the free interface diffusion crystallization channel and chamber features.  If the 
prepolymer layer is too thick, the 22 µm high rounded channels and the 95 µm high 
chambers in the stamped layer are filled with prepolymer and disappear during the stamping 
procedure.  A systematic investigation of stamping procedures with different prepolymer 
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thicknesses confirmed a 2 µm prepolymer thickness was optimal for complete membrane 
bonding and maintaining feature integrity between the crystallization experiment layer and 
the dialysis membrane.  Alternatively, the dialysis reservoir layer does not contain any 
micron-scale features and a 10 µm prepolymer thickness was optimal for complete 
membrane bonding to the dialysis reservoir layer.  The 10 µm prepolymer thickness was also 
used to stamp the edges of the dialysis membrane.  Overall, a total of 12 µm of prepolymer 
material was integrated around the membrane within the dialysis device for complete 
membrane bonding.  
 
Functional Valve Incorporation in the Dialysis Device.  The incorporation of functional 
control valves into the dialysis device requires the use of push down valve geometry to allow 
the free interface diffusion device features to directly contact the dialysis membrane (Figure 
5.9A).  Push up control valves placed below the dialysis membrane and the flow channels do 
not actuate due to the stiffness of the membrane material situated in between the control 
valves and the flow channels.  The primary challenge with the push down valve geometry is 
placing the control valves in close enough proximity to the flow channels given the 95 µm 
height of the crystallization chambers.  When a thin layer of PDMS is spun onto the flow 
layer, the height of the crystallization chambers creates a gap in between the flow channels 
and the control valves and prevents bonding between the layers (Figure 5.9B).  The gap 
between the control valves and the flow layer is alleviated if the uncured flow layer is 
permitted to relax onto the flow mold until the PDMS becomes level with the crystallization 
chambers (Figure 5.9C).  The level flow layer is then bonded to the control layer to create a 
free interface diffusion device with integrated push down control valves (Figure 5.9D).  The 
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stamping procedure for membrane integration is applied to the free interface diffusion device 
and the reservoir layer to complete the dialysis device (Figure 5.9E–F). 
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Figure 5.9:  Overview of dialysis device assembly.  (A) Cross section of the dialysis device 
features.  The green push down control valves are located above the red flow channels and 
are level with the top of the gold crystallization chambers.  The blue dialysis membrane is 
located below the flow and control features and forms the lower boundary of the flow 
channels and the crystallization chambers.  (B) Problematic push down valve incorporation.  
Spinning PDMS onto the 95 µm tall crystallization chambers creates a large gap between the 
flow channels and the control valves.  (C) Solution for valve incorporation.  The gap between 
the control valves and the flow channels is minimized by allowing the uncured PDMS to 
relax on the flow layer until the PDMS is level with the crystallization chambers.   (D) 
Device with functional push down control valves.  (E) Stamping method for dialysis 
membrane integration within the device.   The reservoir layer, the flow layer, and the 
membrane edges are stamped in a thin layer of prepolymer and carefully combined with the 
membrane in the center.  (F) Completed device with integrated dialysis membrane.  Note that 
the completed device is inverted to place the dialysis reservoirs on the top of the device.  See 
Appendix A for the detailed fabrication protocol. 
 
Dialysis Device Validation.  The assembly procedure outlined in Figure 5.8 was successfully 
implemented to construct dialysis devices for membrane protein crystallization (Figure 5.10).  
All components of the dialysis devices were critically examined before any crystallization 
experiments were undertaken.   First, membrane integrity within the dialysis device was 
investigated (Figure 5.11A).  The dialysis reservoirs were filled with water for two hours to 
verify the membrane was completely bonded to the device and does not detach from the 
device during dialysis.  The slight membrane distortion over the flow chambers is the normal 
 130 
result of exposing dialysis membrane to fluid and confirms the flow layer stamping did not 
affect the integrity of the membrane.  As expected, the membrane distortion only occurs in 
areas of the device where the membrane did not come into contact with the prepolymer 
adhesion layer during the stamping procedure.  Next, sample loading into crystallization 
chambers primed with a dialysis reagent was explored (Figure 5.11B).  The chambers were 
loaded using dead-end filling and no leaking occurred between the flow layer features and 
the incorporated dialysis membrane boundary in the chambers.   
 
 
 
Figure 5.10:  Successful membrane integration in the dialysis device.  A dialysis device is 
loaded with red dye in the protein and reagent lines, green dye in the interface control line, 
and blue dye in the containment lines.  The dialysis reservoirs are filled with water.  The 
scale bar represents 1 cm. 
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Figure 5.11:  Validation of the dialysis device features.  (A) Membrane integrity during 
dialysis.  Prolonged exposure to water in the dialysis reservoir does not cause the membrane 
to detach from the dialysis device.  (B) Dead-end filling of crystallization chambers.  The 
dialysis membrane was primed with water for five minutes before loading red dye into the 
flow channels at 5 psi.  (C) Push down valve actuation.  The containment line was filled with 
blue dye and actuated at 20 psi to close the flow channel.  (D) Intact flow channels at the 
membrane border.  The flow channels are intact after the stamping procedure and no leakage 
occurred at the membrane border when the flow channel was loaded with red dye.  (E) 
Seamless integration of the dialysis membrane within the dialysis device.  The scale bars 
represent 200 µm. 
 
 132 
Push down valve actuation was also tested to ensure the control valves were functional in the 
device (Figure 5.11C).  Actuation of the containment control line completely sealed off the 
crystallization reagent inlet from the rest of the device.  The use of the dialysis membrane to 
form one of the walls in the flow channel does not appear to affect valve actuation in the 
dialysis device.  Next, fluid flow across the membrane border during device loading was 
examined (Figure 5.11D).  The protein sample and crystallization reagent inlet ports are 
located outside of the membrane border, requiring the flow channels to cross the membrane 
border during loading.  Fluid was introduced into the device through the protein sample inlet 
port and the fluid traveled across the intact flow channel at the membrane border without 
leaking.  Lastly, the membrane integration within the dialysis device was examined at the 
membrane border and no air pockets were evident (Figure 5.11E).  The membrane border 
was seamlessly integrated into the device as a result of the membrane edge stamping during 
device assembly.  Overall, every component in the device was functional and the dialysis 
device is ready for crystallization experiments. 
 
In conclusion, a dialysis device for membrane protein crystallization was designed and 
constructed for the utilization of lipid bilayer environments in membrane protein 
crystallization experiments.  The dialysis device successfully integrated a cellulose 
membrane into an elastomeric device and is the first demonstration of valve incorporation 
into a device with an integrated membrane.  The dialysis device allows for the exploration of 
novel membrane protein crystallization techniques to incorporate lipids into detergent-
solubilized membrane protein samples during crystallization.  The dialysis device was 
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extensively characterized and validation experiments using KcsA potassium channels and 
lipid vesicles produced protein crystals in a lipid cubic phase environment. 
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Appendix A 
FABRICATION PROTOCOLS 
 
Dialysis Device Design 
 
Figure A.1: Assembled dialysis device.  Two versions of the dialysis device are 
shown with different protein:reagent chamber ratios and different free interface 
diffusion path lengths. 
 135 
 
 
    Figure A.2: Dialysis device rounded channel flow layer mask 
 
 
 
    Figure A.3: Dialysis device chamber flow layer mask 
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    Figure A.4: Dialysis device control layer mask 
 
 
 
  
    Figure A.5: Dialysis device reservoir layer mask 
 137 
Dialysis Device: Mold Fabrication 
4 inch silicon wafer substrate 
 
 
I. Flow Mold—Rounded Channels 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry. 
 
b. Prime Wafers:  2 min hexamethyldisilazane (HMDS) vapor treatment 
 
c. Spin SPR 220-7:  500 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 22 µm 
 
d. Pre-Exposure Bake: 2 min 65 °C / 5 min 115 °C / 2 min 65 °C 
 
e. Expose Wafer:  75 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
f. Develop:   5 min in MF-319 Developer (Microposit) 
Rinse with H20 and dry. 
 
g. Hard Bake:   Ramp from 65 °C to 200 °C. 
Bake for 60 min at 200 °C. 
Ramp down to 65 °C. 
 
 
Flow Mold—Chambers 
 
a. Spin SU8-100:  500 rpm for 20 sec, 136 rpm/sec ramp 
  3000 rpm for 55 sec, 136 rpm/sec ramp 
Let sit for 10 min. 
Film thickness = 95 µm 
 
b. Pre-Exposure Bake: 10 min 65 °C / 30 min 95 °C / 2 min 65 °C 
 
c. Expose Wafer:  65 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
d. Post-Exposure Bake: 5 min 65 °C / 25 min 95 °C / 2 min 65 °C 
 
e. Develop:   2 min in SU-8 Developer (Microchem) 
Rinse with acetone, isopropanol, and dry. 
f. Hard Bake:   Bake for 60 min at 150 °C. 
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II.  Control Mold 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-50:  500 rpm for 20 sec, 136 rpm/sec ramp 
2500 rpm for 55 sec, 136 rpm/sec ramp  
Let sit for 5 min. 
Film thickness = 45 µm 
 
c. Pre-Exposure Bake: 6 min 65 °C / 15 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  45 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 15 min 95 °C / 2 min 65 °C 
 
f. Develop:   2 min in SU-8 Developer 
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
 
III. Reservoir Mold  
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-2025:  3000 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 20 µm 
 
c. Pre-Exposure Bake: 2 min 65 °C / 5 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  25 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 10 min 95 °C / 2 min 65 °C 
 
f. Develop:   1 min in SU-8 Developer  
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
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Dialysis Device: Device Fabrication 
4 inch silicon wafer substrate 
 
 
1. TMCS Treat Molds:  Expose flow mold, control mold, reservoir  
mold, and one blank wafer to trimethylchlorosilane 
(TMCS) for 2 min. 
 
2. Prepare Flow Layer:  Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2500 rpm for 70 sec, 136 rpm/sec ramp. 
     Let PDMS relax for 30 min before curing. 
 
3. Prepare Control Layer: Start while flow layer is relaxing. 
Combine 5:1 GE 615 RTV (20 g A:4 g B). 
 Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 14 g 5:1 onto control mold. 
     Degas for 15 min in bell jar. 
 
4. Cure Flow Layer:  Bake for 40 min at 80 °C. 
 
5. Cure Control Layer:  Bake for 20 min at 80 °C. 
 
6. Control/Flow Bonding: Remove control layer from mold. 
Punch control inlets with 20 gauge punch. 
Cut devices out and clean with tape. 
     Align control devices onto flow layer. 
     Degas aligned device for 5 min. 
     Bake for 120 min at 80 °C. 
 
7. Prepare Reservoir Layer: Start during control/flow bonding. 
Combine 20:1 GE 615 RTV (40 g A:2 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 40 ml 20:1 onto reservoir mold. 
     Degas for 15 min in bell jar. 
     Bake for 60 min at 80 °C.  
 
8. Prepare Stamping Layers: Start while spacer layer is curing. 
Combine 10:1 GE 615 RTV (10 g A:1 g B).  
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 10:1 onto flow mold. 
     Spin first blank wafer at 10,000 rpm for 3 min,  
136 rpm/sec ramp, Film Thickness = 2 µm. 
Spin second blank wafer at 5,000 rpm for 2 min,  
136 rpm/sec ramp, Film Thickness = 10 µm. 
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Cut a single sheet of membrane (Spectra/Por 132680, 
12–14 kDa cutoff) to the size of 5.22 x 1.90 cm. 
 
9. Assemble Device:  Remove bonded device from flow mold. 
     Punch flow inlets with 20 gauge punch. 
     Clean with tape. 
     Remove reservoir layer from mold. 
     Punch reservoir holes with 8 mm punch. 
     Cut reservoir layer down to size and clean with tape. 
     Stamp bonded device in 2 µm stamp for 30 sec. 
     Stamp membrane edges in 10 µm stamp using tweezers. 
     Carefully place membrane onto stamped flow layer. 
     Push all bubbles out using tweezers. 
     Stamp reservoir layer in 10 µm stamp for 30 sec. 
     Carefully place reservoir layer onto membrane/device. 
     Push all bubbles out using tweezers. 
     Place device reservoir side up onto a blank wafer. 
     Cure assembled device at RT overnight. 
     Bake for 120 min at 80 °C. 
 
10. Prepare Blank Layer:  Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
     Bake for 30 min at 80 °C. 
 
11. Complete The Device: Remove device from blank wafer. 
Repunch control and flow inlets with 20 gauge punch. 
Cut devices down to size and clean with tape. 
Place device reservoir-side-up on blank layer. 
Bake for 60 min at 80 °C. 
Remove from blank layer and place on glass slide. 
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Control Version of Dialysis Device Without Membrane: Device Fabrication 
4 inch silicon wafer substrate 
 
 
1. TMCS Treat Molds:   Expose flow mold, control mold, and one blank  
wafer to TMCS for 2 min. 
 
2. Prepare Flow Layer:  Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2500 rpm for 70 sec, 136 rpm/sec ramp. 
     Let PDMS relax for 30 min before curing. 
 
3. Prepare Control Layer: Start while flow layer is relaxing. 
Combine 5:1 GE 615 RTV (20 g A:4 g B). 
 Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 14 g 5:1 onto control mold. 
     Degas for 15 min in bell jar. 
 
4. Cure Flow Layer:  Bake for 40 min at 80 °C. 
 
5. Cure Control Layer:  Bake for 20 min at 80 °C. 
 
6. Control/Flow Bonding: Remove control layer from mold. 
Punch control inlets with 20 gauge punch. 
Cut devices out and clean with tape. 
     Align control devices onto flow layer. 
     Degas aligned device for 5 min. 
     Bake for 120 min at 80 °C. 
 
7. Prepare Blank Layer:  Start during control/flow bonding. 
 Combine 20:1 GE 615 RTV (40 g A:2 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 40 ml 20:1 onto blank wafer. 
     Degas for 15 min in bell jar. 
     Bake for 60 min at 80 °C. 
 
8. Assemble Device:  Remove bonded device from flow mold. 
     Punch flow inlets with 20 gauge punch. 
     Cut out device and clean with tape. 
Place device on blank layer. 
Bake overnight at 80 °C. 
Remove from blank layer and cut device down to size. 
Place on glass slide. 
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Screening Device Design 
 
 
 
 
   Figure A.6: Assembled screening device 
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  Figure A.7: Screening device rounded channel flow layer mask 
 
 
 
  Figure A.8: Screening device chamber flow layer mask 
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  Figure A.9: Screening device control layer mask 
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Screening Device: Mold Fabrication 
3 inch silicon wafer substrate 
 
 
I. Flow Mold—Rounded Channels 
  
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Prime Wafers:  2 min HMDS vapor treatment 
 
c. Spin SPR 220-7:  900 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 12 µm 
 
d. Pre-Exposure Bake: 2 min 65 °C / 5 min 115 °C / 2 min 65 °C 
 
e. Expose Wafer:  45 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
f. Develop:   1 min in MF-319 Developer 
Rinse with H20 and dry. 
 
g. Hard Bake:   Ramp from 65 °C to 200 °C. 
Bake for 60 min at 200 °C. 
Ramp down to 65 °C. 
 
 
Flow Mold—Chambers and I/O Channels 
 
a. Spin SU8-50:  500 rpm for 20 sec, 136 rpm/sec ramp 
  2500 rpm for 55 sec, 136 rpm/sec ramp 
Let sit for 10 min. 
Film thickness = 45 µm 
 
b. Pre-Exposure Bake: 6 min 65 °C / 15 min 95 °C / 2 min 65 °C 
 
c. Expose Wafer:  45 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
d. Post-Exposure Bake: 5 min 65 °C / 15 min 95 °C / 2 min 65 °C 
 
e. Develop:   2 min in SU-8 Developer 
Rinse with acetone, isopropanol, and dry. 
 
f. Hard Bake:   Bake for 60 min at 150 °C.  
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II. Control Mold  
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-2025:  3000 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 20 µm 
 
c. Pre-Exposure Bake: 2 min 65 °C / 5 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  25 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 10 min 95 °C / 2 min 65 °C 
 
f. Develop:   1 min in SU-8 Developer  
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
 
 
 
 
 147 
Screening Device: Device Fabrication 
3 inch silicon wafer substrate 
 
 
1. TMCS Treat Molds:  Expose flow mold, control mold, and one blank wafer  
to TMCS for 2 min. 
 
2. Prepare Flow Layer:  Combine 5:1 GE 615 RTV (30 g A:6 g B). 
 Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 30 g 5:1 onto flow mold. 
     Degas for 15 min in bell jar. 
      
3. Prepare Control Layer: Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
 
4. Cure Flow Layer:  Bake for 20 min at 80 °C. 
 
5. Cure Control Layer:  Bake for 40 min at 80 °C. 
 
6. Flow/Control Bonding: Remove flow layer from mold. 
Punch flow inlets with 14 gauge and 20 gauge punches. 
Cut device out and clean with tape. 
     Align devices onto control layer. 
     Bake for 80 min at 80 °C. 
 
7. Prepare Blank Layer:  Start during flow/control bonding. 
Combine 30:1 GE 615 RTV (30 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
     Bake for 45 min at 80 °C. 
 
8. Assemble The Device: Remove device from control mold. 
Punch control inlets with 20 gauge punch. 
Cut device down to size and clean with tape. 
Place device on blank layer. 
Bake overnight at 80 °C. 
Remove from blank layer and place on glass slide. 
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Formulator Device Design 
 
 
 
Figure A.10: Assembled formulator device 
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      Figure A.11: Formulator device rotary mixer flow layer mask 
 
 
 
 
 
   
 
 
 
 
     Figure A.12: Formulator device rounded channel flow layer mask  
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     Figure A.13: Formulator device I/O channel flow layer mask 
 
 
 
   
 
 
     Figure A.14: Formulator device control layer mask
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Formulator Device: Mold Fabrication 
3 inch silicon wafer substrate 
 
 
I. Flow Mold—Rotary Mixer 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-2015:  3000 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 12 µm 
 
c. Pre-Exposure Bake: 2 min 65 °C / 5 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  20 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 10 min 95 °C / 2 min 65 °C 
 
f. Develop:   1 min in SU-8 Developer  
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
 
 
Flow Mold—Rounded Channels 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Prime Wafers:  2 min HMDS vapor treatment 
 
c. Spin SPR 220-7:  900 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 12 µm 
 
d. Pre-Exposure Bake: 2 min 65 °C / 5 min 115 °C / 2 min 65 °C 
 
e. Expose Wafer:  45 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
f. Develop:   1 min in MF-319 Developer 
Rinse with H20 and dry. 
 
g. Hard Bake:   Ramp from 65 °C to 200 °C. 
Bake for 60 min at 200 °C. 
Ramp down to 65 °C. 
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Flow Mold—I/O Channels 
 
a. Spin SU8-50:  500 rpm for 20 sec, 136 rpm/sec ramp 
  2000 rpm for 55 sec, 136 rpm/sec ramp 
Let sit for 10 min. 
Film thickness = 50 µm 
 
b. Pre-Exposure Bake: 6 min 65 °C / 15 min 95 °C / 2 min 65 °C 
 
c. Expose Wafer:  45 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
d. Post-Exposure Bake: 5 min 65 °C / 15 min 95 °C / 2 min 65 °C 
 
e. Develop:   2 min in SU-8 Developer 
Rinse with acetone, isopropanol, and dry. 
 
f. Hard Bake:   Bake for 60 min at 150 °C.  
 
II. Control Mold 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-2025:  3000 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 20 µm 
 
c. Pre-Exposure Bake: 2 min 65 °C / 5 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  25 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 10 min 95 °C / 2 min 65 °C 
 
f. Develop:   1 min in SU-8 Developer  
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
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Formulator Device: Device Fabrication 
3 inch silicon wafer substrate 
 
 
1. TMCS Treat Molds:  Expose flow mold, control mold, and one blank wafer  
to TMCS for 2 min. 
 
2. Prepare Flow Layer:  Combine 5:1 GE 615 RTV (30 g A:6 g B). 
 Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 30 g 5:1 onto flow mold. 
     Degas for 15 min in bell jar. 
      
3. Prepare Control Layer: Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
 
4. Cure Flow Layer:  Bake for 20 min at 80 °C. 
 
5. Cure Control Layer:  Bake for 40 min at 80 °C. 
 
6. Flow/Control Bonding: Remove flow layer from mold. 
Punch flow inlets with 20 gauge punch. 
Cut device out and clean with tape. 
     Align devices onto control layer. 
     Bake for 80 min at 80 °C. 
 
7. Prepare Blank Layer:  Start during flow/control bonding. 
Combine 30:1 GE 615 RTV (30 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
     Bake for 45 min at 80 °C. 
 
8. Assemble The Device: Remove device from control mold. 
Punch control inlets with 20 gauge punch. 
Cut device down to size and clean with tape. 
Place device on blank layer. 
Bake overnight at 80 °C. 
Remove from blank layer and place on glass slide. 
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Scale-Up Diffraction Device Design 
 
Figure A.15: Assembled scale-up diffraction device 
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  Figure A.16: Scale-up device rounded channel flow layer mask 
 
 
 
   Figure A.17: Scale-up device chamber flow layer mask 
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          Figure A.18: Scale-up device control layer mask 
 
 
                      Figure A.19: Scale-up device reservoir layer mask
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Scale-up Diffraction Device: Mold Fabrication 
3 inch silicon wafer substrate 
 
 
I. Flow Mold—Rounded Channels 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Prime Wafers:  2 min HMDS vapor treatment 
 
c. Spin SPR 220-7:  900 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 12 µm 
 
d. Pre-Exposure Bake: 2 min 65 °C / 5 min 115 °C / 2 min 65 °C 
 
e. Expose Wafer:  45 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
f. Develop:   1 min in MF-319 Developer 
Rinse with H20 and dry. 
 
g. Hard Bake:   Ramp from 65 °C to 200 °C. 
Bake for 60 min at 200 °C. 
Ramp down to 65 °C. 
 
 
Flow Mold—Chambers 
 
a. Spin SU8-100:  500 rpm for 20 sec, 136 rpm/sec ramp 
  1500 rpm for 55 sec, 136 rpm/sec ramp 
Let sit for 15 min. 
Film thickness = 150 µm 
 
b. Pre-Exposure Bake: 10 min 65 °C / 30 min 95 °C / 2 min 65 °C 
 
c. Expose Wafer:  75 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
d. Post-Exposure Bake: 5 min 65 °C / 25 min 95 °C / 2 min 65 °C 
 
d. Develop:   3 min in SU-8 Developer 
Rinse with acetone, isopropanol, and dry. 
 
e. Hard Bake:   Bake for 60 min at 150 °C.  
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II. Control Mold 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-2025:  3000 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 20 µm 
 
c. Pre-Exposure Bake: 2 min 65 °C / 5 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  25 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 10 min 95 °C / 2 min 65 °C 
 
f. Develop:   1 min in SU-8 Developer  
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
 
III. Reservoir Mold 
 
a. Clean Wafers:  Rinse with acetone, isopropanol, and dry.  
 
b. Spin SU8-2025:  3000 rpm for 75 sec, 136 rpm/sec ramp 
Film thickness = 20 µm 
 
c. Pre-Exposure Bake: 2 min 65 °C / 5 min 95 °C / 2 min 65 °C 
 
d. Expose Wafer:  25 sec at 8 mW/cm2 
Karl Suss aligner, soft contact mode, 250 µm gap 
 
e. Post-Exposure Bake: 5 min 65 °C / 10 min 95 °C / 2 min 65 °C 
 
f. Develop:   1 min in SU-8 Developer  
Rinse with acetone, isopropanol, and dry. 
 
g. Hard Bake:   Bake for 60 min at 150 °C. 
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Scale-Up Diffraction Device: Device Fabrication 
3 inch silicon wafer substrate 
 
 
1. TMCS Treat Molds:  Expose flow mold, control mold, reservoir  
mold, and one blank wafer to TMCS for 2 min. 
 
2. Prepare Flow Layer:  Combine 5:1 GE 615 RTV (35 g A:7 g B). 
 Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 6 g 5:1 onto flow mold. 
     Spin at 350 rpm for 70 sec, 136 rpm/sec ramp. 
      
3. Prepare Reservoir Layer: Pour 30 g 5:1 onto reservoir mold. 
     Degas for 15 min in bell jar. 
      
4. Cure Flow Layer:  Bake for 20 min at 80 °C. 
 
5. Cure Reservoir Layer: Bake for 40 min at 80 °C. 
 
6. Prepare Second Flow Layer: Start while reservoir layer is curing. 
Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
 
7. Cure Second Flow Layer: Bake for 25 min at 80 °C. 
 
8. Prepare Control Layer: Start while second flow layer is curing. 
Combine 20:1 GE 615 RTV (20 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 1700 rpm for 70 sec, 136 rpm/sec ramp. 
 
9. Flow/Reservoir Bonding: Remove reservoir layer from mold. 
Punch reservoir holes with 8 mm punch. 
     Cut reservoir layer down to size and clean with tape. 
     Align reservoir layer onto flow layer. 
     Bake for 60 min at 80 °C. 
 
10. Cure Control Layer:  Bake for 60 min at 80 °C. 
  
11. Flow/Control Bonding: Remove flow/reservoir devices from mold. 
Punch control inlets with 20 gauge punch. 
Cut devices out and clean with tape. 
     Align devices onto control layer. 
     Degas aligned device for 5 min. 
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     Bake for 60 min at 80 °C. 
 
12. Prepare Blank Layer:  Start while second flow layer is curing. 
Combine 30:1 GE 615 RTV (30 g A:1 g B). 
    Mix in hybrid mixer: 3 min mix / 5 min degas. 
     Pour 5 ml 20:1 onto flow mold. 
     Spin at 2000 rpm for 70 sec, 136 rpm/sec ramp. 
     Bake for 45 min at 80 °C. 
 
13. Assemble The Device: Remove device from control mold. 
Punch control inlets with 20 gauge punch. 
Cut devices down to size and clean with tape. 
Place device on blank layer. 
Degas device for 5 min. 
Bake overnight at 80 °C. 
Remove from blank layer and place on glass slide. 
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Appendix B 
FORMULATOR RECIPES 
I. Crystallization Survey Solubility Screening Conditions 
Condition Salt Solution Buffer (% Precipitant / % Protein) 
1 0.10 M ammonium acetate 0.1 M sodium acetate pH 4.5 80 / 2.5 
2 0.10 M ammonium acetate 0.1 M sodium acetate pH 4.5 67.5 / 15 
3 0.10 M ammonium acetate 0.1 M sodium acetate pH 4.5 52.5 / 30 
4 0.10 M ammonium acetate 0.1 M sodium acetate pH 4.5 37.5 / 40 
5 0.10 M ammonium acetate 0.1 M sodium acetate pH 4.5 22.5 / 60 
6 0.10 M ammonium acetate 0.1 M sodium acetate pH 4.5 7.5 / 75 
7 0.08 M sodium acetate 0.1 M sodium acetate pH 4.5 80 / 2.5 
13 0.13 M ammonium chloride 0.1 M sodium acetate pH 4.5 80 / 2.5 
19 0.13 M sodium chloride 0.1 M sodium acetate pH 4.5 80 / 2.5 
25 0.05 M potassium sodium chloride 0.1 M sodium acetate pH 4.5 80 / 2.5 
31 0.10 M ammonium sulfate 0.1 M sodium acetate pH 4.5 80 / 2.5 
37 0.18 M sodium nitrate 0.1 M sodium acetate pH 4.5 80 / 2.5 
43 0.05 M magnesium acetate 0.1 M sodium acetate pH 4.5 80 / 2.5 
49 0.05 M magnesium chloride 0.1 M sodium acetate pH 4.5 80 / 2.5 
55 0.05 M magnesium sulfate 0.1 M sodium acetate pH 4.5 80 / 2.5 
61 0.13 M potassium acetate 0.1 M sodium acetate pH 4.5 80 / 2.5 
67 0.08 M potassium chloride 0.1 M sodium acetate pH 4.5 80 / 2.5 
73 0.05 M potassium phosphate 0.1 M sodium acetate pH 4.5 80 / 2.5 
79 0.10 M sodium phosphate 0.1 M sodium acetate pH 4.5 80 / 2.5 
85 0.10 M ammonium acetate 0.1 M sodium citrate pH 6.5 80 / 2.5 
91 0.08 M sodium acetate 0.1 M sodium citrate pH 6.5 80 / 2.5 
97 0.13 M ammonium chloride 0.1 M sodium citrate pH 6.5 80 / 2.5 
103 0.13 M sodium chloride 0.1 M sodium citrate pH 6.5 80 / 2.5 
109 0.05 M potassium sodium chloride 0.1 M sodium citrate pH 6.5 80 / 2.5 
115 0.10 M ammonium sulfate 0.1 M sodium citrate pH 6.5 80 / 2.5 
121 0.18 M sodium nitrate 0.1 M sodium citrate pH 6.5 80 / 2.5 
127 0.05 M magnesium acetate 0.1 M sodium citrate pH 6.5 80 / 2.5 
133 0.05 M magnesium chloride 0.1 M sodium citrate pH 6.5 80 / 2.5 
139 0.05 M magnesium sulfate 0.1 M sodium citrate pH 6.5 80 / 2.5 
145 0.13 M potassium acetate 0.1 M sodium citrate pH 6.5 80 / 2.5 
151 0.08 M potassium chloride 0.1 M sodium citrate pH 6.5 80 / 2.5 
157 0.05 M potassium phosphate 0.1 M sodium citrate pH 6.5 80 / 2.5 
163 0.10 M sodium phosphate 0.1 M sodium citrate pH 6.5 80 / 2.5 
169 0.10 M ammonium acetate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
175 0.08 M sodium acetate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
181 0.13 M ammonium chloride 0.1 M Tris·HCl pH 8.5 80 / 2.5 
187 0.13 M sodium chloride 0.1 M Tris·HCl pH 8.5 80 / 2.5 
193 0.05 M potassium sodium chloride 0.1 M Tris·HCl pH 8.5 80 / 2.5 
199 0.10 M ammonium sulfate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
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Condition Salt Solution Buffer (% Precipitant /  % Protein) 
205 0.18 M sodium nitrate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
211 0.05 M magnesium acetate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
217 0.05 M magnesium chloride 0.1 M Tris·HCl pH 8.5 80 / 2.5 
223 0.05 M magnesium sulfate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
229 0.13 M potassium acetate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
235 0.08 M potassium chloride 0.1 M Tris·HCl pH 8.5 80 / 2.5 
241 0.05 M potassium phosphate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
247 0.10 M sodium phosphate 0.1 M Tris·HCl pH 8.5 80 / 2.5 
253 0.10 M ammonium acetate 0.1 M CAPS1 pH 10.5 80 / 2.5 
259 0.08 M sodium acetate 0.1 M CAPS pH 10.5 80 / 2.5 
265 0.13 M ammonium chloride 0.1 M CAPS pH 10.5 80 / 2.5 
271 0.13 M sodium chloride 0.1 M CAPS pH 10.5 80 / 2.5 
277 0.05 M potassium sodium chloride 0.1 M CAPS pH 10.5 80 / 2.5 
283 0.10 M ammonium sulfate 0.1 M CAPS pH 10.5 80 / 2.5 
289 0.18 M sodium nitrate 0.1 M CAPS pH 10.5 80 / 2.5 
295 0.05 M magnesium acetate 0.1 M CAPS pH 10.5 80 / 2.5 
301 0.05 M magnesium chloride 0.1 M CAPS pH 10.5 80 / 2.5 
307 0.05 M magnesium sulfate 0.1 M CAPS pH 10.5 80 / 2.5 
313 0.13 M potassium acetate 0.1 M CAPS pH 10.5 80 / 2.5 
319 0.08 M potassium chloride 0.1 M CAPS pH 10.5 80 / 2.5 
325 0.05 M potassium phosphate 0.1 M CAPS pH 10.5 80 / 2.5 
331 0.10 M sodium phosphate 0.1 M CAPS pH 10.5 80 / 2.5 
332 0.10 M sodium phosphate 0.1 M CAPS pH 10.5 67.5 / 15 
333 0.10 M sodium phosphate 0.1 M CAPS pH 10.5 52.5 / 30 
334 0.10 M sodium phosphate 0.1 M CAPS pH 10.5 37.5 / 40 
335 0.10 M sodium phosphate 0.1 M CAPS pH 10.5 22.5 / 60 
336 0.10 M sodium phosphate 0.1 M CAPS pH 10.5 7.5 / 75 
 
 
 
Condition Precipitant Stock Concentration (% w/w) 
1-336 100% PEG 300 
337-672 100% PEG 350 MME 
673-1008 100% PEG 550 MME 
1089-1344 50% PEG 1500 
1345-1680 50% PEG 2000 MME 
1681-2016 50% PEG 3350 
2017-2352 50% PEG 5000 MME 
2353-2688 50% PEG 8000 
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II. GKG230D Solubility Screening Conditions 
 
Condition Salt Solution Buffer (% Precipitant / % Protein) 
1 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 70 / 5 
2 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 60 / 15 
3 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 45 / 30 
4 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 30 / 45 
5 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 15 / 60 
6 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 5 / 70 
7 0.3 M sodium acetate 0.1 M citric acid pH 3.5 70 / 5 
13 0.5 M ammonium chloride 0.1 M citric acid pH 3.5 70 / 5 
19 0.5 M sodium chloride 0.1 M citric acid pH 3.5 70 / 5 
25 0.4 M ammonium sulfate 0.1 M citric acid pH 3.5 70 / 5 
31 0.7 M sodium nitrate 0.1 M citric acid pH 3.5 70 / 5 
37 0.2 M sodium thiosulfate 0.1 M citric acid pH 3.5 70 / 5 
43 0.2 M lithium sulfate 0.1 M citric acid pH 3.5 70 / 5 
49 0.2 M sodium formate 0.1 M citric acid pH 3.5 70 / 5 
55 0.2 M magnesium acetate 0.1 M citric acid pH 3.5 70 / 5 
61 0.2 M magnesium chloride 0.1 M citric acid pH 3.5 70 / 5 
67 0.2 M magnesium sulfate 0.1 M citric acid pH 3.5 70 / 5 
73 0.5 M potassium acetate 0.1 M citric acid pH 3.5 70 / 5 
79 0.3 M potassium chloride 0.1 M citric acid pH 3.5 70 / 5 
85 0.2 M potassium phosphate 0.1 M citric acid pH 3.5 70 / 5 
91 0.4 M sodium phosphate 0.1 M citric acid pH 3.5 70 / 5 
97 0.2 M lithium chloride 0.1 M citric acid pH 3.5 70 / 5 
103 0.4 M ammonium acetate 0.1 M MES2 pH 6.5 70 / 5 
109 0.3 M sodium acetate 0.1 M MES pH 6.5 70 / 5 
115 0.5 M ammonium chloride 0.1 M MES pH 6.5 70 / 5 
121 0.5 M sodium chloride 0.1 M MES pH 6.5 70 / 5 
127 0.4 M ammonium sulfate 0.1 M MES pH 6.5 70 / 5 
133 0.7 M sodium nitrate 0.1 M MES pH 6.5 70 / 5 
139 0.2 M sodium thiosulfate 0.1 M MES pH 6.5 70 / 5 
145 0.2 M lithium sulfate 0.1 M MES pH 6.5 70 / 5 
151 0.2 M sodium formate 0.1 M MES pH 6.5 70 / 5 
157 0.2 M magnesium acetate 0.1 M MES pH 6.5 70 / 5 
163 0.2 M magnesium chloride 0.1 M MES pH 6.5 70 / 5 
169 0.2 M magnesium sulfate 0.1 M MES pH 6.5 70 / 5 
175 0.5 M potassium acetate 0.1 M MES pH 6.5 70 / 5 
181 0.3 M potassium chloride 0.1 M MES pH 6.5 70 / 5 
187 0.2 M potassium phosphate 0.1 M MES pH 6.5 70 / 5 
193 0.4 M sodium phosphate 0.1 M MES pH 6.5 70 / 5 
199 0.2 M lithium chloride 0.1 M MES pH 6.5 70 / 5 
205 0.4 M ammonium acetate 0.1 M Hepes pH 7.5 70 / 5 
211 0.3 M sodium acetate 0.1 M Hepes pH 7.5 70 / 5 
217 0.5 M ammonium chloride 0.1 M Hepes pH 7.5 70 / 5 
223 0.5 M sodium chloride 0.1 M Hepes pH 7.5 70 / 5 
229 0.4 M ammonium sulfate 0.1 M Hepes pH 7.5 70 / 5 
235 0.7 M sodium nitrate 0.1 M Hepes pH 7.5 70 / 5 
241 0.2 M sodium thiosulfate 0.1 M Hepes pH 7.5 70 / 5 
247 0.2 M lithium sulfate 0.1 M Hepes pH 7.5 70 / 5 
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Condition Salt Solution Buffer (% Precipitant / % Protein) 
253 0.2 M sodium formate 0.1 M Hepes pH 7.5 70 / 5 
259 0.2 M magnesium acetate 0.1 M Hepes pH 7.5 70 / 5 
265 0.2 M magnesium chloride 0.1 M Hepes pH 7.5 70 / 5 
271 0.2 M magnesium sulfate 0.1 M Hepes pH 7.5 70 / 5 
277 0.5 M potassium acetate 0.1 M Hepes pH 7.5 70 / 5 
283 0.3 M potassium chloride 0.1 M Hepes pH 7.5 70 / 5 
289 0.2 M potassium phosphate 0.1 M Hepes pH 7.5 70 / 5 
295 0.4 M sodium phosphate 0.1 M Hepes pH 7.5 70 / 5 
301 0.2 M lithium chloride 0.1 M Hepes pH 7.5 70 / 5 
307 0.4 M ammonium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
313 0.3 M sodium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
319 0.5 M ammonium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
325 0.5 M sodium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
331 0.4 M ammonium sulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
337 0.7 M sodium nitrate 0.1 M Tris·HCl pH 8.5 70 / 5 
343 0.2 M sodium thiosulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
349 0.2 M lithium sulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
355 0.2 M sodium formate 0.1 M Tris·HCl pH 8.5 70 / 5 
361 0.2 M magnesium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
367 0.2 M magnesium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
373 0.2 M magnesium sulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
379 0.5 M potassium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
385 0.3 M potassium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
391 0.2 M potassium phosphate 0.1 M Tris·HCl pH 8.5 70 / 5 
397 0.4 M sodium phosphate 0.1 M Tris·HCl pH 8.5 70 / 5 
403 0.2 M lithium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
409 0.4 M ammonium acetate 0.1 M TAPS3 pH 9.5 70 / 5 
415 0.3 M sodium acetate 0.1 M TAPS pH 9.5 70 / 5 
421 0.5 M ammonium chloride 0.1 M TAPS pH 9.5 70 / 5 
427 0.5 M sodium chloride 0.1 M TAPS pH 9.5 70 / 5 
433 0.4 M ammonium sulfate 0.1 M TAPS pH 9.5 70 / 5 
439 0.7 M sodium nitrate 0.1 M TAPS pH 9.5 70 / 5 
445 0.2 M sodium thiosulfate 0.1 M TAPS pH 9.5 70 / 5 
451 0.2 M lithium sulfate 0.1 M TAPS pH 9.5 70 / 5 
457 0.2 M sodium formate 0.1 M TAPS pH 9.5 70 / 5 
463 0.2 M magnesium acetate 0.1 M TAPS pH 9.5 70 / 5 
469 0.2 M magnesium chloride 0.1 M TAPS pH 9.5 70 / 5 
475 0.2 M magnesium sulfate 0.1 M TAPS pH 9.5 70 / 5 
481 0.5 M potassium acetate 0.1 M TAPS pH 9.5 70 / 5 
487 0.3 M potassium chloride 0.1 M TAPS pH 9.5 70 / 5 
493 0.2 M potassium phosphate 0.1 M TAPS pH 9.5 70 / 5 
499 0.4 M sodium phosphate 0.1 M TAPS pH 9.5 70 / 5 
505 0.2 M lithium chloride 0.1 M TAPS pH 9.5 70 / 5 
506 0.2 M lithium chloride 0.1 M TAPS pH 9.5 60 / 15 
507 0.2 M lithium chloride 0.1 M TAPS pH 9.5 45 / 30 
508 0.2 M lithium chloride 0.1 M TAPS pH 9.5 30 / 45 
509 0.2 M lithium chloride 0.1 M TAPS pH 9.5 15 / 60 
510 0.2 M lithium chloride 0.1 M TAPS pH 9.5 5 / 70 
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Condition Precipitant Stock Concentration (% w/w) 
1-510 Salt Solutions 
511-1020 100% PEG 300 
1021-1530 100% PEG 550 MME 
1531-2040 50% PEG 1500 
2041-2550 50% PEG 3350 
2551-3060 50% PEG 5000 MME 
3061-3570 50% PEG 8000 
3571-4080 30% PEG 20,000 
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III. GKD72A, GK235KGG, and GKM271I Solubility Screening Conditions 
 
Condition Salt Solution Buffer (% Precipitant / % Protein) 
1 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 70 / 5 
2 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 60 / 15 
3 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 45 / 30 
4 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 30 / 45 
5 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 15 / 60 
6 0.4 M ammonium acetate 0.1 M citric acid pH 3.5 5 / 70 
7 0.3 M sodium acetate 0.1 M citric acid pH 3.5 70 / 5 
13 0.5 M ammonium chloride 0.1 M citric acid pH 3.5 70 / 5 
19 0.5 M sodium chloride 0.1 M citric acid pH 3.5 70 / 5 
25 0.4 M ammonium sulfate 0.1 M citric acid pH 3.5 70 / 5 
31 0.7 M sodium nitrate 0.1 M citric acid pH 3.5 70 / 5 
37 0.2 M sodium thiosulfate 0.1 M citric acid pH 3.5 70 / 5 
43 0.2 M lithium sulfate 0.1 M citric acid pH 3.5 70 / 5 
49 0.2 M sodium formate 0.1 M citric acid pH 3.5 70 / 5 
55 0.2 M magnesium acetate 0.1 M citric acid pH 3.5 70 / 5 
61 0.2 M magnesium chloride 0.1 M citric acid pH 3.5 70 / 5 
67 0.2 M magnesium sulfate 0.1 M citric acid pH 3.5 70 / 5 
73 0.5 M potassium acetate 0.1 M citric acid pH 3.5 70 / 5 
79 0.3 M potassium chloride 0.1 M citric acid pH 3.5 70 / 5 
85 0.2 M potassium phosphate 0.1 M citric acid pH 3.5 70 / 5 
91 0.4 M sodium phosphate 0.1 M citric acid pH 3.5 70 / 5 
97 0.2 M lithium chloride 0.1 M citric acid pH 3.5 70 / 5 
103 0.4 M ammonium acetate 0.1 M sodium citrate pH 5.5 70 / 5 
109 0.3 M sodium acetate 0.1 M sodium citrate pH 5.5 70 / 5 
115 0.5 M ammonium chloride 0.1 M sodium citrate pH 5.5 70 / 5 
121 0.5 M sodium chloride 0.1 M sodium citrate pH 5.5 70 / 5 
127 0.4 M ammonium sulfate 0.1 M sodium citrate pH 5.5 70 / 5 
133 0.7 M sodium nitrate 0.1 M sodium citrate pH 5.5 70 / 5 
139 0.2 M sodium thiosulfate 0.1 M sodium citrate pH 5.5 70 / 5 
145 0.2 M lithium sulfate 0.1 M sodium citrate pH 5.5 70 / 5 
151 0.2 M sodium formate 0.1 M sodium citrate pH 5.5 70 / 5 
157 0.2 M magnesium acetate 0.1 M sodium citrate pH 5.5 70 / 5 
163 0.2 M magnesium chloride 0.1 M sodium citrate pH 5.5 70 / 5 
169 0.2 M magnesium sulfate 0.1 M sodium citrate pH 5.5 70 / 5 
175 0.5 M potassium acetate 0.1 M sodium citrate pH 5.5 70 / 5 
181 0.3 M potassium chloride 0.1 M sodium citrate pH 5.5 70 / 5 
187 0.2 M potassium phosphate 0.1 M sodium citrate pH 5.5 70 / 5 
193 0.4 M sodium phosphate 0.1 M sodium citrate pH 5.5 70 / 5 
199 0.2 M lithium chloride 0.1 M sodium citrate pH 5.5 70 / 5 
205 0.4 M ammonium acetate 0.1 M Hepes pH 7.5 70 / 5 
211 0.3 M sodium acetate 0.1 M Hepes pH 7.5 70 / 5 
217 0.5 M ammonium chloride 0.1 M Hepes pH 7.5 70 / 5 
223 0.5 M sodium chloride 0.1 M Hepes pH 7.5 70 / 5 
229 0.4 M ammonium sulfate 0.1 M Hepes pH 7.5 70 / 5 
235 0.7 M sodium nitrate 0.1 M Hepes pH 7.5 70 / 5 
241 0.2 M sodium thiosulfate 0.1 M Hepes pH 7.5 70 / 5 
247 0.2 M lithium sulfate 0.1 M Hepes pH 7.5 70 / 5 
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Condition Salt Solution Buffer (% Precipitant / % Protein) 
253 0.2 M sodium formate 0.1 M Hepes pH 7.5 70 / 5 
259 0.2 M magnesium acetate 0.1 M Hepes pH 7.5 70 / 5 
265 0.2 M magnesium chloride 0.1 M Hepes pH 7.5 70 / 5 
271 0.2 M magnesium sulfate 0.1 M Hepes pH 7.5 70 / 5 
277 0.5 M potassium acetate 0.1 M Hepes pH 7.5 70 / 5 
283 0.3 M potassium chloride 0.1 M Hepes pH 7.5 70 / 5 
289 0.2 M potassium phosphate 0.1 M Hepes pH 7.5 70 / 5 
295 0.4 M sodium phosphate 0.1 M Hepes pH 7.5 70 / 5 
301 0.2 M lithium chloride 0.1 M Hepes pH 7.5 70 / 5 
307 0.4 M ammonium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
313 0.3 M sodium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
319 0.5 M ammonium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
325 0.5 M sodium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
331 0.4 M ammonium sulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
337 0.7 M sodium nitrate 0.1 M Tris·HCl pH 8.5 70 / 5 
343 0.2 M sodium thiosulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
349 0.2 M lithium sulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
355 0.2 M sodium formate 0.1 M Tris·HCl pH 8.5 70 / 5 
361 0.2 M magnesium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
367 0.2 M magnesium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
373 0.2 M magnesium sulfate 0.1 M Tris·HCl pH 8.5 70 / 5 
379 0.5 M potassium acetate 0.1 M Tris·HCl pH 8.5 70 / 5 
385 0.3 M potassium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
391 0.2 M potassium phosphate 0.1 M Tris·HCl pH 8.5 70 / 5 
397 0.4 M sodium phosphate 0.1 M Tris·HCl pH 8.5 70 / 5 
403 0.2 M lithium chloride 0.1 M Tris·HCl pH 8.5 70 / 5 
409 0.4 M ammonium acetate 0.1 M TAPS pH 9.5 70 / 5 
415 0.3 M sodium acetate 0.1 M TAPS pH 9.5 70 / 5 
421 0.5 M ammonium chloride 0.1 M TAPS pH 9.5 70 / 5 
427 0.5 M sodium chloride 0.1 M TAPS pH 9.5 70 / 5 
433 0.4 M ammonium sulfate 0.1 M TAPS pH 9.5 70 / 5 
439 0.7 M sodium nitrate 0.1 M TAPS pH 9.5 70 / 5 
445 0.2 M sodium thiosulfate 0.1 M TAPS pH 9.5 70 / 5 
451 0.2 M lithium sulfate 0.1 M TAPS pH 9.5 70 / 5 
457 0.2 M sodium formate 0.1 M TAPS pH 9.5 70 / 5 
463 0.2 M magnesium acetate 0.1 M TAPS pH 9.5 70 / 5 
469 0.2 M magnesium chloride 0.1 M TAPS pH 9.5 70 / 5 
475 0.2 M magnesium sulfate 0.1 M TAPS pH 9.5 70 / 5 
481 0.5 M potassium acetate 0.1 M TAPS pH 9.5 70 / 5 
487 0.3 M potassium chloride 0.1 M TAPS pH 9.5 70 / 5 
493 0.2 M potassium phosphate 0.1 M TAPS pH 9.5 70 / 5 
499 0.4 M sodium phosphate 0.1 M TAPS pH 9.5 70 / 5 
505 0.2 M lithium chloride 0.1 M TAPS pH 9.5 70 / 5 
506 0.2 M lithium chloride 0.1 M TAPS pH 9.5 60 / 15 
507 0.2 M lithium chloride 0.1 M TAPS pH 9.5 45 / 30 
508 0.2 M lithium chloride 0.1 M TAPS pH 9.5 30 / 45 
509 0.2 M lithium chloride 0.1 M TAPS pH 9.5 15 / 60 
510 0.2 M lithium chloride 0.1 M TAPS pH 9.5 5 / 70 
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Condition Precipitant Stock Concentration (% w/w) 
1-510 Salt Solutions 
511-1020 100% PEG 300 
1021-1530 100% PEG 550 MME 
1531-2040 50% PEG 1500 
2041-2550 50% PEG 2000 MME 
2551-3060 50% PEG 3350 
3061-3570 50% PEG 5000 MME 
3571-4080 50% PEG 8000 
4081-4590 30% PEG 20,000 
 
 
1 CAPS, 3-(cyclohexylamino)-1-propanesulfonic acid  
2 MES, 2-(N-morpholino)ethanesulfonic acid 
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Appendix C 
CRYSTALLIZATION SURVEY PHASE DIAGRAMS 
1. bR D85S Phase Diagrams:  
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2. bR Phase Diagrams: 
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3. Cbb3 Phase Diagrams: 
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4. AlaRS Phase Diagrams: 
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5. Fis1 Phase Diagrams: 
 
 
 
 
6. P450 1-12G Phase Diagrams:  
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7. SMC/ScpA Phase Diagrams:  
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8. P2X Phase Diagrams:   
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9. AMG Phase Diagrams:   
 
 
 182 
 
 
 
10. VCP/Vimp Phase Diagrams: 
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11. Tf/TfR Phase Diagrams:   
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Appendix D 
GLYCEROL KINASE EXPRESSION AND PURIFICATION PROTOCOLS 
I. Protein Expression 
GKG230D and GKM271I are in pETBlue2 vectors (Novagen) and have non-cleavable C-
terminal HSV and His6-tags. GKD72A and GK235KGG are in pETBlue1 vectors 
(Novagen) and have cleavable N-terminal His6-tags. 
1. Transfect the clones into BL21(DE3) chemically competent cells (Invitrogen). 
• Thaw cells on ice for 10 min. 
• Add 1 µl of the clones to the cells and incubate on ice for 30 min. 
• Heat shock the cells for 30 sec in a 42 °C water bath and return to ice. 
• Add 250 µl of SOC medium to cells and place in shaker for one hour at 37 °C, 
250 rpm. 
• Plate 50 µl of cells onto an LB ampicillin (AMP) plate (50 µg/ml AMP) and 
incubate overnight at 37 °C. 
2. Prepare starter culture and begin protein expression. 
• Pick one colony from the LB AMP plate and place in 100 ml of 37 °C LB 
AMP (50 µg/ml AMP). 
• Shake starter culture overnight at 37 °C, 250 rpm. 
• Prepare 2 L of LB AMP (50 µg/ml AMP) in a 4 L flask and store at 37 °C. 
• The next morning, add the starter culture to the 2 L of LB AMP and shake at 
37 °C, 250 rpm until flask reaches an OD600 of 0.75 (approximately 2 hours). 
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• Inoculate cells with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
shake for 4 hours. 
• Spin down culture for 30 min at 4 °C, 4000 rpm. 
• Remove supernatant, divide into 4 pellets, and store at -80 °C until 
purification. 
 
 
II. Protein Purification for GKG230D and GKM271I 
1. Sonicate cells. 
• Thaw one pellet on ice for 20 min. 
• Resuspend pellet on ice with 45 ml of: 
200 mM sodium chloride 
10 mM Tris·HCl pH 7.4 
1 mM PMSF protease inhibitor 
 
• Sonicate solution on ice to lyse cells using the following recipe: 
a.   Sonicate for 10 sec. 
b.   Pause for 10 sec. 
c.   Repeat 20 sec pattern for 2 min. 
 
• Spin down sonicated solution for 30 min at 4 °C, 5000 rpm. 
• Move supernatant to a clean tube for nickel-nitrilotriacetic acid (Ni-NTA) 
purification. 
2. Ni-NTA purification of supernatant 
• Add 1 ml of Ni-NTA resin (Qiagen) to the supernatant and incubate for 1 hour 
at 4 °C. 
• Load the supernatant/resin mixture into a 10 ml disposable chromatography 
column (BioRad). 
• Wash the column with 20 ml of wash buffer: 
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200 mM sodium chloride 
10 mM Tris·HCl pH pH 7.4 
 
• Elute the protein with an Imidazole gradient: 
1. 2 ml of wash buffer with 20 mM Imidazole 
2. 2 ml of wash buffer with 50 mM Imidazole 
3. 5 ml of wash buffer with 200 mM Imidazole 
 
• Analyze with a PAGE gel to find the protein (usually in the 50 mM fraction).  
• Dialyze the protein overnight at 4 °C for anion exchange into: 
100 mM potassium chloride  
20 mM Tris·HCl pH 8.0 
10 mM glycerol 
1mM βME 
 
3. Anion exchange of Ni-NTA purified sample  
• Concentrate dialyzed protein at 4 °C to 1 ml for anion exchange.  
• Prepare two solutions for anion exchange: 
Solution A:  20 mM Tris·HCl pH 8.0 
10 mM glycerol 
1 mM βME 
 
Solution B: 1M potassium chloride 
20 mM Tris·HCl pH 8.0 
10 mM glycerol 
1 mM βME 
 
• Prepare the Mono Q 5/50 GL column (GE Life Sciences) in the FPLC: 
a. Place line A1 in Solution A. 
b. Place line A2 into H2O. 
c. Place line B1 in Solution B. 
d. Pump-Wash-Purify lines A1, A2, and B1. 
e. Flow line A2 at 0.5 ml/min and connect the column. 
f. Flush one cv (1 ml) of line A2 at 1 ml/min. 
g. Flush one cv of line A1 at 1 ml/min. 
h. Put the column into starting buffer for the sample (90% line A1, 
10% line B1). 
i. Load 1 ml of protein into the injection loop and start purification: 
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1.   Run 0.25 cv of 90% line A1, 10% line B1. 
2.   Pump inject sample. 
a. Set at gradient to 100% line B1 over the course of 15 cv. 
b. Collect 0.5 ml fractions once gradient begins. 
 
• Analyze with a PAGE gel to find the protein (usually around 30–40% B1).  
• Dialyze the protein overnight at 4 °C for gel filtration into: 
20 mM Tris·HCl pH 7.5 
10 mM glycerol 
1mM βME 
 
4. Gel filtration of anion-exchange purified sample 
• Concentrate dialyzed protein at 4 °C to 200 µl for gel filtration.  
• Prepare one solution for gel filtration: 
Solution A:  20 mM Tris·HCl pH 7.5 
10 mM glycerol 
1 mM βME 
 
• Prepare the Superdex 200 10/30 GL column (GE Life Sciences) in the Fast 
Protein Liquid Chromatography (FPLC) system: 
a.   Place line A1 in Solution A. 
b. Place line B1 in H2O. 
c. Pump-Wash-Purify lines A1 and B1. 
d. Flow line B1 at 0.5 ml/min and connect the column. 
e. Flush one column volume (cv) (24 ml) of line B1 at 0.5 ml/min. 
f. Flush one cv of line A1 at 0.5 ml/min. 
g. Load 200 µl of protein into the injection loop and start purification: 
 
1.   Run 0.25 cv of line A1. 
2.   Pump inject sample. 
3. Run 1.25 cv of line A1 and collect 0.5 ml fractions. 
 
• Analyze with a polyacrylamide gel electrophoresis (PAGE) gel to find the 
protein (usually around 12 ml). 
• Collect the fractions with protein, and if the protein is pure enough (at least 
95%), concentrate to 30 mg/ml, flash freeze, and store at -80 °C.   
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• If protein is less than 95% pure, concentrate fractions to 200 µl and run a 
second gel filtration column. 
 
III. Protein Purification for GKD72A and GK235KGG 
1. Sonicate cells. 
• Thaw one pellet on ice for 20 min. 
• Resuspend pellet on ice with 45 ml of: 
200 mM sodium chloride 
10 mM Tris·HCl pH 7.4 
1 mM PMSF protease inhibitor 
 
• Sonicate solution on ice to lyse cells using the following recipe: 
a.   Sonicate for 10 sec. 
b.   Pause for 10 sec. 
c.   Repeat 20 sec pattern for 2 min. 
 
• Spin down sonicated solution for 30 min at 4 °C, 5000 rpm. 
• Move supernatant to a clean tube for Ni-NTA purification. 
2. Ni-NTA purification of supernatant 
• Add 1 ml of Ni-NTA resin to the supernatant and incubate for 1 hour at 4 °C. 
• Load the supernatant/resin mixture into a 10 ml disposable chromatography 
column. 
• Wash the column with 20 ml of wash buffer: 
200 mM sodium chloride 
10 mM Tris·HCl pH 7.4 
 
• Elute the protein with an Imidazole gradient: 
a.   2 ml of wash buffer with 20 mM Imidazole 
b.   2 ml of wash buffer with 50 mM Imidazole 
c.   5 ml of wash buffer with 200 mM Imidazole 
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• Analyze with a PAGE gel to find the protein (usually in the 50 mM fraction).  
• Dialyze the protein overnight at 4 °C for His6-tag cleavage into: 
20 mM Tris·HCl pH 7.5 
10 mM glycerol 
1mM βME 
 
3. Removal of N-terminal His6-tag 
• Prepare His6-tag cleavage reaction using Tobacco Etch Virus (TEV) Protease 
(Invitrogen): 
150 µl 0.1 M dithiothreitol (DTT) 
750 µl 20X TEV Buffer 
1000 U TEV Protease 
• Add dialyzed protein to the cleavage reaction and incubate for 3 hours at 21 
°C. 
• Upon completion of cleavage, perform Ni-NTA purification to remove 
AcTEV Protease and the cleaved N-terminal His6-tags. 
• Add 1 ml of Ni-NTA resin to the reaction and incubate for 1 hour at 4 °C. 
• Load the protein/resin mixture into a 10 ml disposable chromatography 
column. 
• Collect the flow through and wash the column with 20 ml of wash buffer: 
20 mM Tris·HCl pH 7.5 
10 mM glycerol 
1mM βME 
 
• Analyze with a PAGE gel to find the protein (usually in the flow-through).  
• Dialyze the protein overnight at 4 °C for gel filtration into: 
20 mM Tris·HCl pH 7.5 
10 mM glycerol 
1mM βME 
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4. Gel filtration of Ni-NTA purified sample 
• Concentrate dialyzed protein at 4 °C to 200 µl for gel filtration.  
• Prepare one solution for gel filtration: 
Solution A:  20 mM Tris·HCl pH 7.5 
10 mM glycerol 
1 mM βME 
 
• Prepare the Superdex 200 10/30 GL column in the FPLC system: 
a.   Place line A1 in Solution A. 
b.   Place line B1 in H2O. 
c.   Pump-Wash-Purify lines A1 and B1. 
4. Flow line B1 at 0.5 ml/min and connect the column. 
5. Flush one cv (24 ml) of line B1 at 0.5 ml/min. 
6. Flush one cv of line A1 at 0.5 ml/min. 
7. Load 200 µl of protein into the injection loop and start purification: 
 
1.   Run 0.25 cv of line A1. 
2.   Pump inject sample. 
3. Run 1.25 cv of line A1 and collect 0.5 ml fractions. 
 
• Analyze with a PAGE gel to find the protein (usually around 12 ml).  
• Collect the fractions with protein, and if the protein is pure enough (at least 
95%), concentrate to 30 mg/ml, flash freeze, and store at -80 °C.   
• If protein is less than 95% pure, concentrate fractions to 200 µl and run a 
second gel filtration column.  
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Appendix E 
CRYSTALLIZATION EXPERIMENTAL TALLY 
Crystallization 
Target 
Solubility 
Screening 
Phase 
Diagrams 
Screening 
Devices 
Diffraction 
Devices 
Dialysis 
Devices 
Total 
 
19S Lid 3906 1 14 4  7738 
AlaRS 4826 39 15   11234 
AMG 6019 24 4   8707 
bR 3529 17 8 4  7073 
bR D85S 3705 19 7 2  6953 
Cbb3 3459 29 9 8  8507 
Fis1 4840 18 7   7816 
P450 1-12G 3816 9 27 14  12344 
VCP/VimpC 6307 18 10 9  10903 
P2X 6374 45 16   13454 
SMC/ScpA 2767 55 16   10567 
Tf/TfR 8005 17 4   10189 
GKG230D 18095 37 21 19 2 27749 
GK235KGG 8257 0 24 52  19217 
GKD72A 9114 0 10 13  12814 
GKM271I 6698 0 26 54  18338 
GKQ37P 4141 0 9 14  7701 
GKW53G 0 0 16 5  4340 
KcsA Channel 0 0 13 9 50 5270 
Actomyosin 3926 32 5   7430 
B1DGH 10938 65 14 23  21278 
GPCR 2652 0    2652 
hALR2 T113A 3122 0 8 4  5442 
hALR2 F115Y 0 0 8 4  2320 
Hop2/Mnd1 2693 21 24 10  10965 
Mfn1 1347 0    1347 
MukBEF 4008 0    4008 
MukEF 4676 17 4   6860 
Full P450 1-12G  0 0 16 2  4040 
Tf/DNA 2806 0 1   3046 
Tf/DNA Sample 2 8075 6 10   10907 
VimpC 0 25 5   3000 
YxiN RNA-P 3865 52 5   8809 
Total Experiments 151966 39312 85440 25000 1300 303018 
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